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Abstract 
Oral squamous cell carcinoma (OSCC) is a major cause of mortality worldwide, with poor 
prognosis and no clinically proven marker. The molecular mechanism of the disease is not 
clearly understood and treatment options include surgery and/or chemo- and radio-therapy. 
The disease is often diagnosed late at an advanced stage and the 5-year survival rate has not 
improved for the past few years. Hence, there is a requirement for the identification and in-
depth understanding of molecular mechanisms and the biology of oral cancer that might lead 
to the identification of diagnostic, prognostic and therapeutic targets. Gene profiling through 
microarray analysis is a commonly used technique in recent years for gene expression 
analysis in several disease conditions. A lack of clinically proven markers for OSCC 
detection indicates that a single gene or protein might not be responsible and hence 
deregulation of multiple pathways and processes might contribute to the occurrence and 
progression of the disease. This thesis outlines the studies aimed at investigating the 
mechanisms underlying oral cancer occurrence and progression in order to improve further 
treatment strategies to target these mechanisms. 
Chapter two identified pathways and processes involved in oral cancer progression and 
examined how the cells employ different mechanisms for ongoing proliferation. Cell cycle 
regulators involved in G2/M transition were predominantly over expressed in OSCC samples. 
Hepatic stellate cell activation, interferon signaling, G2/M transition and oncostatin-M 
signaling that promote processes including inflammation, cell proliferation, extracellular 
matrix (ECM) remodeling and fibrosis were significantly up regulated in OSCC samples. 
There was no significant difference observed between early, I and II, and late, III and IV, 
stage OSCC samples for the expression of genes that regulate these pathways. However, 
fibronectin 1 (FN1) showed differential expression in early and late stage OSCC samples. 
The unique bundle like network pattern of the desmoplastic reaction leading to scarring of 
   
xvi 
 
fibrous tissue was observed in late stage OSCC samples indicating FN1 might be a diagnostic 
marker to differentiate early and late stage OSCC samples. Matrix metallo proteinase-13 
(MMP13) significant over expression was observed in epithelial islands of late and early 
stage OSCC samples. Compared to the DOK dysplastic oral cell line, the oral cancer cell line 
SCC25 showed marked over expression of MMP13. Further knockdown studies of MMP13 
revealed decreased cell proliferation, migration and invasion of SCC25 cells. This clearly 
indicated MMP13 may be a promising target in oral cancer therapy. 
Chronic inflammation is one of the causal factors for oral cancer occurrence and progression. 
The inflammation process was manifested through hepatic stellate cell activation, interferon 
signaling and oncostatin-M signaling was clearly evident as revealed in chapter 2. Non-
steroidal anti-inflammatory drugs (NSAIDs), especially acetyl salicylic acid (aspirin) plays 
an important role in inducing an anti-inflammatory response in oral cancer cells but its 
molecular mechanisms and targets were not fully understood. Chapter three demonstrated 
that treatment of oral cancer cells with low concentration of aspirin leads to down regulation 
of genes involved in cell cycle regulation especially G2/M transition. Further it also targeted 
genes involved in inflammation, fibrosis and especially ECM remodeling. The main 
pathways significantly expressed were interferon signaling and G2/M transition and the genes 
promoting these pathways were significantly down regulated. Most of the genes that were 
over expressed in OSCC samples that promote the above pathways and processes were down 
regulated by aspirin including MMP13 which was overexpressed in SCC25 cells. Peroxisome 
proliferator-activated receptor gamma (PPARG), down regulated in SCC25 cells and OSCC 
samples showed increased expression in aspirin treated cells. PPARG plays an important role 
in the induction of apoptosis in aspirin-treated cells. The downstream molecule of G2/M 
transition, centrosomal protein of 55 kDa (CEP55), also a cytokinesis promoter was 
significantly repressed in the aspirin treated oral cancer cells.  The broad spectrum effect of 
   
xvii 
 
aspirin targeting the genes that were specifically over expressed in OSCC samples is 
noteworthy and suggests aspirin may be a potential therapeutic drug for oral cancer treatment. 
Keratin-4 (KRT4), strongly expressed in supra basal layer of squamous epithelium, was 
found to be down regulated in OSCC samples. External microarray studies also indicated 
down regulation of the KRT4 gene in the SCC25 oral cancer cell line in comparison to 
normal human oral keratinocytes. Several other gene profiling studies also showed down 
regulation of KRT4 gene expression in OSCC samples. These results suggested a hypothesis 
that KRT4 down regulation might be important for OSCC progression.  Chapter four studied 
the effect of over expression of KRT4 in SCC25 cells. SCC25 cells over expressing the 
KRT4 gene showed morphological changes into clonal like structures further showing an 
epithelial mesenchymal transition (EMT) phenotype. These cells showed increased 
expression of CD44 and N-cadherin leading to an increase in the stemness of the SCC25 
cells. In addition, tumorigenic assays indicated increased stemness in KRT4 transfected cells 
suggesting that KRT4 over expression might lead to increase in the support cell adhesion and 
cell structural elements. The meta-profiling analysis indicated that KRT4 might be a 
prognostic marker as dysplasia samples progressing to cancer showed early down regulation 
of KRT4 gene expression and dysplasia samples that did not progress to cancer did not show 
any significant differential expression of this gene. These results indicated that KRT4 most 
likely did not have a role of therapeutic importance but it might be having an important role 
in prognosis of oral cancer. However to confirm this hypothesis further analysis of a large 
number of clinical samples is required. 
Extracellular matrix (ECM) remodeling is one of the contributing factors to the progression 
of carcinoma. Microarray results from chapter two indicated up regulation of several genes 
involved in ECM remodeling. The SCC25 cell line is a tumorigenic cell line that might 
require remodeled ECM for its survival. A basic model to examine the requirement of ECM 
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for cancer cell survival could be ECM from mammary gland during lactation. Earlier studies 
and our external microarray data analysis indicated that mammary matrix from involuting 
tissue showed up regulation of genes involved in ECM remodeling. Studies in chapter five 
reports a preliminary study to examine the response of oral and breast cancer cells cultured 
on mammary ECM from lactating tissue. Oral and breast cancer cells (SCC25 and MDA-
MB-231) cultured on mammary matrix (derived from lactating tissue) showed dramatic cell 
death. Under the same culture conditions, non-tumorigenic cell lines, mammary epithelial cell 
line (MCF10A) and oral dysplasia cell line (DOK) showed no cell death but cell proliferation 
was affected due to the quiescence promoting property of lactation mammary matrix. Further 
non-tumorigenic and tumorigenic oral and breast epithelial cells did not show cell death when 
cultured on mammary matrix isolated from involuting tissue. A substantial difference in the 
expression of cytokinesis marker, CEP55 was also observed in the cells cultured on lactation 
and involution matrix. This preliminary study is an attempt to understand not only the 
requirement of ECM remodelling factors essential for the growth and survival of cancer cells 
but also the factors present in the lactation matrix that simultaneously halts cell division and 
selectively inhibits the growth of cancer cells. Further studies are required to identify the 
factors in lactation matrix that can halt cell division and induce cell death in cancer cells. 
Collectively, the findings in this thesis suggest that genes involved in the promotion of 
inflammation, G2/M transition, fibrosis and ECM remodelling processes are responsible for 
oral cancer and progression. Aspirin showed a broad spectrum effect by targeting these genes 
and it may be a potential drug in oral cancer therapeutics. KRT4 loss in cells might be a 
prognosis marker to indicate the oral cancer occurrence and progression. Further factors 
responsible for ECM remodelling are essential for the growth of oral malignancy. Together 
these results suggest oral cancer occurrence and progression is due to deregulation of several 
genes involved in multiple pathways and processes and drugs like aspirin with broad 
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spectrum effects are essential for the better treatment of oral cancer potentially leading to 
improvement in the survival rate of OSCC patients. 
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1.1 Introduction 
Head and neck cancers are often associated with high mortality and low survival rates 
(Shingaki et al. 2003; Sun & Califano 2014). Approximately 40% of head and neck cancers 
include cancers of the oral cavity (Funk et al. 2002; Lessa et al. 2013). Oral cancer refers to a 
subgroup of head and neck malignancies that develop at the lips, tongue, salivary glands, 
gingiva, floor of the mouth, oropharynx, buccal surfaces and other intra-oral locations of the 
oral cavity (Warnakulasuriya 2009). Most oral cancers (approximately 90-95%) arise from 
squamous epithelium in oral mucosa and hence are termed as oral squamous cell carcinoma 
(OSCC) (Mignogna, Fedele & Lo Russo 2004; Su et al. 2014).  
1.2 Oral mucosa 
The oral mucosa is comprised of several layers of flat and thin squamous epithelial cells 
arranged in stalks known as stratified squamous epithelium (SSE). The stratification of the 
epithelia is due to a sequential process of proliferation and differentiation of cells. The lower 
layers of epithelium in SSE undergo proliferation and become constricted as the cells move 
upwards and form the outermost epithelial layers. The cells initiate differentiation as they 
start migrating towards the upper layer and become terminally differentiated in the outer 
lining surfaces of the tissue. Mucosa of the oral cavity can be classified into three types based 
on their structure and function: lining, masticatory and specialized mucosa. The anatomical 
sub sites of the oral cavity – lips, soft palate, cheeks (buccal) and floor of the mouth have 
mucosal lining (Figure 1.1). Gingiva and hard palate are lined by strong protective covers 
called masticatory mucosa. The mucosa is composed of specialised structures called taste 
receptors located on the dorsum of the tongue. Lining mucosa constitutes ~60% of the total 
area of the oral epithelium, while specialized and masticatory constitute 15% and 25% 
respectively (Collins & Dawes 1987; Squier & Kremer 2001).  
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Figure 1.1. Sub-anatomical sites of oral cavity.
Illustration of the anatomic sub-sites of the oral cavity lined by the squamous epithelium. 
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1.2.1 Epithelial differentiation and organization in oral mucosa 
 
Stratified squamous epithelium is generally made up of four different layers of cells which 
constitute the outermost cornified layer (stratum corneum), granular layer (stratum 
granulosum), spinal layer (stratum spininosum) and the basal layer (stratum basale) (Figure 
1.2). The keratinocytes present in the basal layer have the ability to divide and the cell 
division cessation occurs after the initiation of terminal differentiation as the basal 
keratinocytes start to move upwards until they reach the outermost surface layer. The 
foremost suprabasal layer of the differentiation compartment is the spinal layer whereas the 
stratum granulosum layer consists of cells that have entered into the stage of terminal 
differentiation. Cells finally reach the corneal layer with already terminal differentiated dead 
cells that are completely replaced by keratinocytes differentiating outwards (Fuchs 1993).  
1.2.1.1 Stratum basale 
 
The cells in the basal layer are cuboidal in shape with a higher nuclear: cytoplasmic ratio and 
are aligned in a perpendicular position to the basement membrane (Figure 1.2). Basal 
keratinocytes are supported by the specialized network of basal lamina and collagen fibrils 
with the help of hemi-desmosomes, the adhesion supporting structures, which connect the 
intermediate filaments to the extracellular matrix (ECM) (Burgeson & Christiano 1997). The 
stratumbasale is responsible for proliferation of all the epithelial tissue (Seery & Watt 2000) 
with the cornification process taking around 28-30 days. However, during excessive 
proliferation and wound healing, the estimated time may reduce further rapidly (Potten, 
Owen & Booth 2002). Keratins comprise of 85% of cellular protein in the keratinocytes 
(Presland & Dale 2000). Basal keratinocytes are supported by two important keratin 
filaments, KRT5 and KRT14 (Dale, Salonen & Jones 1990; Fuchs 1993). 
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Figure 1.2 Representation of structural epithelial organization of oral cavity. 
Morphological classification of the squamous epithelium of normal oral cavity as depicted 
after heamatological and eosin staining. SC: stratum corneum, SG: stratum granulosum, SS: 
stratum spinosum, SB: stratum basale, SE: squamous epithelium and CT: connective tissue. 
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1.2.1.2 Stratum spinosum 
 
The spinal layer, also known as the prickle layer, is the first and foremost layer of the 
differentiated epithelium. A gradual decrease of KRT5 and KRT14 expression can be 
observed in this layer whereas KRT1, KRT10 and KRT6/KRT16 filament expression is 
increased (Fuchs 1993). In the buccal mucosa, stratum filamentosum, an analogue of stratum 
spinosum, is present and has a unique pattern of KRT4 and KRT13 expression (Presland & 
Dale 2000). 
1.2.1.3 Stratum granulosum 
 
The keratinocytes present in this layer synthesize pro-filaggrin, the major protein that 
constitutes keratohyalin granules (Dale, Salonen & Jones 1990). Pro-filaggrin is converted 
into filaggrin and promotes keratinocytes to form flattened shapes(Candi, Schmidt & Melino 
2005). Stratum distendum, an analogue of stratum granulosum present in the buccal mucosa, 
do not contain keratohyalin granules but these keratinocytes consists of KRT4 and KRT13 
cytokeratins(Smith & Dale 1986). 
1.2.1.4 Stratum corneum 
 
The corneal layer is the outermost layer of squamous epithelium and most of the dead cells 
shed from its surfaces after undergoing autolysis due to activation of proteases (Candi, 
Schmidt & Melino 2005). KRT4 and KRT13 expression can be observed in this layer 
(Presland & Dale 2000). 
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1.3 Oral squamous cell carcinoma 
 
Most of the oral cancers are oral squamous cell carcinomas (OSCC) as they represent a 
similar group of neoplasms with common clinical presentation, risk factors, treatment and 
prognosis (Warnakulasuriya 2009). High mortality rates have been observed for oral cavity 
squamous cell carcinomas including oropharynx, hypopharynx, nasopharynx and larynx (Ho, 
Wei & Sturgis 2007). Poor survival rates of oral cancer patients are mainly due to a delay in 
diagnosis and minimal symptoms observed during the early stages of oral cancer (Califano et 
al. 1996). The 5-year survival rates for oropharynx, hypopharynx and nasopharynxcancers 
have improved with the use of surgery followed by adjuvant radiotherapy and chemotherapy, 
but there has been no improvement observed in the 5-year survival rates of oral cavity 
squamous cell carcinomas (Carvalho et al. 2005; Fan et al. 2014).  
1.3.1 Epidemiology 
 
An estimation of 274,000 new cases and 127,000 deaths occur worldwide annually due to 
oral squamous cell carcinoma(Ali, Wani & Saleem 2011). OSCC ranks in the top four most 
common types of cancer in South Central Asia, with a third of the world’s oral cancer 
population located in India.  In India, among males, 320,000 new cancer cases are annually 
diagnosed of which 19% are oral cancers and among females 350,000 new cancer cases arise 
with 7% being oral cancer (Ali, Wani & Saleem 2011; Naik et al. 2007; Parkin et al. 2005). 
In China, approximately 11,900 new cases are annually diagnosed and more than 5,000 
individuals die due to the disease (Parkin et al. 2005). Even though there is an easy 
accessibility of the oral cavity, mortality rates are still in high number as the disease is 
diagnosed at advanced stage.  Visual examination of oral cavity is the most widely used 
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screening test for oral cancer. Due to this, early stage cancers are not detected early 
(Sankaranarayanan et al. 2005).  
1.3.2 Etiological factors for OSCC 
 
Oral cancer aetiology is multifactorial and the most common risk factors include use of 
tobacco, excessive consumption of alcohol and chewing of betel quid (Warnakulasuriya 
2009). Major etiological factors for the cause of oral cancer include tobacco and alcohol 
leading to an impaired immune system in oral cancer suffering patients with increase in 
tumor progression and metastasis (Das, Khanna & Khanna 1986; Manchanda, Sharma & Das 
2006). Betel quid, also known as paan, contains areca nut from the Areca cathecu and slaked 
lime, which is enclosed in a betel leaf Piper betle (Gupta & Ray 2003). In south Asian 
countries, especially in India, paan consumption is common whereas this habit is not present 
in Papua New Guinea, Taiwan and China (Gupta & Warnakulasuriya 2002). Betel quid 
chewing is a risk factor for oral submucosal fibrosis and further OSCC development (Lee et 
al. 2011). Several chemicals like nitrosamines, N-nitoso-guvacoline and 3-propionitrile are 
present in the betel quid and the 3-propionitrile is a carcinogenic agent ('Betel-quid and 
areca-nut chewing and some areca-nut derived nitrosamines'  2004). The lime in the betel 
quid, calcium hydroxide, increases the pH to alkaline conditions in the oral cavity and this 
condition favours the reactive oxygen species (ROS) formation leading to damage of the 
epithelial cells ('Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines'  
2004). Excessive consumption of alcohol and tobacco use also increases the risk for oral 
cancer (Blot et al. 1988; La Vecchia et al. 1997). Tobacco consists of several carcinogenic 
agents predominantly aromatic hydrocarbons that initiate carcinogenesis in the oral tissues 
(Dipple et al. 1985). The by-products of nicotine (present in tobacco) metabolism further 
increase ROS resulting in genotoxicity(Bartsch et al. 1999). Due to changes in sexual 
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behaviour and lifestyle, human papilloma virus also poses a risk for increased occurrence of 
oral cancer (Ang & Sturgis 2012). 
1.3.3 Pre-malignant lesions in OSCC 
 
OSCC progresses due to sequential genetic variations initiated by epithelial modifications 
followed by dysplastic morphology and further progression into carcinoma (Schepman & 
Van der Waal 1995).  A precancerous lesion is characterized by the development of cancer 
prone properties due to an alteration in the tissue compared to normal tissue (Schepman & 
Van der Waal 1995). Recently, World Health Organization (WHO) has suggested the term 
“potentially malignant oral lesions” to describe the pre-malignant lesions (Warnakulasuriya, 
Johnson & van der Waal 2007). Most commonly occurring pre-malignant lesions are 
leukoplakia, erythroplakia and oral submucosal fibrosis (OSMF) (Figure 3). Transformation 
of pre-malignancy into malignancy for leukoplakia is 0.13% to 19.8% (Scheifele & Reichart 
2003). Erythroplakia is known to have a higher than 50% malignancy transformation rate 
(Bouquot & Ephros 1995). For OSMF 4.5% to 7.6% malignant transformation rate has been 
reported and chewing of areca nut is known to be the causative factor for OSMF (Sinor et al. 
1990). 
1.3.3.1 Leukoplakia 
 
According to WHO, oral leukoplakia is defined as a white lesion or patch that cannot be 
scraped or rubbed off (Abidullah et al. 2014). Occurrence of leukoplakia might be due to 
excessive tobacco use and leuoplakia often regresses due to termination of smoking habit 
(Abidullah et al. 2014). Leukoplakia is characterized by the expansion of epithelial cells with 
hyperplasia though cellular atypia is not observed. Abnormal patterns of keratinization, also 
known as hyper-ortho keratinization or hyper-para keratinization is observed. Hyper-
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orthokeratinization represents aberrant expansion of the cornified layer of epithelium while 
hyper-para keratinization shows incomplete patterns of keratinization in the cornified layer. 
Few oral leukoplakia lesions can display dysplastic morphology with pre-malignant features 
showing cellular atypia where the epithelial cells show loss of stratification and maturation 
(Warnakulasuriya et al. 2008). 
1.3.3.2 Erythroplakia 
 
Erythroplakia is described as a red analogue to leukoplakia characterized by a red lesion or 
patch that can be diagnosed by clinical examination (Boy 2012).  Appearance of 
erythroplakia lesions is rarely observed and the lesions show features of caricinomain-situ 
with a great potential for invasion and metastasis (Hunter, Parkinson & Harrison 2005).  
1.3.3.3 Oral submucous fibrosis 
 
Oral submucosal fibrosis is a chronic disease that affects the oral cavity with inflammation 
reaction and fibro elastic alteration of lamina propria resulting in the oral mucosa stiffness 
leading to an inability to open the mouth (Pindborg & Sirsat 1966). This condition is 
considered as a pre-malignant condition with respect to its conversion into the malignant 
stage (Warnakulasuriya, Johnson & van der Waal 2007). It is associated with betel nut 
chewing and excessive habitual chewing may result in malignancy of the oral cavity 
(Tilakaratne et al. 2006). 
1.3.4 Malignant lesion/squamous cell carcinoma 
 
Squamous cell carcinoma (SCC) is a malignant invasive epithelial lesion with characteristic 
features of squamous cell differentiation (Figure 1.3). Only a few dysplastic conditions can 
transform into a malignant epithelial cancer (Sugerman & Savage 1999) and most of the SCC 
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tumours of the oral cavity are bordered with adjacent dysplastic epithelium (Hogewind et al. 
1989). Stromal invasion does not appear clinically during the transformation of pre-malignant 
tissue into carcinoma in-situ(Warnakulasuriya et al. 2008). Further, the conversion of 
carcinoma in-situ into malignant and invasive cancer requires steps necessary for the 
degradation or break down of the basement membrane, the protective sheath of the oral 
squamous epithelium. The breakdown further allows the tumour cells to migrate and invade 
the stromal region and either grow into individual cells or as group of cells thus forming 
tumour islands (Kramer, Shen & Zhou 2005). As well, these tumour cells can enter into 
muscle, adipose tissue or bone, though some tumour cells show minimal invasive features 
(Hunter, Parkinson & Harrison 2005). Based on the resemblance with the normal epithelium, 
SCC is differentiated into three grades. Grade-1 is a low grade tumour that resembles normal 
epithelium and is well differentiated with defined spinal, basal and keratinized cells. The 
other characteristic features of these tumour cells include a large nucleus, high mitotic index 
and necrosis though cellular atypia. High grade (Grade -3) tumours show very little 
resemblance to the normal squamous epithelium of oral cavity with poorly differentiated cells 
and having remarkable features of tumour cells. Grade -2 tumours show intermediate features 
with moderately differentiated cells between high and low grade tumours (Akinyamoju et al. 
2013; Anneroth, Batsakis & Luna 1986). The histological grading of the tumours is 
problematic due to their accuracy (Noguti et al. 2012) and there is a requirement for more 
accurate clinical markers for diagnostic and prognostic purposes. 
1.4 Molecular pathogenesis of oral squamous cell 
carcinoma 
Oral squamous cell carcinoma development is a multistep progression that involves several 
environmental factors such as carcinogens and genetic predisposition (Califano et al. 1996). 
The aetiological factors discussed earlier can promote continuous inflammation that can 
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induce severe damage to genetic material leading to genetic variations. Further accumulation 
of these variations cause transformation of premalignant lesions into invasive carcinoma 
leading to activation of oncogenes and inactivation of tumour suppressor genes allowing cells 
to proliferate, invade and metastasize (Hanahan & Weinberg 2000).  
1.4.1 Genetic variations during OSCC development 
 
Based on the previous studies of genetic alterations in oral squamous cell carcinoma, the 
most common variation is loss of chromosomal region 9p21. This loss is an early event in 
oral carcinogenesis and is found in the majority of the dysplastic lesions of oral mucosa 
(Califano et al. 1996; Mao et al. 1996; van der Riet et al. 1994). This particular region 
encodes tumour suppressor genes inactivated by promoter hypermethylation p16 and 
p14ARF(Reed et al. 1996). During early carcinogenesis, loss of chromosome 3p region is yet 
another common event (Garnis et al. 2003). The chromosomal 3p region consists of tumour 
suppressor genes fragile histidine triad gene (FHIT) and RSSFIA (Figure 1.4) that are 
inactivated by hypermethylation and exon deletion (Dong et al. 2003; Kisielewski et al. 1998; 
Mao et al. 1996). Further transformation of pre-malignant lesions into malignant tumours 
occurs due to p53 mutation and loss of heterozygosity in the chromosomal region of 17p 
(Rousseau et al. 2001). Hence, loss of 9p, 3p and 17p is attributed as an early event occurring 
during dysplasia condition and loss of chromosomal regions 18q and 13q are usually 
observed in the oral malignant lesions (Califano et al. 1996).  
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Figure 1.3 Normal epithelium, pre-malignant and malignant condition of oral cavity. 
H & E section of oral epithelium of normal mucosa (A), moderate dysplastic condition of 
leukoplakia on the floor of the mouth (B), and squamous cell carcinoma of buccal mucosa 
(C).A and B are adapted from (Hunter, Parkinson & Harrison 2005) 
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Figure 1.4Genetic variations leading to multistep oral carcinogenesis. 
Normal mucosa transformation into dysplasia due to deletion and loss of heterozygosity at 
specified different chromosomal regions. Further amplification of cyclinD1 and mutation of 
p53 leads to oral carcinogenesis modified from (Lippman, Sudbo & Hong 2005). 
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1.4.2 Oncogenes and tumour suppressor genes 
Proto-oncogenes undergo genetic alterations and become oncogenes mediating signals of cell 
survival and growth leading to carcinogenesis (Klein & Klein 1985). These oncogenes 
encode proteins that can promote uncontrolled cell division by overriding the checkpoints at 
G/M, G/S and M-phase of the cell cycle (Field 1995). Tumour suppressor genes mediate 
negative regulation of cell growth (Weinberg 1991). These genes transduce signals to induce 
cell cycle arrest and promote apoptosis. In contrast to oncogenes that acquire mutations in a 
single alleles of the gene for their activation, tumour suppressor genes are often inactivated in 
cancers by means of several processes that include deletion and/or point mutation occurring 
in both alleles of the genes (Yokota & Sugimura 1993). Inactivation of tumour suppressor 
genes leads to uncontrolled cell division and malignant phenotype (Levine 1997). 
Carcinogens released from excessive alcohol and tobacco use lead to mutations in tumour 
suppressor and proto-oncogenes further leading to uncontrolled cell proliferation (Hecht 
2003; Rodu & Jansson 2004). Previous studies have reported mutations in proto-oncogenes 
such as RAS, MYC, CCND1 and EGFR contributing to gain of function properties leading to 
evasion of apoptosis and promotion of uncontrolled cellular growth (Vogelstein & Kinzler 
2004). Mutations in tumour suppressor genes contribute to loss of function for controlling the 
cell growth and division. Tumour suppressor genes like RB, TP53, p16INK4A/p14ARF and 
PTEN were reported in OSCC (Vogelstein & Kinzler 2004). Accumulation of genetic 
variations for about 20 to 30 years will eventually precede to the progression of OSCC 
(Schwartz 2000).  
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1.4.3 Field Cancerization 
 
Field cancerization was first described in 1953 while examining pathological slides of head 
and neck cancer patients (Slaughter, Southwick & Smejkal 1953). It was found during the 
examination that most of the epithelium surrounding tumours had undergone morphological 
changes and some patients were showing an independent malignant area. It was concluded 
from this observation that due to over exposure of carcinogen, the affected area will be more 
susceptible to multiple foci development of malignant transformation. Many researchers have 
since made an effort to find the molecular mechanisms underlying field cancerization. The 
clinical manifestations of field cancerization can arise due to individual molecular events 
affecting many cells distinctly, or a molecular event occurring in a single progenitor clone 
that results in clonal expansion or alternate ways of undergoing adjacent spread across the 
mucosa (Slaughter, Southwick & Smejkal 1953). Alterations in a single cell occurs either by 
activation of an oncogenes and/or inactivation of a tumour suppressor gene leading to a 
growth advantage and expansion into clone forminga mass of cells or a tumour (Fearon & 
Vogelstein 1990). The genetic variations that occur depend on environmental factors and 
vary from individual to individual.  
1.4.4 Molecular outcomes towards field cancerization 
 
Accumulation of genetic alterations results in a range of tumours with different stages such as 
benign, potentially malignant and malignant (Fearon & Vogelstein 1990). Low expression 
levels of type2 ABH antigen was found in the surrounding normal mucosa of head and neck 
SCC (HNSCC) tumours in comparison to the normal mucosa of healthy individuals, which 
makes ABH type 2 antigen a promising negative marker (Bongers et al. 1996). Cyclin D1 
was found in the surrounding normal mucosa of the HNSCC tumours in comparison to the 
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normal mucosa of healthy individuals (Bartkova et al. 1995). Epidermal growth factor 
receptor (EGFR) was found to be elevated in the normal mucosa that is associated with the 
tumours (Eisbruch et al. 1987). Increased TGF-α mRNA expression was observed in tumour 
associated normal mucosa in comparison to normal mucosa (Szymanska et al. 2010). B-cell 
lymphoma 2 (BCL2) expression was absent in the tumour associated normal mucosa in 
comparison to the healthy normal mucosa (Birchall et al. 1997). Vascular markers (CD31, 
αvβ3, VwF and α-SMA) were elevated in the normal mucosa surrounding tumours in 
comparison to normal mucosa without tumours (El-Gazzar, Macluskey & Ogden 2005). The 
most important marker for field cancerization is p53 and p53 positive cells were found to be 
increase progressively from normal to dysplasia to carcinoma (El-Gazzar, Macluskey & 
Ogden 2005; Shin et al. 1994). The above molecular findings suggest that the normal mucosa 
surrounding tumours exhibit several genetic alterations in comparison to healthy normal 
mucosa. Additional research is required to determine whether the markers expressed 
exceptionally in normal mucosa associated with the tumours have carcinogenic influence. 
1.5 Microarray as a platform for gene expression 
profiling of OSCC 
 
Oral cancer involves a number of anomalous genetic events occurring at the molecular level 
resulting in low grade dysplasia to malignant tumours. For normal cells to become 
transformed and tumorigenic there are several factors that influence the staged progression of 
oral cancer namely, environmental exposure, carcinogens, dietary habits etc. However, the 
events that occur for the development of precancerous lesions to malignant tumours are not 
yet fully understood (Kao et al. 2009). Recent studies reveal that transformation of 
precancerous cells to cancer cells is associated with several genetic aberrations (tumour 
promoting and tumour suppressor genes) comprising events of somatic mutations followed 
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by epigenetic factors, environmental factors like cytokines, growth factors, hormones, 
vitamins and prostaglandins(Kao et al. 2009). These conditions can change the nature of the 
cells for enabling, impeding or prohibiting their transformation into tumor cells, or even 
changing them to the normal phenotype. In addition, these sequences of events act on 
biological molecules such as DNA, RNA and cell processes such as protein synthesis, cell 
replication, cell cycles, cell communication and thus can be helpful in determining potential 
biomarkers for early detection of precancerous cells and cancer cells (Kao et al. 2009). The 
outcome of the Human Genome Project and microarray technology has provided an 
opportunity for researchers to analyze the role of genes in studying cancer progression. The 
microarray platform can be used in many ways such as finding copy number variations, 
single nucleotide polymorphisms, measuring gene level changes and methylation of 
promoters (DeRisi et al. 1996). Recently several genes have been identified using microarray 
technology (Figure 1.5)especially gene expression arrays, that specifically relate to squamous 
cell carcinoma of the oral cavity(Table 1.1).  
The use of microarray for gene expression profiling was described in 1995 (Schena et al. 
1995) and eukaryotic whole genome profiling was reported in 1997 (Lashkari, McCusker & 
Davis 1997). The number of gene expression studies has increased since then and it has been 
developed as a routine tool in studying the carcinogenesis and most of the OSCC related 
microarray studies have observedchanges in the expression profiles of OSCC(Churchill 
2002). Further development of whole exome arrays has enabled researchers to find the genes 
and pathways changed in an unbiased manner even at the single gene level resulting in 
understanding more complex changes and the pathways associated with the development and 
progression of cancer (Weber 2002). Gene expression profiles help to identify biomarkers 
that allow differentiation between normal and pre-malignant lesions, to identify and 
differentiate tumour subgroups and also to identify and predict clinical behaviour (Ha et al. 
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2009; Viet & Schmidt 2010). Several studies have used gene expression arrays and identified 
gene expression profiles that distinguish between malignant carcinoma, pre-malignant lesions 
and normal samples (Table 1.1).  
Cluster analysis of gene expression profile studies indicate that malignant tumours and pre-
malignant lesions cluster together apart from the normal mucosal epithelium supporting the 
fact that aberrations in gene expression often start before the development of malignancy(Ha 
et al. 2003; Mendez et al. 2002). Using gene expression profiling, a 25 gene signature panel 
was found to distinguish malignant OSCC tumours and the normal mucosa and further 
validation study of this panel showed an accuracy of 87% on three individual datasets (Ziober 
et al. 2006). Premalignant lesion (leukoplakia) were also distinguished from OSCC malignant 
cancer in a gene expression profile study and the findings suggested a panel of 11 genes to 
distinguish the two samples types with an almost 97% accuracy (Kondoh et al. 2007). 
Another study showed a nine gene signature to differentiate malignant lesions, premalignant 
lesions and normal mucosa (Liu et al. 2011). Even though these results determined the 
outcome of gene expression profile studies which may be exploited as biomarkers for 
diagnostic or prognostic purposes in the clinical setting, the outcome of each of these studies 
differ from each other due to the ethnicity, patient history and selection, using different array 
platforms and tumour heterogeneity.  
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Figure 1.5Gene expression array using microarray technology. 
RNA is isolated from the tumour samples collected either before treatment or during surgery 
and labelled with a detectable fluorescent dye marker, and hybridized on the array chip 
containing specific gene probes. Based on the fluorescent intensity of the gene probe, the 
expression levels of the genes are measured and summarized using normalization methods. 
Gene expression patterns are classified based on the intensity or expression changes and 
samples can be classified. 
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Table 1.1Selected gene expression studies of OSCC. 
 
Microarray 
Platform 
Genes 
Identified Findings Cohort References 
Illumina 648 
Genes related to ECM and inflammation 
may become markers for early prediction 
Normal – 12; 
Tumor -12 
(Tanis et 
al. 2014) 
Affymetrix 2207 
25 gene signature to predict non-oral 
tumors with 87% accuracy 
Normal- 13,  
Tumor - 13 
(Ziober et 
al. 2006) 
CLIA/ISO 696 
Differentiating nodal metastasis from 
non-nodal metastatic samples 
Samples- 94 
Validation -222 
(van Hooff 
et al. 2012) 
Affymetrix 167 
Genes that can differentiate between 
radio-sensitive and radio-resistant cells 
HSC2- 
radioresistant 
HSC-3 
Radiosensitive 
(Ishigami 
et al. 2007) 
Agilent 263 
Cell communication and integrin 
mediated cell adhesion pathways 
significantly differentiate 
Normal – 15 
OSCC – 15 
(Suhr et al. 
2007) 
Affymetrix 131 
LAMC2, COL4A!, COL1A1 and PADI1 
was significantly differentiating normal 
and cancer samples 
OSCC-119 
Normal - 35 
(Chen et al. 
2008) 
Affymetrix 281 
Genes related to immune response and 
epithelial differentiation found to be 
significantly over expressed 
Normal – 8 
OSCC - 9 
(Cheong et 
al. 2009) 
Illumina NA 
Proinflammatory cytokines and immune 
response genes responsible for OSCC 
progression 
Normal –HOK 
OSCC- SCC9, 
SCC15, SCC25 
(Rao et al. 
2010) 
Acegene, 
HSKbio 
20 gene 
signature 
20 gene signature panel was identified 
with 88% accuracy to differentiate 
positive and negative nodal groups 
OSCC – 15 
Normal – 15 
(Kato et al. 
2006) 
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Differential gene expression patterns were used to distinguish between HPV positive and 
HPV negative oral squamous cell carcinoma (Martinez et al. 2007). Recently, several 
biomarkers were identified from several studies but these biomarkers lacked sensitivity and 
specificity towards the early detection of oral cancer (Table 1.2). Genes that play an 
important role in the progression of malignant OSCC, TYMS and CCND1 were sensitive to 
chemotherapeutic agents, cisplatin and fluorouracil, while the RBBP4 gene was sensitive to 
radiation therapy as revealed by gene expression studies (Lohavanichbutr et al. 2009). Many 
genome profile studies have provided an understanding of the nature of OSCC tumours by 
providing information on the abnormal genes and pathways that play an important role in 
carcinogenesis (Suhr et al. 2007; Toruner et al. 2004; Ziober et al. 2006). However, most of 
these studies have tried to decipher the specific pathway, mechanism or gene underlying the 
cancer progression. Since there is an absence of a universal tumor marker, a combination of 
several markers may be useful and more accurate for oral cancer. Combination of several 
candidate biomarkers resulted in 90% sensitivity and 83% specificity in oral cancer detection 
(Hu, Loo & Wong 2007). 
In the era of personalized medicine, it is important to provide the analysis as part of an 
holistic approach which considers gene expression level changes in the whole genome. 
Further, a set of genes in the major pathways can be considered as a gene panel for the 
prediction of the disease with more sensitivity and specificity.  
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Table 1.2Recent biomarkers discovered for diagnostic, prognostic and therapeutic 
purpose from selected studies. 
 
Markers  Function Negative aspects Study 
Podoplanin Marker for oral cancer risk 
in OPL patients 
Needs validation in larger 
studies 
(Kawaguchi 
et al. 2008) 
SbdYWHAZ
, 
Stratifin&hn
RNPK 
Constitute OPL biomarkers Validation in larger studies is 
required 
(Matta et al. 
2008) 
PTEN Lack of PTEN expression 
may be prognostic factor of 
the SCC of tongue 
Validation in larger studies is 
required 
(Baldwin 
2001) 
CYP1A1, 
GSTM1 & 
Zinc finger 
protein 217 
 Polymorphisms in these 
genes have high risk of 
OSCC 
Validation in larger studies is 
required 
(Sato et al. 
1999) 
MMP-2 To identify metastatic 
phenotype and treatment 
monitoring in oral cancer 
Validation in large number of 
samples 
(Patel et al. 
2007) 
OPN Osteopontin expression in 
OSCC is associated with 
tumor progression and can 
serve as prognostic factor 
In many cancer conditions it has 
worse prognosis. Information 
has to be more clear by the 
studies from the tissue arrays 
(Chien et al. 
2009) 
Glut-1 Can be used as prognostic 
marker for routine 
assessment of OSCC 
Has to be tested at diagnosis 
stage in larger number of OSCC 
samples 
(Eckert et al. 
2008) 
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1.6 Oral cancer treatment strategies 
 
Present treatment strategies for early stage (I and II) oral cancer includes either surgical 
procedures or radiation therapy. For late stage cancers (III and IV), treatment is usually  
surgery followed by radiation therapy (Fujii 2014). With the combination treatment of 
surgery with radiotherapy (pre or post operation) and/or chemotherapy, there has been no 
marked increase in the 2-year and 5-year survival rates for late stage oral cancer patients 
which currently is approximately 20% and 12% respectively (Reichard et al. 1993). The aim 
of cancer treatment is to eradicate the tumour, repair the affected area and avoid subsequent 
tumour recurrence. The objective of treatment changes in incurable cases and treatment is 
given for improving the quality of life until patient’s death (Shah & Gil 2009). Radiation 
therapy is given as a treatment along with surgery or chemotherapy to destroy cells that are in 
mitosis by DNA fragmentation, though treatment can also damage the surrounding normal 
cells (Mazeron et al. 2009). Also, treatment by surgery can lead to functional loss of oral 
structures (Parsons et al. 2002). Radiotherapy cannot be used as a treatment before surgery in 
OSCC patients as it can lead to increase in the fibrosis condition of the tumour tissues 
(Spencer, Ferguson & Wiesenfeld 2002).  Chemotherapy is a general treatment given to 
OSCC patients before surgery or post-surgery in combination with radiation therapy to 
reduce tumour volume and metastasis by destroying the malignant cells (Calais et al. 1999). 
The common drugs used for treating OSCC include 5-fluorouracil, methotrexate and 
hydroxyl urea (Zheng, Qiu & Zhang 2008). Targeted drugs like cetuximabare used to target 
epidermal growth factor receptor (EGFR) that is abnormally over expressed in carcinomas 
and its expression further increases due to radiation therapy (Eriksen et al. 2004). Treatment 
with chemotherapeutic drugs is related to frequent toxicity in patients with OSCC and tumour 
cells try to switch on alternate pathways if a single molecule is targeted, and hence long term 
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treatments often result in patient relapse due to recurrence (Forastiere et al. 2003).Recent and 
advanced treatment strategies include viral-therapy, immunotherapy, cancer vaccines and 
gene therapy which require further research and are still in the early stage of development 
(Gebremedhin et al. 2014; Ladeinde et al. 2005; Lim et al. 2014). Recent evidence suggests 
that oral cancer occurrence and progression is mainly due to inflammation (Gallego, Junquera 
& Llorente 2009; Piemonte, Lazos & Brunotto 2010). Therefore, most of the recent studies 
are trying to target chronic inflammation for improving the survival rates of oral cancer 
patients (Hsu et al. 2012; Rao et al. 2010). 
1.6.1 Chronic inflammation as a target in oral cancer treatment 
 
Chronic inflammation due to continuous exposure to chemical, viral and bacterial agents 
increases risk for cancer occurrence (Hussain & Harris 2007). Abnormal regulation of 
inflammatory signalling due to certain autoimmune responses and constant soft tissue injury 
can also contribute to high risk of cancer (Schafer & Werner 2008). Accumulation of 
chemokines, cytokines, reactive oxygen species, prostaglandins and nitrogen radicals in the 
tissue microenvironment occurs due to chronic inflammation (Colotta et al. 2009). Repeated 
exposure to these inflammatory responses lead to inactivation of tumour suppressor genes 
and activation of oncogenes further resulting in uncontrolled cell division followed by genetic 
instability with increased susceptibility to cancer (Moore et al. 2010). Chronic inflammation 
occurs commonly in oral mucosa and it is rare for these inflammatory responses to induce 
cancer progression i.e., unless the inflammation is recurrent with strong inflammatory 
response and/or followed by over exposure to the carcinogens (Mantovani 2010). Further, the 
altered cells due to changes in the microenvironment of the tissue due to increase in the 
immune response elements also influence genes that control proliferation (Grivennikov, 
Greten & Karin 2010).  
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1.6.2 The relationship between tumorigenesis and inflammation 
 
Several agents such as alcohol, tobacco and several other infectious agents mediate 
inflammation by activation of nuclear transcription factors, the activator protein 1(AP1), 
signal transducers and activators of transcription 3 (STAT3) and the nuclear factor NB 
(NFNB). The downstream effect of these molecules after their activation include regulation of 
cell proliferation, apoptosis, angiogenesis and production of several pro-inflammatory 
cytokines, including prostaglandins, proteinases and growth factors (Aggarwal & Gehlot 
2009; Aivaliotis et al. 2012; Hussain & Harris 2007). Therefore, these transcription factors 
direct tumour cells in inducing unrestrained cell division and inflammation (Figure 1.6).  
Cancers that develop rapidly show a high inflammatory response, further inducing the 
genomic instability by secretion of reactive nitrogen species and reactive oxygen species that 
lead to DNA damage and deregulation of processes such as DNA damage repair, checkpoint 
control in the each phase of the cell cycle and regulation of apoptosis (Schafer & Werner 
2008). Induction of cell proliferation and differentiation by reactive nitrogen species occurs 
through the mitogen activated protein kinase signaling pathway and these factors not only 
suggest a role for inflammation in cancer development and progression but also in the initial 
transformation of cells(Schafer & Werner 2008). The transcription factors, NF-κB, AP1 and 
STAT3 induce over expression of apoptotic inhibitory and cell cycle checkpoint genes, 
survivin, cyclin-D, MC1, c-MYC, BCL2 and c-FLIP leading to loss of genomic instability 
(Aggarwal & Gehlot 2009).  Among the prostaglandin family members that induce 
inflammation, prostaglandin E2 (PGE2) is the most involved member in tumorigenesis (Kim 
et al. 2010).   
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Figure 1.6Representation of interaction between inflammation and cancer. 
Transcription factors, AP1, STAT3 and NFkB, regulate activation of oncogenes and produce 
inflammatory response that contributes towards cancer progression and development. 
Modified from (Mantovani 2010). 
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Cyclooxygenase 2 (COX2) is required for the synthesis of PGE2, and COX2 expression 
levels are increased in epithelial tumours (Chen et al. 2004; Kim et al. 2010).  Chemical 
metabolites secreted by the excessive consumption of betel quid, areca nut, tobacco and 
alcohol leads to production of higher amounts of reactive oxygen species, prostaglandins, 
IL8, TGFE, IL6, TNFD, fibroblast growth factor and platelet derived growth factor by 
inflammatory cells and oral keratinocytes to stimulate fibrosis(Border & Noble 1994; Chiang 
et al. 2002; Chiu et al. 2001; Khan et al. 2012). The evidence above clearly suggest a role for 
inflammation for promoting uncontrolled cell proliferation for the development and 
progression of cancer. Hence, there is a strong requirement for the study of compounds that 
can show a broad spectrum inhibitory effect on the genes and the pathways that are not only 
associated with promotion of inflammation process but also on cell cycle progression 
pathways of oral cancer. 
1.6.3 Role of non-steroidal anti-inflammatory drugs in controlling 
inflammation and cancer progression 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) includes indomethacin, sulindac, 
piroxicam, ibuprofen and aspirin (acetylsalicylic acid), compounds that are structurally 
different but with a similar action inhibiting the inflammation process, and which impact on 
the activity of cyclooxygenase (COX)  enzymes for altered synthesis of prostaglandins 
('Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, 
myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of 
patients. Antiplatelet Trialists' Collaboration'  1994).NFkB activation is associated with an 
increased tumorigenicity and resistance to chemotherapeutic agents and hence it is considered 
a target for anti-tumour therapy (Kim, Hawke & Baldwin 2006; Verma 2004). Aspirin is 
known to inhibit the NFkB activity by interacting with IKKB (Kim, Hawke & Baldwin 
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2006).  Cyclin D1 is known to be a regulator for cell cycle progression and it is often over-
expressed in tumours (Khan et al. 2014). Therefore it is also considered as a potential 
therapeutic target for the prevention of cancer (Musgrove et al. 2011). Most of the NSAIDs 
down regulate the expression of cyclin-D1 by repressing NF-κB activity in the tumour cells 
(Takada et al. 2004). Aspirin is an acetyl salicylic compound known to show anti-
inflammatory properties by inhibiting cox-2 and NF-κB mechanisms further inhibiting the 
pro-inflammatory cytokine production ('Collaborative overview of randomised trials of 
antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged 
antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration'  
1994). Aspirin reduces the incidence and mortality rates of several cancers as well as 
cardiovascular diseases ('Routine aspirin or nonsteroidal anti-inflammatory drugs for the 
primary prevention of colorectal cancer: U.S. Preventive Services Task Force 
recommendation statement'  2007). The benefit of aspirin in prevention of colorectal cancer is 
now well established (Ferrandez, Piazuelo & Castells 2012). The risk of colorectal cancer 
development has been reduced by 50% among individuals consuming aspirin in comparison 
to individuals not using aspirin (Suh, Mettlin & Petrelli 1993). Recently, the beneficial effects 
of aspirin were observed in oesophageal cancers, gastric cancers, lung cancers, breast cancers 
and prostate cancers (Algra & Rothwell 2012; Bosetti et al. 2012; Burn et al. 2011; Chan et 
al. 2007; Dhillon et al. 2011; Jacobs et al. 2012). Aspirin is a common drug consumed by 
people in general and further studies investigated that the use of aspirin can reduce the risk of 
head and neck cancer (Wilson et al. 2011). Aspirin at low concentrations induced apoptosis in 
oral cancer cells and the effect appeared to be specific as there was no effect on normal oral 
keratinocytes(Rao et al. 2010). Aspirin can also inhibit NF-κB activity which is responsible 
for promoting the inflammatory response in oral cancer cells, and aspirin also inhibited 
several pro-inflammatory cytokines (Rao et al. 2010). Aspirin is better known for its anti-
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inflammatory activity in oral cancer and other cancer cells as described earlier but there is 
lack of understanding of the molecular mechanisms employed by aspirin which will enable 
improved understanding of its effects on the expression and regulation of genes that are 
targets in oral cancer prevention. 
1.7 Gene therapy in OSCC 
The main aim of gene therapy is to introduce genetic material into the target cells without 
causing any damage to the normal cells or tissues (Xi & Grandis 2003). Oral cancer can be 
targeted using a gene therapy approach either by direct application or injecting the agent 
directly into the tumour due to easy accessibility of primary and recurrent tumours (Xi & 
Grandis 2003). Aberration of tumour suppressor gene, p53 is an early event in oral 
carcinogenesis and the p53 gene is mutated frequently in oral squamous cell carcinomas 
(Lopez-Martinez et al. 2002).  The p53 gene was frequently altered and mutated in oral 
squamous cell carcinoma and therefore was targeted using gene therapy using adeno-viral 
vector Ad5CMV-p53 and this application is currently in the phase III clinical trials. It is 
applied through intramucosal injection which is followed by a mouth wash(Liu et al. 1994). 
This treatment has been  shown to inhibit the progression of the disease in pre-malignant 
lesions without any toxic effects (Liu et al. 1994). Mice studies using intra-tumoral injection 
of Allovectin-7 (USA) repressed the growth of tumours in the head and neck region(Gleich 
2000). This drug leads to a combination and co-expression of leukocyte antigene (HLA-B7) 
with the beta2-microglobulin gene. This study has progressed to the pre-clinical stage but 
further studies have to be conducted prior to human studies (Gleich 2000). Therapeutic 
recombinant proteins encapsulated in a microcapsule form are capable of secreting an 
important angiogenic inhibitor, angiostatin, which can be localized to the tumours without 
affecting the other organs (Cirone, Bourgeois & Chang 2003). 
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Transfection is a predominant tool that comprises of introduction of foreign nucleic acids into 
cells to study functions of gene and its products in the cells (Recillas-Targa 2006). Genetic 
material can be inserted into the genome and can be stably transfected where cells can 
express the gene and synthesize the protein(Glover, Lipps & Jans 2005). Studies using 
knockdown of specific genes arealso emerging as a powerful technique to study the changes 
in the phenotype of the cell (Brazas & Hagstrom 2005). The siRNA duplexes specific for a 
gene introduced into the cell forms RNA-induced silencing complex (RISC) that inhibits the 
specific gene expression (Castanotto & Rossi 2009). Overexpression of miRNA-126 in the 
OSCC cell line, SCC15, induced apoptosis and suppressed the cell proliferation, invasion and 
colony formation ability of the cells indicating its role as tumour suppressor gene (Yang, Wu 
& Ling 2014). Several recent transfection studies performed in oral squamous cell carcinoma 
cell lines provided functional information of each genes differentially regulated in OSCC 
samples (Table 1.3).Understanding the functional role of genes is essential in anti-cancer 
research and transfection studies can give a clear picture of the role of specific genes in 
tumour progression. Knowing the functional aspects of the gene provides information on the 
potential role of the gene in tumour progression or suppression. 
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Table 1.3Functional aspects of genes that were recently studied in OSCC using 
transfection procedures. 
 
Gene Purpose of transfection  OSCC cell line Effect Reference 
ADAM17 Overexpression SCC9 Induces cell proliferation 
(Simabuco 
et al. 2014) 
miR-29a Overexpression SCC25 Inhibit tumorigenesis 
(Lu et al. 
2014) 
CDC7 Overexpression SCC9 Induce cell proliferation 
(Cheng et 
al. 2013) 
miR-125b Overexpression HSC2 & HSC3 Decreases cell proliferation 
(Shiiba et 
al. 2013) 
Flotillin-1 Knockdown Tca8113 Decreases cell proliferation 
(Xiong et 
al. 2013) 
Lin28a Overexpression TOSCC23 Increases cell proliferation 
(Hayashi et 
al. 2013) 
Survivin Knockdown HSC3 Decreases cell proliferation 
(Su et al. 
2010) 
CCND1 Knockdown Tca8113 Decreases cell proliferation 
(Zhou et 
al. 2009) 
ORAOV1 Knockdown CAL27 Induces apoptosis 
(Jiang et 
al. 2008) 
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1.8 Extracellular matrix remodelling 
 
Carcinoma includes tumour cells supported by the stromal microenvironment consisting of 
fibroblasts, blood vessels, inflammatory cells and seldom myofibroblasts(De Wever et al. 
2008; Kellermann et al. 2007). Recent evidence indicates that the stroma not only supports 
the carcinoma cells but also plays a major role in developing the malignant 
phenotype(Khamis et al. 2011). Stromal alterations have been reported in many malignancies 
including oral squamous cell carcinoma (Desmouliere, Guyot & Gabbiani 2004; Lewis et al. 
2004; Sobral et al. 2011). Inflammation supports the tumour microenvironment by providing 
essential factors to the tumour microenvironment(Lisanti et al. 2014). It provides growth 
factors, survival factors that inhibit apoptosis; factors that promote angiogenesis, enzymes 
that can degrade or modify the extracellular matrix (ECM) remodelling that allows the 
processes of  invasion and metastasis, angiogenesis, and also signals that facilitate the 
activation of epithelial mesenchymal transition (EMT) (Hanahan & Weinberg 2011). The 
inflammation process allows the release of reactive oxygen species into the tumour 
microenvironment creating a chain of genetic responses by inducing mutations in the genetic 
material for which inflammation is emerging hallmark of cancer (Hanahan & Weinberg 
2011). Small changes in the stiffness and composition of the ECM selectively either support 
or halt the cellular proliferation by controlling the expression of genes associated with cell 
cycle regulation and progression (Dike & Ingber 1996; Huang, Chen & Ingber 1998; Rana et 
al. 1994). ECM plays an important role in the regulation of cellular differentiation processes 
and cytoskeleton architecture (Roskelley, Desprez & Bissell 1994). Changes in the ECM 
composition or structure can lead to fibrosis, where stiffening of tissue occurs due to 
increased deposition and crosslinking of collagen, and fibrosis is often associated with an 
increased risk of developing cancer (Colpaert et al. 2003; Martin & Boyd 2008). The 
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interaction between the extracellular matrix and the cells through cell surface adhesion 
receptors drives the process of differentiation and leads to cancer development(Daley & 
Yamada 2013; Tlsty & Coussens 2006). Fibrosis of tissue and changes in ECM composition 
may lead to tumour development and progression by regulating factors secreted by 
inflammation and angiogenesis (Balkwill, Charles & Mantovani 2005; Coussens et al. 1999).  
1.8.1 Extracellular matrix and mammary gland 
 
The mammary gland is a distinctive organ that undergoes morphological changes at puberty, 
pregnancy, lactation and involution(Topper & Freeman 1980). Branching of the ducts occur 
laterally to form tree like structures with simultaneous proliferation and differentiation of 
epithelial cells occurs during pregnancy and lactation, and during involution the epithelial 
cells undergo apoptosis and the tissue remodelling that returns the mammary structure to its 
virgin state (Gjorevski & Nelson 2011; Watson & Khaled 2008). It is a unique model to study 
tissue remodelling as the activity of the matrix metallo proteinases (MMPs) in mammary 
tissue are very high during involution. The MMPs are ECM degrading enzymes synthesized 
as zymogens and their action can be inhibited by tissue inhibitors of metalloproteinases 
known as TIMPs (Egeblad & Werb 2002; Sternlicht & Werb 2001). Other than MMPs, 
cysteine proteases called cathepsins are also secreted in higher amounts during involution 
(Guenette et al. 1994). Laminin-5 cleavage occurs during involution to produce the bioactive 
products as reported in previous studies (Giannelli et al. 1999; Schenk et al. 2003). One study 
reported that breast cancer cells co-injected with the extracellular matrix isolated from the 
involuting mammary gland showed aggressive tumours with metastasis to liver, kidney and 
lung in comparison to the cells co-injected with ECM isolated from nulliparous mammary 
gland (McDaniel et al. 2006). During involution, several inflammatory response elements are 
elevated including COX-2, which is a target towards cancer prevention (Kwan et al. 2007). 
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During weaning the involuting mammary gland undergoes several changes including increase 
in the inflammatory responses leading to an increase in the risk of breast cancer, especially 
pregnancy associated breast cancer post-partum and NSAIDs can reduce the tumour 
promoting ability of the involuting mammary ECM (Lyons et al. 2011; O'Brien et al. 2011). 
Earlier studies indicated that during lactation, the proliferation of mammary epithelial cells 
decreases (Capuco et al. 2003; Knight & Peaker 1982). Expression levels of proteases and 
their inhibitors in the extracellular matrix are reciprocal during lactation and involution 
periods of mammary gland development (Green & Lund 2005). Reduction in the proliferation 
of mammary epithelial cells during lactation may be due to regulatory signals from the 
extracellular matrix. Recent studies from our laboratory revealed that ECM modulates the 
behaviour of mammary epithelial cells in culture and these cells are regulated by the phase of 
lactation from which the ECM was isolated (Wanyonyi et al. 2013). If the ECM of lactating 
mammary gland can contribute towards the reduction in the cell proliferation of cancer cells, 
it would be interesting to examine the effects of different cancer cell lines.  
1.8.2 Targeting the micro environment of the tumour 
Several studies have been performed to target the tumour micro environment using various 
methods of delivery approaches such as cytokines, vectors, cytokines, gels, targeted systemic 
therapy and nanoparticles (Gandhi, Tekade & Chougule 2014; Omidi & Barar 2014; Yin et 
al. 2014). In addition, most of the studies on animal models and humans have demonstrated 
that direct injection of antibodies, cytokines and chemotherapeutic agents into intra-tumoral 
region is effective and feasible (Nelson, Fisher & Robinson 2014). Intra-tumoral direct 
injections are performed in humans using the help of computed tomography and has been 
successfully implemented in liver cancer (Livraghi et al. 1986), melanoma (Oratz et al. 
2003), colorectal cancer (Mariani et al. 1993), lung cancer (Celikoglu et al. 2006) and also in 
head and neck cancer (Duvillard et al. 2004). The modified ECM components of the tumour 
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microenvironment can be normalized thereby reducing malignancy of the tumour cells 
(Vosseler et al. 2005). Therefore, growing evidence and frequency of research studies 
indicate that targeting the tumour microenvironment is very essential to control the tumour 
growth and development. 
1.9 Summary and aims of the study 
Hypothesis: Many recent gene profile studies have identified a single gene or protein that 
might be responsible for oral cancer progression. In the era of personalized medicine, oral 
cancer treatment is still a challenge to clinicians due to lack of knowledge on the broad 
effects of genes and/or pathways responsible for oral cancer progression. Understanding these 
mechanisms will lead to the discovery of biomarkers that are of diagnostic, prognostic and 
therapeutic relevance. 
Summary: Oral squamous cell carcinoma (OSCC) is a cancer with high incidence and 
mortality rates in comparison to other malignancies. It is unfortunate that most malignant oral 
tumours go unnoticed until they are in advanced stages. Even though there is a lot of interest 
in new diagnostic and prognostic methodology in the last few years, there is still a lack of 
specific tumour markers for the identification of malignant lesions of the oral cavity. The 5-
year survival rates of OSCC have not improved in the last few decades due to an absence of 
clinically proven markers and the high mortality rates in oral cancer is mainly due to 
diagnosis of the disease in advanced stages. The collective efforts of genomics approaches 
can be used as a tool to identify unique markers that can be used for prognostic, diagnostic or 
therapeutic potential for OSCC. Oral cancer is one of the few cancer types where it is 
possible to obtain biopsies at all stages of carcinogenesis. Hence, it is possible to define a 
genetic progression model of this disease which will enable the discovery of early markers 
that can predict the diagnosis, prognosis and if possible therapeutics of the disease. The 
molecular mechanisms, pathways and processes involved in the progression of oral cancer by 
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gene profiling of oral cancer genome determined in a broader picture will provide clues 
towards the identification of biomarkers for diagnostic, prognostic and therapeutic purposes. 
Aspirin is widely used as an anti-inflammatory drug but the other molecular mechanisms to 
induce anti-tumorigenic properties are still not known. Therefore, understanding the 
molecular targets of aspirin will give a clear picture to determine whether it can target the 
candidate genes that are potential targets in prevention of oral cancer. ECM is a connecting 
bridge between cells and the extracellular environment and the earlier studies indicated that 
mammary ECM from lactating animals can reduce proliferation and also controls cellular 
behaviour of epithelial cells. It is still not clear if the ECM controls the growth of cells during 
lactation. 
The specific aims of this study are: 
 Collection of biopsy samples from patients with early (stage I and II) and late 
(stage III and IV) stage OSCC including their surrounding normal mucosa. The 
first aim of the study is to identify a gene profile of advanced stage oral cancer in 
comparison to the paired normal mucosa samples by using microarray analysis 
and further pathway analysis to understand the molecular mechanisms that 
underpin oral cancer progression. Ethically approved human oral cancer samples 
will be used for the purpose of this study. 
 The second aim of the study is to understand the therapeutic role of aspirin in 
controlling oral cancer progression by describing the gene profile of aspirin 
treated cells in comparison to non-treated oral cancer cells by using microarray 
analysis. This study will also use in-vitro tumorigenic studies to examine the 
effects of aspirin on tumorigenic properties of oral cancer cells. 
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 The third aim of the project is to examine the effects of transfecting the KRT4 
gene into the oral cancer SCC25 cell line and the subsequent tumourigenicity of 
oral cancer. 
 The fourth aim of the study is to examine the effect of mammary extracellular 
matrix from lactating gland on the proliferation of oral cancer cells and breast 
cancer cells. 
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2 Overexpression of genes regulating G2/M 
transition, inflammation and fibrosis 
processes leads to oral cancer progression 
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2.1 Summary 
Oral Squamous Cell Carcinoma (OSCC) has no clinically proven biomarker and the 5-year 
survival rate has not improved in recent decades. In this study, we compared the gene 
expression profile of late stage OSCC samples and corresponding normal margins using an 
Affymetrix Human Gene-1.0ST array. The advanced OSCC gene profile was examined for 
statistically significant differential expression using xRAYbiotique systems and significant 
pathways using Ingenuity pathway analysis software. Pathways involved in hepatic stellate 
cell activation, G2/M transition, interferon and oncostatin-M signaling were most 
significantly correlated with increased fibrosis, inflammation, cell proliferation and 
extracellular matrix (ECM) remodelling. Most of the genes regulating these pathways were 
up regulated in early and late stage OSCC samples. Only FN1 expression was significantly 
different between early and late stage OSCC samples as analysed by QPCR and 
immunohistochemical staining and therefore FN1 may represent a promising diagnostic 
marker. Further Q-PCR analysis of genes expressed in the dysplastic and OSCC cell line, 
DOK and SCC25 respectively, indicated no significant difference in genes regulating 
interferon signaling and G2/M transition suggesting the possibility that these pathways are an 
early event in progression of the disease. It was also observed that MMP13 gene expression 
in SCC25 cells was significantly higher than in DOK cells and this protease may play an 
important role in fibrosis and ECM remodelling that is essential for malignancy. This was 
consistent with reduced proliferation and tumorigenic properties of oral cancer lines 
following knockdown of MMP13 gene expression indicating MMP13 may have a role of 
therapeutic importance in oral cancer progression. The current study is the first to associate 
up regulation of genes involved in the hepatic stellate cell activation pathway with OSCC 
progression and to correlate knockdown effects of MMP13 for decreased tumorigenic 
properties of SCC25 cells. 
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2.2 Introduction 
 
Oral cancer is a serious disease throughout the world with an incidence and mortality of 
275,000 and 120,000 patients respectively every year (Gupta & Johnson 2014; Parkin et al. 
2005). In Asian populations, the incidence of oral cancer has increased in the past few years 
(Masood, Yasmin & Kayani 2013). More than 90% of oral cancers are estimated to be 
squamous cell carcinoma (Sklenicka et al. 2010; Thomas et al. 2003) and oral squamous cell 
carcinoma (OSCC) is the most prevalent cancer in men and fourth most common cancer in 
women in India (Dikshit et al. 2012; Ferlay et al. 2010). The incidence and mortality rates of 
OSCC are high in the Indian population due to an increase in risk factors such as smoking, 
tobacco and alcohol consumption (Jemal et al. 2011). Despite the considerable research focus 
in therapeutics and diagnostics, the 5-year survival rate of OSCC is 50% and has remained 
unchanged for the past few decades and is much lower in comparison with cancers of 
colorectal, breast, and cervix origin (Geum et al. 2013; Schantz 1993). The absence of a 
clinically proven biomarker for oral cancer has been problematic (Okamoto et al. 2002; 
Wikner et al. 2014) and often patients with OSCC are diagnosed at late stages (Stage III and 
IV) of the disease and have a poor prognosis for recovery (Ribeiro, Kowalski & Latorre 
2000). 
Microarray analysis has emerged as a powerful tool for analysing the gene expression profile 
of cancer tissues compared to the normal controls and provides insights into disease 
pathology by revealing the pathways and processes involved and identify the targets for 
diagnostic and therapeutic purposes (Todd & Wong 2002). Earlier gene profile studies 
revealed information on differentially regulated genes, either to be up or down regulated, in 
the oral cancer samples (Mendez et al. 2002; Toruner et al. 2004). Due to tumour 
heterogeneity of OSCC (Ziober et al. 2006), and even after decades of research in the area of 
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oral oncology, the absence of a clinically proven biomarker clearly indicates that the cause of 
OSCC is most likely not due to a single gene and hence it is essential to focus on the 
interactions and molecular pathways involved in oral cancer progression by examining the 
entire gene transcriptome. Knowledge of the differential expression of genes, interactions 
between them and their association with specific pathways and processes is essential to 
identify factors responsible for OSCC progression.  
To elucidate the molecular mechanisms underlying the pathogenesis of OSCC, we examined 
the gene profile of late stage tumour samples (Stage III and IV) compared with the normal 
adjacent lesions from the same patient by microarray analysis. Further we have compared the 
expression of candidate genes in a dysplastic (DOK) and OSCC (SCC25) cell line to find 
differential expression of genes. The study aims to perform in-depth and broad examination 
of gene profiling of late OSCC, mapping and interactions of genes expressed to better 
understand the markers associated with potential therapeutic importance. A better description 
of molecular interactions in advanced OSCC samples will give a clearer role of genes, 
intracellular pathways and functional processes involved towards early OSCC detection and 
prediction, of progression, therefore enabling new therapeutic strategies to improve the 
survival rate of patients. 
2.3 Materials and methods 
 
2.3.1 Collection of oral cancer tissue 
Ten surgically resected late stage oral squamous cell carcinoma (OSCC, Stage III and IV) 
samples and six normal tissue samples were collected from patients at Saroj Gupta Cancer 
Centre and Research Institute, Kolkata before any chemotherapy and radiotherapy 
intervention. Normal samples were obtained from the surrounding part of the tumour from 
the same patient. Clinical parameters of the patient samples used were outlined in the Table 
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2.1. Cancer stages were determined according to the Union for International Cancer control 
(UICC) designated classification(Webber et al. 2014). The present study was approved by the 
Samkshema Independent Ethics Committee at Hyderabad and patient consent was also 
obtained.  
2.3.2 Cell culture 
SCC25 cells and DOK cells were obtained from American Type Culture Collection (ATCC) 
and European Collection of Cell Cultures (ECACC). SCC25 was cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) - F12 (Gibco) supplemented with 400 ng/ml 
hydrocortisone (Sigma) and 10% foetal bovine serum (Invitro technology). DOK cells were 
cultured in DMEM supplemented with 5μg/ml Hydrocortisone, 2mM Glutamine (GIBCO) 
and 10% foetal bovine serum (FBS). SCC25 and DOK cells were cultured at 37ͼC with 5% 
CO2.  
2.3.3 Sample preparation, RNA preparation and microarray 
analysis 
Patient samples were preserved immediately after surgical removal in All Protect Tissue 
Reagent (Qiagen) at -70ͼC until use. RNA was extracted using either the AllPrep 
DNA/RNA/Protein mini kit or RNeasy mini kit (Qiagen). RNA isolation from SCC25 and 
DOK cells was performed using RNeasy mini kit (Qiagen). RNA was quantified using a 
Biophotometer (Eppendorf) and the quality of RNA was confirmed by agarose gel 
electrophoresis. The extracted RNA (500 ng) was used to generate sense strand cDNA using 
the Ambion® WT expression kit (Ambion) and following manufacturer’s instructions. The 
samples were hybridized to the Affymetrix Human Gene 1.0 ST gene chip array according to 
the Affymetrix protocols. Normal samples (n=6) were obtained at a maximum distance from 
the tumour (n=10). All the tumour samples considered for microarray analysis were 
belonging to the late stage OSCC (Stage III & IV). The samples used for microarray 
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represents different biological replicates. Technical replicates were not used for microarray 
analysis. The arrays (n=16) were scanned with an Affymetrix Gene chip scanner 3000 7G. 
The scanned array images were processed with Affymetrix Gene Chip Console (AGCC), and 
the CEL files were extracted for further analysis. The present microarray data can be obtained 
from gene expression omnibus with reference series number as GSE56532.  
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Table 2.1 Clinical characteristics of the oral cancer patients. 
 
Characteristics Sample No. 
Gender 
Male 41 
Female 26 
Age group 
25-35 13 
36-50 27 
51-65 22 
66-80 5 
Postoperative Stage 
I 16 
II 20 
III 21 
IV 10 
Tumor location 
Buccal Mucosa  27 
Tongue 22 
Gingiva 17 
Lip 1 
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2.3.4 Statistical analysis of microarray data 
The 16 input CEL files were assigned to two groups (6 normal and 10 tumour) for data 
processing, differential gene expression analysis and alternative splicing xRAY Excel® 
Array analysis software (Biotique Systems, www.biotiquesystems.com/Products-
Solutions/XRAY) was used. Each probe score was corrected for background by subtracting 
the median expression score of background probes with similar GC content. The samples 
were normalized with full quantile normalization (Irizarry et al. 2003). Mixed model, nested 
analysis of variance was used to identify significant gene expression and alternative 
splicing(Montgomery 2000). Multiple tests correction was performed using the Benjamini 
and Hochberg method to find a significant P-Value and fold change(Hochberg & Benjamini 
1990). 
2.3.5 Pathway analysis 
Raw CEL files from the microarray experiment were submitted to a web based program for 
pathway analysis (Ingenuity® systems, www.Ingenuity.com). This iReport identified top 
scoring pathways, processes and diseases for differentially expressed mapped genes 
identifying the biological processes, pathways, and/or diseases that were most significant to 
the data set. Genes from the dataset that underwent a 2-fold change were examined for 
association with biological processes, pathways, and/or diseases in Ingenuity’s knowledge 
Base were considered for the analysis. The Right-tailed Fisher’s exact test was used to 
calculate a P-Value to determine the probability that each biological process, pathway, and/or 
disease assigned to that data set was due to chance alone. 
2.3.6 Identification of molecular interactions between 
differentially expressed genes 
A dataset of differentially expressed genes and corresponding expression values was analysed 
in iReport. Each gene or probeset identifier was mapped to its corresponding gene in the 
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Ingenuity Knowledge base. A 2-fold change in expression and a P-Value of 0.05 was set to 
identify genes whose expression was significantly differentially regulated. These genes were 
then used to query a global molecular network developed from information contained in 
Ingenuity’s knowledge base. This query identified molecular interactions between 
differentially expressed genes in the dataset. 
2.3.7 SiRNA and transfection 
The siRNA oligo duplexes targeting MMP13 gene (human) were purchased from Qiagen. 
The targeting sequences include – 5’ AACGAAATATCAAAGTCATTA-3’. Sense and 
antisense strand of the duplex were as follows:  Sense - 5’-
CGAAAUAUCAAAGUCAUUATT-3’; Antisense – 5’ 
UAAUGACUUUGAUAUUUCGTT-3’. AllStars negative control from Qiagen was used as a 
control. The siRNAoligo duplexes were transfected in SCC25 cells using Lipofectamine 2000 
(Invitrogen) reagent following manufacturer’s instructions.  
2.3.8 Cell proliferation assay 
The SCC25 cells were transfected with MMP13 siRNA duplexes and the allStar negative 
control, and cultured for 48h. MTS solution (Promega) was added and the cells were 
incubated for 4h and absorbance measured at 490nm. Cell viability was expressed as a 
percentage relative to the control cells. 
2.3.9 Transwell migration and invasion assay 
In-vitro migration and invasion assays were performed using 8 μm pore transwell chambers 
(Corning). Inserts were coated with Matrigel (Life Technologies) in cold serum free media 
for the invasion assay.  Cells (105) were suspended in serum free media in the upper chamber 
of the transwell containing 100 μl of serum free media (24-well plate). Complete media (750 
μl) was placed in the lower chamber and incubated for 48h at 37ͼC. Media was removed after 
incubation from the upper chamber which was washed twice with PBS. Cells were fixed in 
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formaldehyde and washed twice with PBS. Methanol was added to the cells and incubated at 
room temperature for 20 min. Cells were washed twice with PBS and stained with giemsa 
(Sigma) for 15 min. Non-migrated and non-invaded cells were scraped off from the top 
surface of the upper chamber and images were obtained using the microscope. Cell migration 
and invasion was measured in percentage relative to the control. 
2.3.10 Colony formation assay 
SCC25 cells transfected with control siRNA (AllStars negative control) and MMP13-siRNA 
were seeded (1x103) in each of 6- well plates. Cells were incubated at 37ͼC for 7 days. Media 
was removed and cells were washed twice with 1x PBS. Cells were fixed with methanol for 
15 min at room temperature. Cells were stained with crystal violet at room temperature for 15 
min. Excessive staining was removed by washing the fixed cells with water. Colonies with a 
minimum count of 50 cells were considered for analysis and further quantified using 
microscopic analysis. The experiment was repeated three times.  
2.3.11 Immunofluorescence 
Cells were fixed with paraformaldehyde 4% (w/v) washed with ice cold PBS, treated with 
0.1% (v/v) triton X-100 in PBS and finally washed twice with PBS. Blocking was performed 
for 1 h using 1% BSA in PBS. The blocking solution was discarded and primary antibody 
(Rabbit polyclonal anti-MMP13 antibody, Genetex) was added and incubated overnight at 
4ͼC. Primary antibody solution was removed and secondary antibody was added (anti-rabbit 
alexa fluor-488, Life Technologies) and incubated for one hour at room temperature. Cells 
were washed three times with PBS and Hoechst dye (Sigma) was used (0.1 μg/ml) to stain 
the nucleus by incubating cells at room temperature for 15 min. Cells were washed with PBS 
and the intensity of the fluorescence was observed using a fluorescent microscope (Nikon, 
Melville, USA). Images were captured using software NIS elements F 3.0 (Nikon, Melville, 
USA). A secondary conjugated antibody alone was used as a negative control.  
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2.3.12 Quantitative real time polymerase chain reaction (Q-
PCR) 
Differential expression of genes in normal and tumour tissue samples was quantified using 
SYBR green and analysis of melting point dissociation curve analysis was performed 
according to the manufacturer protocol (Applied Biosystems). Total RNA isolated from the 
tissue specimens and cell lines as specified in the methods was reverse transcribed to generate 
complimentary DNA using Superscript VILO (Invitrogen) and Superscript III following the 
kit protocol. The cDNA (25 ng) was used to perform quantitative real time PCR in a 10 μl 
reaction on an ABI 7900 HT detector system. Primer sequences (Sigma) designed using PCR 
primer design tool Primer3 (Rozen & Skaletsky 2000) and gene specificity was checked 
using the National Center for Biotechnology Information nucleotide database. The QPCR 
included an initial denaturing step for 3 minutes at 95ͼC, followed by 40 cycles of 95ͼC for 
30 seconds, 60ͼC for 30 seconds and 72ͼC for 30 seconds. The expression of each gene was 
normalized using the GAPDH housekeeping gene and relative expression was calculated 
using Delta delta Ct method (Livak & Schmittgen 2001). The list of the primers is included in 
Table 2.2. For the QPCR analysis of normal, early and late stage samples, biological 
replicates (n=10) and technical replicates (n=3) were used for each sample. QPCR analysis in 
the cell lines had biological and technical replicates (n=3).  
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Table 2.2 List of primers used in quantitative-PCR analysis 
 
 
 
 
Genes Fwd Primer (5' to 3') Rev Primer (5' to 3') Product Size 
MMP13 TCCCTTGATGCCATTACCAGTCTC AAAACAGCTCCGCATCAACC 100 
SPP1 GCCGAGGTGATAGTGTGGTTTA CGCTTTCCATGTGTGAGGTGAT 114 
TGFB1 ATGAACCGGCCTTTCCTGCTTCT TCCGTGGAGCTGAAGCAATAGT 113 
FN1 GCATAAGGTTCGGGAAGAGGTTGT GGAAACTGTGTAGGGGTCAAAGCA 100 
CCL5 CGTGCCCACATCAAGGAGTATT TTCTCTGGGTTGGCACACACTT 104 
IL8 CCTGATTTCTGCAGCTCTGTGT TTGGGGTGGAAAGGTTTGGAGT 102 
ICAM1 ACAGTGACCATCTACAGCTTTCCG ATTCAGCGTCACCTTGGCTCTA 120 
C-MET CCGAAGTGTAAGCCCAACTACAGA ACTTGTCGGCATGAACCGTTCT 114 
IL1A TGCCCAAGATGAAGACCAACCA TCTTAGTGCCGTGAGTTTCCCA 113 
IL1B AGGGACAGGATATGGAGCAACA CGCAGGACAGGTACAGATTCTT 120 
PLK1 TGCACAGTGTCAATGCCTCCAA TCCGAATAGTCCACCCACTTGCT 115 
FOXM1 CGCCGGAACATGACCATCAAAA TTCACCGGGAACTGGATAGGTA 110 
CEP55 TGTGGCTCCAAACTGCTTCAAC TCATACACGAGCCACTGCTGAT 102 
STAT1 CGTGGACGAGGTTTTGTAAG AGAGAGGGAGCAGGTGTTTT 105 
STAT2 AGAGCCAGATTTGCCCTGTGAT TGGGTCACCATTCGGCATGATT 103 
OAS1 GCCTAGTCAAGCACTGGTACCAAA TCCCTCGCTCCCAAGCATAGA 102 
PLAU TGCTGACCCACAGTGGAAAACA CCCCAGCTCACAATTCCAGTCAA 105 
MMP1 CACAACTGCCAAATGGGCTTGA AGCACATTCTGTCCCTGAACAGC 106 
MMP3 ATTGGATGGAGCTGCAAG GACCACTGTCCTTTCTCCTA 119 
LAMA3 AGGGAAGTTTGCCTGGAAACTC CTTCAGGCATCCCACAAAGCTGTT 116 
ITGA6 TGGACAGCAAGGCGTCTCTTAT AAGGCTCGCATGAGAATGTCCAAG 103 
POSTN GATGGAGTGCCTGTGGAAAT CTTCTGTTTCTCCACCTCCAGT 109 
COL4A1 GCTGTGGATCGGCTACTCTTTTGT CACTCGATGAATGGCGCACTTCTA 120 
GAPDH TCACCAGGGCTGCTTTTAACTC TGCCATGGGTGGAATCATATTGGA 111 
  Chapter 2 
73 
 
2.3.13 Immunohistochemistry (IHC) 
Tumour tissues were fixed in 10% formalin, dehydrated and embedded in paraffin 
immediately. To perform IHC, sections were cut into 4 μm sections, deparaffinised in xylene 
and hydrated in a series of alcohol dilutions. The sections were treated with hydrogen 
peroxide (3% in methanol) to block endogenous peroxidase activity. Antigen retrieval was 
performed using 10 mM citrate buffer and boiling sections at 95ͼC for 25 minutes. Sections 
were blocked with 5% of goat serum (Invitrogen) for 30 minutes. Subsequently, sections 
were incubated with primary antibody (Rabbit polyclonal anti-MMP13 antibody, Genetex, 
1:100 and Rabbit polyclonal anti-FN1 antibody, Genetex, 1:100) overnight at 4ͼC. HRP-
conjugated goat anti-rabbit HRP (1:100, Abcam) was used as secondary antibody and the 
sections were treated for 1 h at room temperature. The 3, 3-‘Diaminobenidine (DAB, Sigma) 
was used for detection. Finally the sections were mounted with DPxhistamount (Sigma). 
Primary antibody was replaced by non-inducing serum in negative controls. Images were 
captured and analysed using Nikon microscope and NIS-Elements F 3.0 software (Melville, 
USA). ImageJ was used to analyse the stained and unstained sections as per the software 
instructions(Abramoff MD, Magalhaes PJ & S. 2004). The staining score was calculated 
based on the area and intensity of staining. For each section, a minimum of five fields were 
analysed in a ‘blind’ assessment and the staining percentage score was determined. The 
intensity of staining was scored as follows; - +1, weak; +2, moderate; +3, strong. The staining 
intensity obtained was multiplied with the percentage of positive stained cells to produce a 
staining score for FN1 and MMP13 (Shimada et al. 2005; Tanaka et al. 2003). Statistical 
significance was assessed by using the Mann-Whitney U-test and the P-Value <0.05 was 
considered as significant. 
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2.3.14 Statistical Analysis 
The student’s t-test was used for the analysis of significance for the study of cell 
proliferation, cell migration, clonogenic assay, cell invasion and Q-PCR analysis. A P-Value 
< 0.05 was considered significant. 
2.4 Results 
2.4.1 Microarray analysis of late stage oral squamous cell 
carcinoma (OSCC) samples 
To identify changes in gene expression between late stage (Stage III and IV) OSCC samples 
(n=10) and normal samples (n=6), microarray analysis was performed using Affymetrix 
Human Gene 1.0ST arrays. The data analysis using xRAYbiotique software revealed 1194 
genes significantly differentially expressed at the gene level, 228 genes significantly 
expressed at exon level and 129 genes expressed at gene and exon level (Figure 2.1A).  The 
principal component analysis (PCA) plot (Figure 2.1B) indicated that the two groups (normal 
and late stage OSCC samples) showed good separation. Prior to PCA analysis, normalization 
was performed using robust multi-array average (RMA) algorithm followed by log 
transformation and variance stabilization. Heat map analysis with hierarchial clustering 
showed differential gene expression patterns clearly separated normal samples from late stage 
OSCC samples (Figure 2.1C, up regulated and down regulated genes indicated as red and 
yellow).  
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Figure 2.1 Gene profiling study of late stage (Stage III and IV) OSCC and adjacent 
normal tissue samples. 
A) Venn diagram of significantly expressed genes in OSCC. Microarray data analysis was 
performed as described in methods section and the Venn diagram shows 1194 genes 
significantly expressed at gene level; 228 genes significantly expressed at exon level and 129 
genes expressed at gene and exon level. B) Two dimensional principal component analysis 
(PCA) plot for normal and late stage oral cancer samples. Normal tissues are represented in 
red circles and OSCC tissues are represented in blue circles. The 2D-PCA of normal and 
OSCC samples represents distinctive patterns of gene expression. C) Hierarchical clustering 
of microarray data generated from normal and OSCC samples.Significant differential 
expression was observed in normal and OSCC tissues. The quantitative changes in terms of 
expression are represented graphically with colour. Up regulated mRNA levels are shown as 
red and down regulated mRNA levels are represented by yellow. 
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2.4.2 Pathway analysis 
Differentially expressed genes in late stage OSCC compared with normal samples were 
subjected to pathway analysis using Ingenuity pathway analysis (IPA, Ingenuity Systems, 
www.ingenuity.com). The IPA generated iReport showed canonical pathways based on the 
gene expression values and mapping of the genes expressed in the IPA database. Significant 
pathways expressed in late stage OSCC include hepatic stellate cell activation, interferon 
signaling, cell cycle: G2/M check point, mitotic role of polo like kinases and OSMR 
signaling (Figure 2.2 A to E). Genes regulating these pathways were up regulated (shown in 
yellow to red). Up regulation of genes involved in cell cycle progression and segregation of 
chromosomes processes was observed (Table 2.3). Further genes promoting fibrosis and 
inflammation were also up regulated in late stage OSCC samples (Table 2.4). It was also 
observed that KRT4 gene was down regulated in late stage samples (-59.71). 
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Table 2.3 List of genes belonging to cell cycle progression and chromosome segregation 
processes expressed in late stage OSCC samples. 
Cell Cycle  Chromosome segregation 
Symbol Fold Change Symbol Fold Change 
AURKA 4.418 TOP2A 3.913 
CDC20 4.392 PLK1 3.756 
PDPN 4.381 CCNB1 3.715 
CDK1 4.149 BUB1 3.712 
DLGAP5 4.035 NCAPG 3.702 
STAT1 4.013 CCNB2 3.478 
CKS2 3.983 CCNA2 3.431 
TOP2A 3.913 CENPF 3.258 
MKI67 3.893 NDC80 3.193 
CENPI 3.854 ECT2 3.098 
PLK1 3.756 CENPE 3.078 
CCNB1 3.715 SKA3 3.047 
BUB1B 3.712 KIF2C 2.904 
FOXM1 3.565 PTTG1 2.744 
CDKN3 3.44 EXO1 2.732 
CCNA2 3.431 NUF2 2.691 
CENPF 3.258 TAP2 2.609 
CENPE 3.078 SGOL1 2.608 
SKA3 3.047 NCAPH 2.581 
KIF11 3.004 NUSAP1 2.45 
CDC25B 2.978 SPC25 2.393 
KIF2C 2.904 BRCA1 2.375 
PTTG1 2.744 BRCA2 2.367 
NUF2 2.691 AURKB 2.353 
CTLA4 2.616 NCAPG2 2.252 
CCNE2 2.593 SMC4 2.172 
CDK6 2.566 DSN1 2.139 
CDCA5 2.528 ZWINT 2.043 
HELLS 2.499 NEK2 2.018 
NUSAP1 2.45 
KIF15 2.438 
BRCA1 2.375 
KNTC1 2.368 
BRCA2 2.367 
AURKB 2.353 
CCNE1 2.264 
BORA 2.255 
PCNA 2.212 
PKMYT1 2.182 
CDCA8 2.177 
CENPA 2.045 
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Table 2.4 List of genes involved in inflammation and fibrosis processes expressed in late 
stage OSCC samples 
Fibrosis Inflammation 
Symbol Fold Change Symbol Fold Change 
MMP1 40.274 MMP1 40.274 
MMP12 27.889 CXCL10 24.048 
CXCL11 24.691 S100A7A 10.002 
CXCL10 24.048 SPP1 9.228 
MMP13 18.745 IL24 9.05 
PTHLH 13.933 KRT17 8.878 
CXCL9 10.586 PLA2G7 7.645 
SPP1 9.228 SERPINE1 7.313 
SERPINE1 7.313 IL1A 7.269 
CXCL13 7.019 MMP9 6.235 
IFI27 6.542 IL8 5.787 
MMP9 6.235 CTSL2 5.546 
IFI6 6.182 IGHG3 4.863 
CDSN 5.915 IL1B 4.753 
PLAU 4.898 OLR1 4.422 
IL1B 4.753 XDH 4.343 
POSTN 4.429 IL12RB2 4.285 
IFIT1 4.403 STAT1 4.013 
PDPN 4.381 CCL5 3.894 
XDH 4.343 ICOS 3.834 
IFIT3 4.29 CFB 3.662 
HMGA2 4.279 NT5E 3.618 
STAT1 4.013 FCGR3A 3.577 
MMP7 3.901 CXCL1 3.431 
MKI67 3.893 EIF2AK2 3.229 
OAS2 3.883 CA2 3.214 
NT5E 3.618 FN1 3.062 
EIF2AK2 3.229 CTSL1 3.024 
IFI35 3.07 TNFRSF9 2.974 
FN1 3.062 PTTG1 2.744 
MX1 2.937 CTLA4 2.616 
STAT2 2.635 TNFAIP3 2.599 
TNFAIP3 2.599 NCF2 2.51 
VAV2 2.579 TNFRSF12A 2.498 
OAS1 2.548 TGFB1 2.44 
TGFA 2.53 STAT4 2.432 
TGFB1 2.44 CASP5 2.396 
ITGA2 2.432 IL4R 2.258 
STAT4 2.432 CD276 2.111 
ICAM1 2.105 ICAM1 2.105 
PPARG -4.583 PPARG -4.583 
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Figure 2.2 Pathway analysis using Ingenuity software for the gene expression profile of 
late OSCC samples in comparison with normal tissue samples. 
Differentially expressed genes with fold change value > 2 was marked in yellow and <2 were 
marked in blue. Fold change value is directly proportional to the intensity of the color. A) 
Hepatic stellate cell activation pathway. During liver fibrosis, accumulation of ECM proteins 
(fibronectin, laminin and collagen) occurs due to toxins initiating pro-inflammatory events 
leading to activation of hepatic stellate cell leading to fibrosis condition. As represented in 
the figure IL1A and IL1B initiated regulation of pro-inflammatory cytokines. Further up 
regulation of TGFB1, MMP1, MMP9, MMP13 and FN1 in late OSCC samples indicated 
increase in fibrosis condition. B) Interferon signaling pathway. Interferon signaling mediated 
by STAT1 and STAT2 is significantly up regulated in OSCC tissues and the downstream 
effectors of STAT1 and STAT2 that mediate inflammatory process, IFI35, OAS1, IFIT1, 
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IFIT3, and IFI35 were also up regulated.  C) Cell cycle: G2/M DNA damage checkpoint 
regulation. G2/M checkpoint prevents the damaged DNA from entering into mitosis. Chk2 
molecule inhibits CDC25 that activates CDC2 which is required for its entry into mitosis. 
Cyclin B1, which is required for the activity of CDC2 for the cells to make mitotic entry, 
along with CDC2 and CDC25 are up regulated in OSCC samples. D) Mitotic role of polo like 
kinases pathway. Polo like kinases regulate events during G2/M transition and mitosis. PLK1 
activates CDC25 which inturn activates CDC2 that binds to CCNB1 essential for mitosis 
entry. During mitosis EG5 is activated by CyclinB-CDC2 complex for centrosome separation 
and MKLP1 is essential for cytokinesis. The main role of polo like and their regulators are up 
regulated in OSCC samples to promote the cells entry into mitosis phase. E) Oncostatin-M 
signaling. OSM binds to OSMR to mediate inflammatory response through JAK-STAT 
regulating the expression of matrix metalloproteinases and urokinase plasminogen activator. 
As depicted in the figure genes involved in the pathway include: OSMR, STAT1, MMP1, 
MMP3, MMP13 and PLAU are up regulated in the OSCC samples. 
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2.4.3 Gene expression changes attributed to matrix remodelling in 
OSCC samples 
Gene profile of late stage OSCC also revealed genes associated with matrix remodelling.  
Genes belonging to the family of matrix metalloproteinases (MMP7, MMP10, and MMP11), 
matricellular proteins (TNC, POSTN), cysteine proteases (CTSL, CTSV), collagen and 
laminin family members (COL4A1, COL4A5, LAMC3, LAMB2 and LAMA2) were up 
regulated in late stage OSCC samples (Table 2.5). 
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Table 2.5Regulation of genes related to matrix remodeling in late OSCC samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genes 
Probe set 
ID FC value 
SPP1 8096301 9.23 
PPARG 8077899 -4.58 
LAMA3 8020551 3.24 
LAMB3 7924029 3.03 
LAMC2 7908072 16.6 
MMP7 7951217 3.9 
MMP10 7951259 15.26 
MMP11 8071758 4.66 
ITGA6 8046380 3.16 
ITGB4 8009951 2.67 
TNC 8163637 4.69 
POSTN 7971077 4.43 
LOXL2 8149774 2.84 
CTSL 8156228 3.02 
CTSV 8162652 5.55 
COL4A1 7972750 2.36 
COL4A5 8169294 2.18 
TGFB1 8037005 2.44 
MET 8135601 3.54 
IL1B 8054722 4.75 
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2.4.4 Comparison of significant genes expressed in early and late 
stage OSCC samples that regulate significant pathways 
Quantitative-PCR (QPCR) analysis was performed to confirm the mRNA levels of significant 
genes (SGs) that regulate the pathways of hepatic stellate cell activation, interferon signaling, 
cell cycle: G2/M check point, mitotic role of polo like kinases, interferon signaling and 
oncostatin-M signalling (Table 2.6) for normal, early (I and II) and late (III and IV) stage 
OSCC samples. These genes were also involved in the regulation of fibrosis, inflammation, 
extracellular matrix (ECM) remodelling and cell cycle progression (Table 2.3, 2.4 and 2.5). 
QPCR results revealed that the expression of MMP13, SPP1, TGFB1, CCL5, IL8, ICAM1, 
C-MET, IL1A and IL1B, which are involved in hepatic stellate cell activation and promotion 
of processes such as fibrosis and inflammation, were significantly up regulated in early and 
late stage OSCC sample relative to normal samples except FN1. There was no significant 
difference in the expression of these genes between early and late stage OSCC samples 
except for FN1. FN1 levels were significantly up regulated in late stage OSCC samples and 
there was no significant difference found in the expression levels between normal and early 
stage OSCC samples.There was a significant difference observed in the FN1 mRNA 
expression between the early and late stage OSCC samples (Table 2.6). PLK1, FOXM1 and 
CEP55 involved in the regulation of G2/M transition and polo like kinases showed significant 
up regulation in early and late stage OSCC relative to normal tissue but there was no 
significant difference between the early and late stage samples. The genes for STAT1, 
STAT2, and OAS1 involved in regulating interferon signaling; PLAU, MMP1 and MMP3 
downstream molecules of oncostatin-M signalling, also showed significant up regulation in 
early and late stage OSCC samples but no significant difference between  the two cancer sets. 
The LAMA3, ITGA6, POSTN and COL4A1 genes involved in ECM remodelling showed 
significant up regulation in early and late stage OSCC samples in comparison to normal 
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samples, but there was no significant difference observed between the early and late stage 
OSCC samples. 
Table 2.6 QPCR analysis of significant genes in normal, early and late stage OSCC 
samples. 
Relative normalized expression S.D (±) 
P-Value (Relative to 
normal) 
P-Value 
(Relative 
to Early 
OSCC) 
Genes 
Late OSCC 
(n=10) 
Early 
OSCC 
(n=10) 
Normal 
(n=10) Late OSCC 
Early 
OSCC Normal 
Late 
OSCC 
Early 
OSCC 
Late 
OSCC 
MMP13 231.1533 162.2228 1.353352 69.37159 41.48991 0.770716 0.001937 0.000553 0.202498 
SPP1 0.409263 0.574788 0.020946 0.085109 0.074335 0.009987 0.000129 3.76E-07 0.080111 
TGFB1 23.36367 32.09017 10.23651 3.326921 5.844844 2.763409 0.003559 0.001667 0.105413 
FN1 123.0797 25.53701 11.44475 15.25394 9.788367 4.176765 6.94E-07 0.101007 2.05E-05 
CCL5 357.122 516.3899 31.81868 58.1808 97.39592 6.216879 1.41E-05 5.01E-05 0.08869 
IL8 147.9487 183.1339 6.892985 14.14757 24.50022 2.394028 5.8E-09 5.74E-07 0.114789 
ICAM1 6856.548 5389.794 1836.376 618.8626 767.795 367.2009 8.13E-07 0.000284 0.077116 
C-MET 19.9204 19.8823 2.252895 5.423905 8.222841 1.06746 0.002503 0.023793 0.498479 
IL1A 18422.21 19251.31 3697.483 3462.124 4671.457 1064.695 0.000363 0.002241 0.444098 
IL1B 1.317698 1.534694 0.176168 0.274327 0.372345 0.032825 0.000313 0.000948 0.322283 
PLK1 3.217122 3.815098 0.097129 0.538423 0.559855 0.018145 8.66E-06 1.57E-06 0.225688 
FOXM1 0.165306 0.116764 0.018901 0.030753 0.01233 0.001741 7.94E-05 1.58E-07 0.080079 
CEP55 0.983867 0.806346 0.046874 0.075076 0.10319 0.005009 1.39E-10 4E-07 0.090574 
STAT1 0.305854 0.497722 0.066813 0.058495 0.141553 0.009811 0.000393 0.003546 0.113173 
STAT2 0.967534 0.963531 0.139242 0.143732 0.196581 0.01976 1.03E-05 0.000286 0.493532 
OAS1 1.480949 1.750707 0.614231 0.293228 0.291167 0.083458 0.005398 0.00073 0.261068 
PLAU 0.002125 0.00153 0.000232 0.000515 0.000231 3.99E-05 0.000889 1.44E-05 0.153084 
MMP1 1.027861 0.803088 0.000186 0.290788 0.232292 4.62E-05 0.001185 0.001408 0.276711 
MMP3 9.057806 7.790247 0.039769 2.534307 0.470992 0.007406 0.001123 1.36E-12 0.314423 
LAMA3 22.13872 42.56149 2.694283 5.6991 12.47107 0.237554 0.001565 0.002502 0.07684 
ITGA6 71180.75 70934.16 10862.31 11711.3 13511.35 1657.71 3.74E-05 0.000168 0.494574 
POSTN 12.68779 13.56169 4.193475 1.104289 1.218887 0.12443 2.33E-07 2.32E-07 0.300842 
COL4A1 21.79066 25.89998 3.616557 2.43811 2.137086 0.259545 3.57E-07 2.62E-09 0.11057 
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2.4.5 Immunohistochemical analysis of FN1 expression in early 
and late stage OSCC samples 
To further validate the differential expression of FN1 in early and late stage OSCC samples, 
immunohistochemical (IHC) examination was performed using 9 normal, 14 early and 15 late 
stage tumour samples. FN1 staining in normal samples was restricted to the stromal region 
containing fibroblasts and the staining was weak to moderate without specific pattern (Figure 
2.3A).  Further, early stage OSCC samples also showed weak to moderate staining in the 
stromal region surrounded by epithelial islands. Late stage OSCC samples showed strong 
staining with a network like pattern similar to a desmoplastic reaction, largely due to dense 
fibrous tissue around the epithelial tumour island leading to a scarring reaction (Figure 2.3A). 
There was no significant difference between the well (WD), moderate (MD) and poorly (PD) 
differentiated samples of early and late stage OSCC sections (Figure 2.3A). The IHC score 
indicated that there was no significant difference between normal and early stage OSCC 
samples but the score showed significant difference between the early and late stage samples 
(Figure 2.3B). 
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Figure 2.3 Immunohistochemical analysis of FN1 expression in normal, early (stage I 
and II) and late (stage III and IV) OSCC samples. 
A) Immunohistochemical staining of FN1 in normal oral (n=9), early tumor (n=14) and late 
stage tumor oral cancer samples (n=15) was performed. FN1 staining showed network pattern 
of staining supporting the epithelial islands. Strong staining was observed in late stage OSCC 
samples in comparison with normal and late stage OSCC samples. B) Shows the graph for 
FN1 staining in normal oral tissue, early and late stage OSCC tissue samples. WD, MD and 
PD represent well, moderate and poorly differentiated status of the clinical samples. IHC 
staining scores for FN1 were calculated as: staining intensity multiplied with the percentage 
of positive cells.  The results represented the mean values and the Mann-Whitney U-test was 
used to calculate the statistical significance and *P-Value less than 0.05 was considered 
significant. Comparison between normal and early stage OSCC tumour samples showed non-
significant (ns). 
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Figure 2.4 Quantitatve-PCR analysis of candidate genes in SCC25 and DOK cell lines. 
Q-PCR analysis of MMP13, SPP1, FOXM1, CEP55, IL1A, IL1B, STAT1 and OAS1 genes 
in DOK and SCC25 cell line was performed. GAPDH was used as control for normalization. 
*P-Value < 0.05 was considered as significant.   
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Figure 2.5Immunohistochemical staining and analysis of MMP13 expression in normal, 
early (stage I and II) and late (stage III and IV) OSCC samples. 
A) Immunohistochemical staining of MMP13 in normal oral (n=9), early tumor (n=14) and 
late stage tumor oral cancer samples (n=15) was performed. MMP13 stain was observed in 
epithelial invasive front of the epithelial regions in early and late stage OSCC samples. 
MMP13 staining was not observed in normal samples. B) Graph showing MMP13 IHC 
staining score in normal, early and late stage OSCC tissue samples was calculated as: staining 
intensity multiplied with the percentage of positive cells.  The results represented the mean 
values and to calculate the statistical significance, Mann-Whitney U-test was used. *** 
indicates P-Value less than 0.0001 when compared between normal vs late and normal vs 
early stage OSCC samples. Comparison between normal and early stage OSCC tumour 
samples did not show any statistical significance (ns). 
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2.4.6 Comparison of significant genes in the dysplastic (DOK) and 
oral cancer cell line (SCC25) that regulate significant 
pathways 
QPCR analysis of the tongue dysplastic (DOK) and OSCC (SCC25) cell lines, examined 
differential expression of FOXM1 and CEP55 that promote G2/M transition, STAT1 and 
OAS1 that promote interferon signalling, and MMP13, SPP1, IL1A and IL1B that promote 
hepatic stellate cell activation. The results showed a significant difference in the expression 
levels of only the MMP13 and SPP1 genes in DOK and SCC25 cells. SPP1 and MMP13 
showed up regulation (~25 and ~150 fold) in SCC25 cells compared to DOK cells (Figure 
2.4). 
2.4.7 MMP13 expression in early and late stage OSCC samples 
To examine the presence of MMP13 in clinical specimens, further immunohistochemical 
analysis was performed in 9 normal, 14 early and 15 late stage tumour samples. MMP13 
expression was either not detected or present at very low levels in normal samples. In early 
and late stage OSCC samples, MMP13 staining was observed in the invasive front of the 
epithelial region. The staining was strong and restricted to the epithelial region (Figure 2.5A). 
Further, the IHC score indicated that there was no significant difference between early and 
late stage OSCC samples but the score showed a significant difference between the normal, 
early and late stage samples (Figure 2.5B). 
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2.4.8 MMP13 gene knockdown by siRNA and its effects on cell 
viability in SCC25 cells 
The marked increase in the MMP13 gene expression in SCC25 cells compared to the 
dysplastic DOK cell line was consistent with immunofluorescence analysis also showing an 
increase in the intensity of MMP13 staining in SCC25 cells compared to DOK cells (Figure 
2.6A). Gene silencing was performed using siRNA duplexes specific to human MMP13 gene 
in SCC25 cell lines. An MTS assay was used to measure the effect of the MMP13 gene 
knock down on the viability of SCC25 cells. It was observed that there was a significant 
decrease in the viability of cells following MMP13 knock down in cells at Day1 and the 
effect extended to Day3 (Figure 2.6B) when compared to the control cultures of cells (no 
siRNA and AllStars negative control). Since a significant effect on viability of SCC25 cells 
was observed on Day 2, MMP13 gene expression was examined on Day2 of incubation with 
siRNA. Approximately 65% to 75 % of mMMP13 gene knock down was observed at 48 h of 
siRNA treatment (Figure 2.6C).  
2.4.9 MMP13 knock down and its effects on tumorigenic 
properties of SCC25 cells 
To observe the effects of MMP13 gene knock down on the tumorigenic effects of SCC25 
cells, colony formation assay and in-vitro migration and invasion assays were performed. The 
colony formation assay revealed a significant reduction in the formation of colonies in the 
MMP13 knock down cells (Figure 2.6D). Further, the in-vitro migration and invasion assay 
revealed a significant decrease in the number of MMP13 knockdown cells (Figure 2.6E).  
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Figure 2.6 MMP13 knockdown using siRNA transfection method and its effects on cell 
proliferation, gene expression and tumorigenic properties. 
A. Immunofluorescence analysis of MMP13 expression in SCC25 and DOK cells. Cells were 
treated with MMP13 primary antibody followed by staining with anti-rabbit alexafluor 488 
(green). Nucleus was stained using Hoechst dye (Blue). Original magnification is 200 x with 
scale bar 50μm. B. SCC25 cells transfected with MMP13 siRNA, AllStars negative control 
and no siRNA (no RNA duplexes but with transfection reagent) were analysed for cell 
viability using MTS reagent. Graph was plotted relative to control in percentage. Experiment 
was repeated thrice and student t-test was performed to attain P-Value and * P-Value less 
than 0.05 was considered significant. C. Q-PCR analysis was performed for the SCC25 cells 
transfected with allStars negative control and MMP13-siRNA for 48h. The expression values 
were normalized to GAPDH relative to control (allStars negative control). *** indicates 
significant P-Value < 0.0001. D. Clonogenic or colony formation assay. SCC25 cells 
transfected with control (allStars negative control) and MMP13 siRNA were plated in 1 x 103 
numbers in each of 6-well plate and allowed to grow for 7 days. Colonies were stained with 
crystal violet and colonies with more than 50 cells were considered for the quantification. 
Graph was plotted relative to control and *** indicates P-Value < 0.0001. E. In-vitro cell 
migration and invasion assay. Cells transfected with control (AllStars negative control) and 
MMP13-siRNA were analysed for cell migration and invasion assay. Number of cells 
invaded and migrated were quantified and graph was plotted relative to control and *** 
indicates P-Value < 0.0001. All the experiments were performed in triplicate where 
biological and technical triplicates for each experiment were considered for statistical 
analysis. 
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2.5 Discussion 
In the current study, gene profiling was performed on late stage (Stage III and IV, n=10) oral 
squamous cell carcinoma (OSCC) and their matching adjacent normal mucosa (n=6) samples 
to identify gene signatures that can differentiate normal and late stage OSCC. Data analysis 
was performed to obtain genes that were significantly differentially regulated in late stage 
OSCC, and Ingenuity Pathway Analysis software was used to identify cellular pathways with 
a putative role in the progression of oral cancer. 
2.5.1 Hepatic stellate cell activation pathway revealed genes 
associated with fibrosis, inflammation and ECM 
remodelling 
Hepatic stellate cell activation (HSC) activation was the most significant pathway altered in 
oral cancer samples which is consistent with chronic fibrosis in hepatocellular carcinoma 
(Coulouarn & Clement 2014) resulting from accumulation of chemokines, cytokines, ECM 
proteins, matrix metallo-proteinases (MMPs) secretion leading to HSC activation (Powell et 
al. 1999). Q-PCR analysis of candidate genes (MMP13, TGFB1, FN1, STAT1, CCL5, IL8, 
ICAM1, C-MET, IL1A, IL1B, MMP1) regulating the HSC pathway showed significant over 
expression in early and late stage OSCC samples consistent with a potential role in oral 
malignant progression.  
Osteopontin (SPP1), a glycophospho protein, plays a pivotal role in ECM remodelling, HSC 
activation inducing fibrosis (Mannaerts et al. 2010) and bone tissue development (Denhardt 
& Noda 1998). Overexpression of SPP1 was observed in OSCC samples but not in normal 
mucosa (Devoll et al. 1999) which is similar to the current QPCR analysis showing a 
significant increased SPP1 mRNA levels in OSCC samples in comparison with normal 
samples. Only fibronectin (FN1) mRNA expression showed a significant increase in the late 
stage OSCC samples compared to early stage OSCC samples and IHC analysis of FN1 
  Chapter 2 
99 
 
staining indicated strong staining only in late stage OSCC samples. These results were 
consistent with FN1 expression at high levels during fibrosis (Binkley et al. 2004) and FN1 
staining in late stage samples showed a desmoplastic reaction with a bundle like network 
pattern irrespective with the differentiation status of the clinical samples. Further validation 
in large number of samples is required before FN1 can be determined to show promise as a 
diagnostic marker to differentiate early and late stage OSCC samples. 
2.5.2 G2/M transition is an essential step for oral cancer 
progression 
Polo like kinase 1 (PLK1) is highly expressed and is essential during G2/M transition of cell 
cycle (Donaldson et al. 2001). PLK1 phosphorylates FOXM1 during G2/M transition and 
FOXM1 becomes active leading to enhanced expression of mitotic regulators promoting cell 
proliferation (Fu et al. 2008).  In the current study, microarray analysis and further QPCR 
validation of PLK1 and FOXM1 showed a significant over expression of mRNA levels in late 
and early stage OSCC samples indicating G2/M transition is essential for malignant 
progression. FOXM1 target and regulated genes such as CDK2, TGFA, CCND2, CCNB2, 
CCNA2, CCNE2, CDC25B, CDC20, PLK1, AURKB, CENPF, KIF20 (Wierstra & Alves 
2007) and CEP55 (Walk & Weed 2011), that play an important role in cell cycle progression 
and segregation of chromosomes were over expressed and up regulated in the late stage gene 
profile. Previous studies indicated tumours show over expression of genes involved in 
chromosome segregation (Jallepalli & Lengauer 2001) and the current study has provided 
further evidence to the same trend in late stage OSCC samples. The direct target of FOXM1 
and downstream effector molecule of G2/M transition is CEP55 that also promotes 
cytokinesis (Gemenetzidis et al. 2009).  QPCR analysis of FOXM1 and CEP55 in early and 
late stage OSCC samples showed significant over expression compared to normal samples 
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showing that genes involved in G2/M transition are essential for cell proliferation in early and 
late oral malignant samples. 
2.5.3 Interferon and oncostatin-M signalling promote 
inflammation in OSCC malignant samples 
Interferon signalling and oncostatin-M signalling were among the significant pathways 
differentially regulated in late stage OSCC samples. STAT1 and STAT2, mediators of 
interferon signaling, and their targets BAK, TAP1, IRF1, IFI35, IFIT1, OAS1, MX1, IFIT3, 
IFI35 were up regulated in the late stage OSCC gene profile. Specifically, QPCR analysis of 
STAT1, STAT2 and their downstream target OAS1 confirmed the up regulation of these 
genes in early and late stage OSCC. These studies are consistent with an earlier study 
showing the key regulator of interferon signaling, STAT1, is up regulated in OSCC tissues 
(Mendez et al. 2007) and also plays an important role in regulating oncostatin-M signalling. 
QPCR analysis of downstream regulators of STAT1: PLAU, MMP1, MMP3 and MMP13 
showed significant increase of gene expression in early and late stage OSCC samples. It has 
been reported that increased levels of PLAU, a serine protease, promotes cancer progression 
by degrading ECM (Look et al. 2002). Taken collectively, these observations suggest that 
STAT1 may have a key role in inducing incessant inflammation leading to deposition of 
MMPs and matricellular proteins which further increased fibrotic conditions.  
2.5.4 Extracellular Matrix (ECM) remodelling in oral squamous 
cell carcinoma 
The extracellular matrix (ECM) is divided into two types, interstitial and basement, based on 
their function (Frantz, Stewart & Weaver 2010). Basement membrane that contains type IV 
collagen and laminin as one of the major components divides the epithelial cells from the 
connective tissue and provides a structural support to the cells and the interstitial matrix, 
which provides support between the cells in the connective tissue and contains mostly 
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collagen, fibronectin and proteoglycan (Frantz, Stewart & Weaver 2010). Microarray data 
from the current study has shown over expression of genes in OSCC samples that are 
implicated in ECM remodelling such as laminin-5 subunits (LAMA3, LAMB3 and LAMC2), 
fibronectin (FN1), matrix metalloproteinases (MMP1, MMP3, MMP7, MMP9, MMP10, 
MMP11, MMP12 and MMP13), growth factor (TGFB1), POSTN, CTSL, CTSV, ITGA6, 
ITGB4,COL4A1 and COL4A5. Periostin, POSTN, a matricellular protein, interacts with αv 
integrins to modulate the expression of downstream targets that include growth factor 
TGFB1, collagen, chemokines, fibronectin and α-smooth muscle actin, to remodel the ECM 
supporting the tumour and creating the niche through fibrogenic stellate cell activation 
(Bonnet et al. 2009; Erkan et al. 2007; Snider et al. 2008; Uchida et al. 2012). This protein 
plays an important role in the processes of angiogenesis, metastasis and invasion by inducing 
the expression of MMP9, MMP10 and MMP13 and also promotes growth of OSCC cells in 
an anchorage independent manner (Deraz et al. 2011; Kudo et al. 2012a; Kudo et al. 2012b; 
Kudo et al. 2006). Therefore, the microarray data from the current study has demonstrated 
increased expression of POSTN along with its regulators such as TGFB1, FN1, MMP9, 
MMP10 and MMP13, thus providing evidence for a potential role of POSTN and its targets 
in ECM remodelling in oral cancer.  
Laminin-5, composed of α3, β3 and γ2 chains, is present in the basement membrane of 
normal epithelium and provides mechanistic and protective support to the epithelium 
(Rousselle et al. 1995). Overexpression of laminin-5 chains by epithelial cells and fibronectin 
generated by myofibroblast cells in the stromal region is regulated by TGFB1, leading to 
ECM remodelling (Berndt et al. 1995; Borsi et al. 1990; Korang et al. 1995). Integrin α6β4 is 
a laminin-332 binding receptor that provides adhesive support and induces cellular migration 
during wound healing process (Litjens, de Pereda & Sonnenberg 2006). Integrin α6β4 
develops a pro-invasive role by associating with receptor tyrosine kinase MET to further 
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activate migratory signals (Janes & Watt 2006). In the current study, QPCR analysis of 
ITGA6, COL4A1 and LAMA3 genes showed significant over expression in late and early 
stage OSCC samples consistent with ECM remodelling and myofibroblast activation to 
support the tumour niche that is essential for oral cancer progression.  
Tenascin-C (TNC), another matricellular member, is highly expressed during tissue 
regeneration (Orend & Chiquet-Ehrismann 2006) and earlier studies showed TNC induced 
expression of MMP-9 and MMP-13 led to invasive behaviour of cancer cells (Hancox et al. 
2009; Ilunga et al. 2004). However, another class of proteases, cysteine proteases, also play a 
role in ECM remodelling (Ilunga et al. 2004) includes Cathepsin L forms: CTSL and CTSV, 
up regulated in the late stage OSCC as revealed from the current microarray study. 
Cathepsin-L is known to cleave fibronectin and laminin(Ishidoh & Kominami 1995). 
Together, these observations strongly suggest the ECM remodelling process is essential for 
oral cancer malignancy. 
2.5.5 Differential regulation of significant genes in DOK and 
SCC25 indicates G2/M transition and interferon signalling 
may be an early event and MMP13 expression a later event 
during oral carcinogenesis 
An examination of genes involved in fibrosis and ECM remodelling (IL1A, IL1B, MMP13 
and SPP1), mediators of interferon signalling (STAT1), the downstream molecule of 
interferon signalling (OAS1) involved in inflammation, CEP55 and FOXM1, a regulator for 
several targets involved in cell cycle progression, segregation of chromosomes and G2/M 
transition, were examined by QPCR analysis and only MMP13 and SPP1 showed significant 
difference in expression in SCC25 cells compared to DOK cells. No significant difference in 
the expression of genes promoting interferon signaling and G2/M transition between SCC25 
and DOK cells was observed and this may indicate that these events might be early during 
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transformation from normal tissue to dysplasia. SPP1 showed significant increased 
expression with ~25 fold change difference in SCC25 cells compared to DOK cells. An 
earlier study has shown that knockdown of SPP1 gene expression by siRNA reduced cell 
growth and invasion of the OSCC cell line (Muramatsu et al. 2005). The MMP13 gene 
showed an increased level of expression in SCC25 cells (~150 fold change) compared to 
DOK cells. IHC analysis of the MMP13 protein in oral cancer biopsy tissue showed the score 
was significantly higher in early and late stage OSCC samples and staining was focused to 
the invasive front of the epithelial region consistent with its potential role in oral malignancy. 
This indicates expression of the SPP1 and MMP13 genes may occur during the beginning of 
malignancy stage. 
2.5.6 MMP13 knockdown reduced cell proliferation and 
tumorigenic properties in oral cancer cells 
Analysis of MMP13 in SCC25 and DOK cells using immunofluorescence revealed a high 
intensity stain preferentially in SCC25 cells confirming the QPCR results. Further siRNA 
treatment specific for MMP13 in SCC25 cells decreased cell proliferation significantly. In 
addition, analysis of colony formation, migration and invasion revealed a significant 
reduction in these activities suggesting MMP13 plays an essential role in the tumourigenicity 
of oral cancer cells and may be a target of therapeutic importance. Previous studies related to 
melanoma, breast cancer and glioblastoma also indicated increased MMP13 expression 
contributing to tumourigenicity and thus MMP13 can be a potential therapeutic target for 
these cancer types (Inoue et al. 2010; Meierjohann et al. 2010; Nannuru et al. 2010). 
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2.6 Conclusion 
This study has provided a more detailed understanding of the molecular pathways and 
processes in oral cancer. The lack of clinically proven biomarkers indicates that OSCC most 
likely develops from changes in a complex environment and associated multicellular systems. 
To our knowledge, this is the first study to report that OSCC progression is associated with 
the genes regulating hepatic stellate cell activation eventually leading to inflammation, 
fibrosis and ECM remodelling to promote tumour growth and progression. Therefore, the 
data indicates that broad spectrum therapeutic drugs are required to target these genes, thus 
controlling tumour growth and preventing tumour cells from proliferating by using 
alternative pathways. 
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3 Aspirin inhibits G2/M progression and 
the interferon pathway and induces the 
expression of PPARG and CASP9 in oral 
cancer cells. 
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3.1 Summary 
The incidence and mortality rate of oral cancer is amongst the highest of all cancers. A major 
cause is attributed to several factors including chronic inflammation. Non-steroidal anti-
inflammatory drugs (NSAID) like aspirin are known to have anti-inflammatory properties 
and can be used to treat cancer cells, but the molecular mechanisms altered by aspirin are not 
fully understood in oral cancer cells. This study is the first to report the changes in the gene 
expression profile of aspirin-treated oral cancer cells (SCC25). Ingenuity pathway analysis 
showed 1422 differentially regulated genes in treated cells compared to untreated cells, and 
the most significant pathways altered included cell cycle checkpoint: G2/M transition and 
interferon signalling. In addition, most of the over expressed genes in oral squamous cell 
carcinoma (OSCC) samples identified from our previous microarray study were down 
regulated in aspirin-treated SCC25 cells. In-vitrotumorigenesis assays showed that aspirin 
reduced tumorigenicity and increased sensitivity to apoptotic signals and expression of gene 
markers for myoepithelial cells, invasion, metastasis and epithelial to mesenchymal transition 
(EMT). The data suggests induction of apoptosis and inhibition of cell growth is triggered by 
activation of PPARG and CASP9 in aspirin-treated cells, and this activation is apparent at 
both the level of gene and protein expression. These data suggest aspirin may be a potential 
therapeutic for oral cancer with a broad spectrum effects on genes involved in major 
processes that include cell cycle progression, inflammation, EMT, metastasis and invasion.  
3.2 Introduction 
Oral squamous cell carcinoma (OSCC) is a major disease that is affecting worldwide 
(Greenlee RT et al. 2001). Advanced treatment strategies have not improved the 5-year 
survival rate of oral cancer patients due to low efficacy and high toxicity of treatment 
regimens (Kim, Kies & Herbst 2002; Papadimitrakopoulou VA et al. 1997; Sano & Myers 
2007).  Prolonged and continuous exposure to agents such as viruses, bacteria and chemicals 
  Chapter 3 
107 
 
that induce chronic inflammation most likely increase the risk of cancer (Colotta et al. 2009; 
Hanahan & Weinberg 2011; Mantovani et al. 2008) possibly leading to genetic instability and 
over-expression of oncogenes and down-regulation of tumour-suppressor genes (Feller, Altini 
& Lemmer 2013). The microenvironment in the tumour will be impacted by reactive oxygen 
species (ROS), nitrogen radicals, chemokines and cytokines to increase evasion from 
protective immune responses and to promote cell proliferation, and survival  (Colotta et al. 
2009; Lin & Karin 2007). Continuous over-expression of immune responsive elements also 
triggers the process of fibrosis(Chiang et al. 2002; Jeng JH et al. 2003). Recent studies have 
linked the role of inflammation to promoting epithelial to mesenchymal transition (EMT) 
(Sansone & Bromberg 2011) and further acquisition of cancer stem cell (CSC) like properties 
(Lopez-Novoa & Nieto 2009; Singh & Settleman 2010).  
Non-steroidal anti-inflammatory drugs (NSAIDs) include structurally different groups of 
compounds that have a similar action against inflammation by inhibiting prostaglandin 
synthesis and activity of cyclooxygenase (COX) enzymes ('Collaborative overview of 
randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and 
stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet 
Trialists' Collaboration'  1994). Aspirin is a member of the NSAIDs and has emerged as an 
anti-inflammatory and chemo-preventive agent (Ulrich, Bigler & Potter 2006). Nuclear 
factor-kB (NF-kB), a nuclear transcription factor, which plays a primary role in the 
inflammation process and is over expressed in many cancer cell types (Bharti & Aggarwal 
2002) including oral cancer (Rao et al. 2010) is one of the targets of aspirin. Aspirin binds to 
the inhibitor of NF-κB which leads to inactivation and further inhibition of DNA binding 
capacity of NF-κB(Kopp & Ghosh 1994; Stark et al. 2001). It has been reported that daily 
aspirin intake will reduce cancer metastasis leading to reduction in the number of early cancer 
deaths (Rothwell et al. 2012).  Generally, evidence is emerging to show that aspirin induces 
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anti-inflammatory effects in many tumour cell types, by impacting on COX enzymes 
(Alfonso et al. 2014) and NF-kB (Rao et al. 2010). However, the broader effects of aspirin on 
tumour cells have not been examined. Indeed, the study of the molecular mechanisms exerted 
by aspirin on the inhibition of oral carcinogenesis has not elucidated the molecular targets or 
pathways that are clinically relevant (Rao et al. 2010). 
In our previous microarray data analysis (GSE56532), significant expression of candidate 
genes related to cell cycle, fibrosis and inflammation in early and advanced stage OSCC 
samples has indicated the importance of these processes in progression of oral cancer. It was 
also observed that the nuclear receptor, peroxisome proliferator-activated receptor gamma 
(PPARG) was significantly down regulated in malignant tissues in comparison with the 
normal surrounding tissues (GSE56532). Earlier studies showed NSAIDs can activate 
PPARG (Lehmann et al. 1997) and aspirin treatment has induced apoptosis in OSCC cell 
lines, but no cytotoxic effect was observed in normal human oral keratinocytes when aspirin 
was included in media at 2.0 mM concentration (Rao et al. 2010). Oral cancer occurrence and 
progression is not attributed to chronic inflammation alone and other processes such as 
fibrosis (Chaturvedi et al. 2013), cell cycle (Schoelch et al. 1999), EMT (Krisanaprakornkit 
& Iamaroon 2012) and several genetic alterations (Pérez 2009) also contribute toward tumour 
progression.   
Despite anti-inflammatory effects, the specific molecular mechanisms exerted by aspirin in 
oral cancer cells are still unknown. In this study, we have used microarray analysis to 
examine the effect of aspirin on the oral squamous cell carcinoma cell line, SCC25. 
 
 
  Chapter 3 
109 
 
3.3 Materials and Methods 
3.3.1 Clinical samples 
Oral squamous cell carcinoma (OSCC) samples and their surrounding normal tissue were 
obtained with informed consent from OSCC patients before undergoing treatment at the 
Cancer Centre Welfare Home & Research Institute, Kolkata. Ethical approval for sample 
collection and the analysis of these samples was obtained from Samkshema Independent 
Ethics Committee at Hyderabad. Tumour samples were collected from the patients (n=49) 
having tumours at different sub-sites of oral cavity: buccal mucosa (n=14),floor of the mouth 
(n=15), gingiva (n=9) and tongue (n=11) with 24 samples belonging to early and 25 samples 
late stage OSCC. The staging of the clinical samples were designated according to the Union 
for International Cancer Control (UICC) classification(Webber et al. 2014). 
3.3.2 Cell lines 
The SCC25 cell line was obtained from the American type culture collection (ATCC) and 
cultured in 1:1 mixture of DMEM and Ham’s F12 medium with 10% fetal bovine serum, 2.5 
mM L-glutamine, 400 ng/ml hydrocortisone, 100 μg/ml streptomycin and 100 μg/ml 
penicillin. The DOK cell line was purchased from the European collection of cell cultures 
(ECACC) and was maintained in DMEM containing 2mM Glutamine, 5μg/ml 
Hydrocortisone and 10% fetal bovine serum. These cell lines were cultured at 37ͼC with 5% 
CO2. 
3.3.3 Aspirin treatment of SCC25 cells and MTS assay 
Aspirin (Acetylsalicylic acid; Sigma-Aldrich), was added to DMEM/F12 complete growth 
media. Aspirin was dissolved in ethanol and tested at a final concentration of 0.5mM to 20 
mM. Ethanol was added to media at 1:400 and the control media included ethanol only. After 
treating cells (5 x 103) with aspirin for 72h, MTS solution (promega) was added and cells 
were incubated for 4h and absorbance measured at 490nm. Cell viability was expressed as a 
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percentage relative to the control cells. Biological and technical replicates (n=3) each were 
considered for the statistical analysis of MTS assay. 
3.3.4 Cell cycle analysis 
SCC25 cells treated with either 2.0 mM aspirin or vehicle for 72 h were trypsinized and fixed 
with 70% ice-cold ethanol and kept at 4ͼC overnight. Cells were washed with ice-cold 
phosphate buffered saline (PBS), stained with 50μg/ml propidiumidodide (in PBS) mixed 
with 125 μg/ml of RNase A and placed in the dark at 37ͼC  for 30 min. Cells were again 
washed with ice cold PBS and DNA content measured using BD Canto Flow Cytometer. 
3.3.5 Annexin V staining 
Apoptosis was determined in the SCC25 cells using Annexin V and propidium iodide 
staining (Life Technologies). Briefly, cells were washed with PBS and incubated with either 
aspirin (2.0 mM) or vehicle for 72h. Cells were collected and annexin V and propidium 
iodide staining was performed according to manufacturer’s instructions, before performing 
flow cytometry analysis using BD a Canto Flow Cytometer.  
3.3.6 RNA isolation and Quantitative PCR (Q-PCR) 
Total RNA was isolated from SCC25 and DOK cells using an RNeasy mini kit (Qiagen) and 
following the manufacturer’s protocol. Tumour samples from patients were collected and 
immediately transferred to All Protect Tissue Reagent (Qiagen) and stored at -70qC until 
further use. RNA was isolated from the tissue samples using All Prep DNA/RNA/protein 
isolation kit (Qiagen). Superscript III (Invitrogen) was used to synthesize cDNA from total 
RNA according to manufacturer’s instructions. The cDNA (25ng) was used to perform 
quantitative Real Time PCR (qPCR) in a 10μl reaction volume on an ABI 7900 HT Detector 
system with Sybr green PCR master mix (Applied Biosystems) according to the 
manufacturer’s protocol. Primer sequences were designed using PCR prime design tool 
Primer3 (Rozen & Skaletsky 2000) and gene specificity was checked using the National 
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Center for Biotechnology Information nucleotide database. Steps followed during qPCR to 
generate amplification curves include an initial denaturing step for 30 minutes at 95°C, 
followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 seconds. 
Primer sequences for PPARG included Fwd – 5’ AAATGCCTTGCAGTGGGGATGT 3’; 
Rev – 5’ TCAGCTGGTCGATATCACTGGA 3’ and GAPDH included Fwd – 5’ 
TCACCAGGGCTGCTTTTAACTC 3’; Rev – 5’TGCCATGGGTGGAATCATATTGGA 3’. 
The expression of PPARG was normalized to housekeeping gene GAPDH using the Delta 
delta Ct method. 
3.3.7 Microarray and data analysis 
Total RNA isolated from aspirin-treated and untreated SCC25 cells was analysed on a 2100 
bioanalyzer (Agilent Technology, ON, CA). RNA samples that showed a RNA integrity 
number above 9.4 were used for gene expression analysis. cRNA synthesis (Ambion), 
labelling, hybridization and scanning of arrays (Illumina) was done following the 
manufacturer’s instructions. Human HT 12 v. 4 arrays (Illumina) was used to analyse gene 
expression in aspirin-treated and untreated cells, each in biological triplicates. The raw data 
from Genome Studio Version 1.9.0 (Illumina) passed Illumina’s sample QC metrics. Analysis 
of microarray data was performed using Ingenuity® iReport™. Probeset intensities were 
summarized and normalized using RMA, and significant differential expression was 
determined by a moderated t-test (Limma) using an FDR-adjusted P-Value cut-off of 0.05. 
The data was submitted to Gene Expression Omnibus (GEO) database and is available with 
the accession number GSE58162. 
3.3.8 Identification of significant pathways, biological processes 
and diseases 
iReport (Ingenuity) was used to identify the significant biological processes, pathways and 
diseases in the data set with a fold change cut off of 1.5. These significant processes, 
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pathways and disease associated genes present in Ingenuity’s Knowledge Base were 
considered for analysis. Right-tailed Fischer’s exact test was used to calculate P-Values. 
3.3.9 Identification of significant molecular interactions between 
differentially expressed genes 
The data set of differentially expressed genes from aspirin treated and untreated SCC25 cells 
were analyzed using iReport (Ingenuity Systems). Each probeset or gene identifier was 
mapped to its corresponding gene in the Ingenuity Knowledge Base. A fold change cut off of 
1.5 was set to identify genes whose expression was significantly differentially regulated. 
These genes were then used to query a global molecular network developed identified 
molecular interactions between differentially expressed genes in the dataset. 
3.3.10 Clonogenesis (colony forming) assay 
SCC25 cells were seeded at a density of 1x103 cells in each well of a 6- well plate and 
cultured overnight in complete culture media. Media was removed and the cells were treated 
with 2.0 mM aspirin in the media for 7 days. Cells were washed with 1x PBS and fixed in 
methanol for 15 min at room temperature. Cells were subsequently stained with crystal violet 
for 15 min at room temperature and washed with water. Colonies with more than 50 cells 
were considered for analysis using microscopy and quantified. The experiment was repeated 
twice in triplicate and the number of colonies in untreated cells was used as a control. A P-
Value of <0.05 was considered significant. 
3.3.11 Flowcytometry for CEP55 staining 
SCC25 cells cultured with and without 2.0 mM of aspirin treatment for 72 h were analysed 
using flow cytometry. Cells were washed with PBS and harvested using 0.25% (w/v) trypsin-
EDTA solution. Cells were collected, washed twice with PBS and fixed with 70% (v/v) 
ethanol for one hour on ice. Cells were washed twice with 1% (w/v) BSA in PBS, 0.1% (v/v) 
triton X-100 in PBS was added to the cells at room temperature for 15 min and cells 
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harvested by centrifugation for 1000 g for 5 min. Cells were blocked in 3 % (w/v) BSA in 
0.1% (v/v) triton X-100 in PBS. Cells were incubated in primary antibody (anti-rabbit 
monoclonal CEP55 antibody, Abcam) in 3 % (w/v) BSA in 0.1% (v/v) triton X-100 in PBS 
for 30 min at room temperature. Cells were washed twice in 3 % (w/v) BSA in 0.1% (v/v) 
triton X-100 in PBS by centrifugation at 400 g for 5 min and secondary antibody (anti rabbit 
alexafluor 488) in 3 % (w/v) BSA in 0.1% (v/v) triton x 100 in PBS was added to cells. Cells 
were washed twice and resuspended in in 3 % (w/v) BSA with 1% sodium azide (w/v) in 
PBS and further analysed using the FACS Canto (Becton Dickinson) instrument and FACS 
DIVA software.  Secondary conjugated antibody only was used as a negative control. 
3.3.12 Migration assay 
Cells were grown to confluence in a 6-well plate. Cells were scraped with a sterile 200Pl 
pipette tip and washed with PBS. Cells were then incubated with serum free media with and 
without 2.0 mM aspirin for 72 h. The wound healing process was observed under the 
microscope and images obtained from different fields of the same scratch. Cell migration was 
analysed using ImageJ software(Abramoff MD, Magalhaes PJ & S. 2004). The experiment 
was repeated in triplicate and a P-Value of <0.05 was considered as significant. 
3.3.13 Sphere formation assay 
The method of sphere culture was based on a previous study (Chen et al. 2012). SCC25 cells 
were harvested using 0.25% (w/v) trypsin-EDTA solution and cell counted. Cells were plated 
at 3 x 104 cells per well on agarose coated 6-well plates-with and without 2.0 mM aspirin in 
culture media. Cells were cultured for 7 days and media changed every 2 days.  
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3.3.14 Immunofluorescence 
SCC25 cells were fixed with 4% (w/v) paraformaldehyde and washed twice with ice cold 
PBS. Cells were treated with 0.1% (v/v) triton X-100 in PBS, washed again with PBS twice 
and blocked using 1% BSA in PBS for one hour. Blocking reagent was removed and primary 
antibody was added and incubated overnight at 4ͼC. Primary antibody solution was removed 
and an appropriate fluorescence tagged secondary antibody was added and incubated for one 
hour at room temperature. Cells were washed with PBS twice and Hoechst dye (Sigma) was 
added (0.1 μg/ml) and incubated at room temperature for 15 min to stain the nuclei. Cells 
were washed twice with PBS and observed under the fluorescent microscope (Nikon, 
Melville, USA). Images were captured using NIS Elements F 3.0 (Nikon, Melville, USA). 
The conjugated secondary antibody only was used as a negative control. A list of primary and 
secondary antibodies and their dilutions are presented in the Table 3.1. 
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Table 3.1List of primary antibodies and their dilutions used in immunofluorescence 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.15 Immunohistochemistry 
To examine the expression of PPAR-γ protein in normal, early and late stage OSCC tissue 
samples, immunohistochemistry was performed on formalin fixed paraffin embedded tissue.  
Tumour tissue and adjacent normal sections stored at - 80ͼC were fixed in 10% formalin, 
dehydrated and embedded in paraffin immediately. Thin sections (4 μm) prepared and 
deparaffinised using xylene, and further hydrated in series of ethanol dilutions (100%, 90% 
and 70% (v/v)). The sections were treated with hydrogen peroxide (3% in methanol) to block 
the endogenous peroxidase activity. Antigen retrieval was performed using 10mM citrate 
buffer by boiling the sections at 95ͼC for 25 minutes. Sections were treated for 30 minutes 
with 5% of goat serum (Invitrogen) as a blocking solution. Sections were incubated with 
primary antibody (rabbit polyclonal PPARG antibody, Abcam) overnight at 4ͼC. Sections 
Primary 
Antibody 
Supplier and catalogue 
number 
Dilution Species  Secondary Antibody 
CEP55 Abcam, ab170414 1:250 Rabbit Alexa fluor 488 (Life 
Technologies) 
PPARG Abcam, ab19481 1:50 Rabbit Alexa fluor 488 (Life 
Technologies) 
KRT14 Abcam, LL002 1:200 Mouse Alexa fluor 594 (Life 
Technologies) 
MMP13 Genetex, GTX100665 1:100 Rabbit Alexa fluor 488 (Life 
Technologies) 
Vimentin Dako, M0725 1:100 Mouse Alexa fluor 594 (Life 
Technologies) 
E-Cadherin Cell signaling technology, 
3195S 
1:200 Rabbit Alexa fluor 488 (Life 
Technologies) 
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were treated with HRP- conjugated goat anti-rabbit HRP (1:100, Abcam) as a secondary 
antibody for 60 minutes at room temperature. The 3, 3- Diaminobenzidine (DAB, Cell 
Signaling Technology) was used for the detection. Nuclear counter staining was performed 
using haematoxylin (Polysciences) and the sections were mounted with DPxhistamount 
(Sigma). Images were captured and analysed using a Nikon Eclipse Ti-S microscope and 
NIS-Elements F 3.0 (Melville, USA). ImageJ software was used to analyse stained and 
unstained sections using software instructions(Abramoff MD, Magalhaes PJ & S. 2004). 
Staining was scored based on the intensity and area of staining. A minimum of 5 fields for 
each section was analysed in a ‘blind’ assessment and the staining percentage score was 
determined. The intensity of staining was scored as follows; - +1, weak; +2, moderate; +3, 
strong. Primary antibody was replaced by non-inducing serum in negative controls to assess 
the staining specificity. The staining intensity obtained was multiplied with the percentage of 
positive stained cells to produce a staining score for PPARγ(Shimada et al. 2005; Tanaka et 
al. 2003). Statistical significance was assessed by using the Mann-Whitney U-test and a P-
Value of <0.05 was considered as significant. 
3.3.16 Statistical analysis 
Statistical significance analyses for each experiment was performed by the two tailed 
student’s t-test method using excel software.  
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3.4 Results 
3.4.1 Aspirin induces cell death in SCC25 cell line 
To find the concentration of aspirin that induces apoptosis, MTS assays were initially 
performed in the oral squamous cell carcinoma (OSCC) cell line (SCC25) and the dysplastic 
keratinocyte cell line (DOK), following incubation with 0 - 20 mM aspirin for 72 h at 37qC 
(Figure 3.1A and B). After 72 h, aspirin induced a significant reduction in viable SCC25 cell 
number at aspirin concentrations ≥ 2.0 mM (Figure 3.1A). Cell viability was completely 
inhibited at 20 mM aspirin and the IC50 was observed between 2 mM and 5 mM aspirin for 
SCC25 cells. Treatment of DOK cells with 20 mM aspirin showed that approximately 30% of 
cells were viable (Figure 3.1B) and the IC50 was approximately 10 mM suggesting that 
aspirin was more effective at reducing cell viability of SCC25 cells than DOK cells. 
In SCC25 cells the MTS assay revealed 2.0 mM aspirin treatment resulted in ~30-40 % 
reduction in cell viability. To determine whether apoptosis contributed to this decrease in cell 
viability annexin V and propidium iodide staining was performed followed by flow 
cytometry analysis. Annexin V and propidium iodide staining showed that treatment with 
2mM aspirin resulted in a 22.3% increase in the early and late apoptotic cells (Q4 and Q2, 
Figure 3.1C). Furthermore, ~25% reduction in live cells (Q3) was observed in aspirin treated 
cells compared to untreated cells (relative to control).  
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3.4.2 Aspirin treatment reduces the proportion of cells in the S, 
G2/M and G0/G1 phases of the cell cycle 
Cell cycle analysis was performed for aspirin-treated (2.0 mM) and untreated SCC25 cells by 
propidium iodide staining after 72 h of culture. Profiles of flow cytometer analysis (Figure 
3.1D) indicated that aspirin exposure led to a decrease in G2/M phase by 41% and S - phase 
by 23% relative to untreated cells. The decrease in cells in the G0/G1 might be due to an 
increase in the apoptotic cells in aspirin treated cells. Taken together, these results indicate 
that aspirin induces cell cycle arrest by inhibiting the cell division and growth of oral cancer 
cells. 
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Figure 3.1 Aspirin treatment inhibits the growth of oral cancer cells. 
(A) SCC25 cells and (B) DOK cells  treated with different concentrations of aspirin (0 to 
20mM) were evaluated  for viability using MTS reagent and the results were plotted relative 
to control (without treatment).  * indicates significant differences between aspirin treated and 
untreated cells (Student’s t-test, p<0.05). (C) Aspirin treated SCC25 cells were evaluated for 
apoptosis by annexin V and propidium iodide staining. (D) Cell cycle analysis of SCC25 
cells treated with aspirin using propidium iodide staining and flow cytometry. Sorted 
populations of the treated cells were classified as: a – apoptotic cells, b – G0/G1, c – S and d 
– G2/M. The obtained results were further quantified and expressed as a percentage of the 
cell population (right panel). 
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3.4.3 Gene profiling of aspirin treated and untreated oral cancer 
cells 
To better understand the molecular mechanisms and cellular changes following aspirin 
treatment at the level of gene expression, microarray analysis of SCC25 cells treated with 2.0 
mM of aspirin for 72 h was compared with untreated SCC25 cells. The principal 3D 
component analysis (PCA) plot (Figure 3.2A) for batch corrected expression values 
illustrated the quality of separation between the two experimental groups. The cluster 
dendrogram (Figure 3.2B) represents the similarity in gene expression between samples of 
aspirin treated and untreated groups and demonstrated a closer similarity within the treated 
group (ASP1, ASP2 and ASP3) and untreated group (CTRL1, CTRL2 and CTRL3) than 
between the groups. To find the similarity between the samples of the same group, a heat map 
was generated for the batch corrected expression values (Figure 3.2C) and showed that the 
samples of each group were almost identical (blue) when compared to the different groups 
(yellow). Patterns in the heat map indicate there are prominent biological differences or 
confounding sources of variance, such as batch effects when comparisons were performed 
between samples of two groups, but not in the samples of the same group. A volcano plot 
(Figure 3.2D) showed a comparison of fold change (FC) verses statistical significance and 
suggested that aspirin had induced significant differential regulation of 1422 genes with a P-
Value ≤ 0.05.  
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Figure 3.2 Gene profiling of aspirin treated and untreated SCC25 cells. 
The principal component analysis illustrates the quality of separation between the aspirin 
treated and untreated groups in 3D version. (B) Cluster dendrogram shows correlation in gene 
expression among aspirin treated (ASP1, ASP2 and ASP3) and untreated (CTRL1, CTRL2 
and CTRL3) oral cancer SCC25 samples. (C) Between-Sample Heatmap of batch-corrected 
expression values where each square represents the distance between two samples, where 
blue means the two samples are similar, and yellow means they are different. The Volcano 
plot (D) showing fold change on x-axis and the statistical significance of differential 
expression (P-Value) on y-axis with 1422 differentially regulated genes. 
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3.4.4 Signaling pathway analysis 
1422 genes that were differentially expressed in aspirin treated oral cancer cells with a P-
Value ≤ 0.05 and FC ≥ 1.5 were subjected to pathway analysis using the Ingenuity Pathway 
Analysis (IPA, Ingenuity Systems, www.ingenuity.com) software where iReport was 
generated after uploading the data set files of gene expression values and gene identifiers. All 
the genes were mapped to each of the canonical pathways present in the IPA database. The 
most significant pathways expressed in aspirin treated cells were involved in mitotic 
regulation, G2/M DNA damage check point regulation and interferon signalling. The genes 
that putatively regulate these pathways were significantly down-regulated following aspirin 
treatment (Figures 3.3A, B and C). Among the processes most differentially expressed in 
aspirin-treated cells were genes that regulate the segregation of chromosomes. These genes 
were significantly down-regulated following aspirin treatment (Table 3.2).  
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Table 3.2List of genes that regulate segregation of chromosomes process in aspirin-
treated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symbol: Name 
Fold 
Change 
SKA3: spindle and kinetochore associated complex subunit 3 -1.508 
SGOL1: shugoshin-like 1 (S. pombe) -1.515 
ESPL1: extra spindle pole bodies homolog 1 (S. cerevisiae) -1.654 
NCAPG2: non-SMC condensin II complex, subunit G2 -1.72 
SKA1: spindle and kinetochore associated complex subunit 1 -1.729 
INCENP: inner centromere protein antigens 135/155kDa -1.837 
CENPW: centromere protein W -1.837 
BUB3: BUB3 mitotic checkpoint protein -1.927 
ZWINT: ZW10 interacting kinetochore protein -2.015 
GPSM2: G-protein signaling modulator 2 -2.037 
SPC25: SPC25, NDC80 kinetochore complex component -2.053 
ECT2: epithelial cell transforming sequence 2 oncogene -2.07 
NUF2: NUF2, NDC80 kinetochore complex component -2.102 
PLK1: polo-like kinase 1 -2.234 
SMC4: structural maintenance of chromosomes 4 -2.255 
LMNA: lamin A/C -2.492 
CENPF: centromere protein F, 350/400kDa -2.679 
NDC80: NDC80 kinetochore complex component -2.699 
MAD2L1: MAD2 mitotic arrest deficient-like 1 (yeast) -2.819 
NCAPD2: non-SMC condensin I complex, subunit D2 -2.826 
PTTG1: pituitary tumor-transforming 1 -3.064 
NEK2: NIMA-related kinase 2 -3.281 
BUB1: BUB1 mitotic checkpoint serine/threonine kinase -3.349 
HJURP: Holliday junction recognition protein -3.774 
NCAPG: non-SMC condensin I complex, subunit G -3.793 
CENPE: centromere protein E, 312kDa -3.866 
TPX2: TPX2, microtubule-associated -3.982 
KIF2C: kinesin family member 2C -4.168 
NUSAP1: nucleolar and spindle associated protein 1 -4.305 
AURKB: aurora kinase B -4.357 
CCNB1: cyclin B1 -4.448 
TOP2A: topoisomerase (DNA) II alpha 170kDa -4.909 
CCNA2: cyclin A2 -5.231 
AURKA: aurora kinase A -5.541 
CCNB2: cyclin B2 -6.635 
  Chapter 3 
125 
 
 
 
A
  Chapter 3 
126 
 
 
 
 
 
 
B
C
  Chapter 3 
127 
 
Figure 3.3 Pathway analysis using Ingenuity software for the gene expression profile of 
aspirin treated oral cancer cells in comparison with the untreated cells. 
The differentially regulated genes with fold change value > 1.5 were marked in yellow and < 
-1.5 were marked in blue. Intensity of the colors, yellow and blue, is directly proportional to 
the fold change value. A) Genes involved in mitotic role of polo like kinases (ESPL1, 
PPP2CA, CDC25C, PLK4, PKMYT1, CDC7, PLK1, FBXO5, KIF11, PTTG1, CDC20, 
KIF23, PRC1, CCNB1, CDK1 and CCNB2) are significantly down regulated and CDC16 
that is up regulated. B) G2/M check point in the cell cycle is essential for the control of DNA 
damage. The downstream effect of ATM and ATR genes was seen (down regulation of 
CDC25C, PLK1, SFN, SKP1, PKMYT1, YWHAB, CKS2, CCNB1, TOP2A, CDK1 and 
CCNB2). CDK7, involved in DNA repair, is up regulated. In 14-3-3 complex, sub units beta 
and gamma are down regulated C) Interferon signaling mediated by STAT1 and STAT2 is 
significantly down regulated in the aspirin treated cells. Downstream effectors of STAT1 and 
STAT2 that promote inflammation, IFI35, OAS1, IFIT1, IFIT3, and IFI35 were also down 
regulated. 
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3.4.5 Aspirin treatment down regulates cell cycle progression and 
inflammation and activates apoptosis in oral cancer cells 
Differentially expressed genes in aspirin-treated cells were divided into 3 categories; cell 
cycle regulation (Figure 3.4A), apoptosis (Figure 3.4B) and inflammation (Figure 3.4C), 
based on their significant expression and function. It is evident from the pathway analysis 
that aspirin potentially impacted on the cell cycle, especially the G2M check point. Up 
regulation of cell cycle regulators that also include G2/M transition promoting genes is 
evident in oral cancer progression (Schoelch et al. 1999) and more than 50 genes involved in 
the cell cycle progression were down regulated in aspirin treated cells (Figure 3.4A).  Aspirin 
treatment dramatically reduced the expression of genes involved in the regulation of cell 
cycle. IPA  also revealed expression of genes that also played an important role in inducing  
apoptosis- such as peroxisome proliferator activator gamma (PPARG), caspase9 (CASP9), 
protein kinase c zeta (PRKCZ) and insulin receptor substrate (IRS2) in aspirin treated 
cells(Figure 3.4B). Aspirin treatment down regulated expression of MCL1 (Figure 3.4B), 
which is a member of anti-apoptotic BCL2 family that plays an important role in regulating 
cell survival was found to be over expressed in OSCC samples  (Mallick et al. 2009). 
Although extensive study of miRNAs was not performed, based on the provision of the 
details in the illumina array used for the current gene profiling study, differentially regulated 
miRNAs were also expressed. Mir-1228, known to be down regulated in apoptotic cells (Yan 
& Zhao 2012), was down regulated and the MOAP1 gene that mediates caspase-dependent 
apoptosis (Tan et al. 2001) was up-regulated in the aspirin treated cells (Figure 3.4B). Aspirin 
treatment significantly down regulated the expression of chemokines (CXCL1, CXCL10 and 
CXCL14) and several other pro-inflammatory genes (SAA1, PTGS1, OAS1, OAS3, 
IL1RAP, LUM, TNFAIP6, FKBP3, LUM and CD86) in SCC25 cells (Figure 3.4C). 
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Figure 3.4 Differential regulation of significantly expressed genes of present microarray 
data and our previous OSCC data set (from GSE56532) using heat map representation. 
Heat map was generated using hierarchical clustering explorer software. Tri color series 
(blue, red and white) was used to differentiate the expression of genes. Red represents up 
regulation, white represents no change and blue represents down regulation of genes. 
Intensity of the color is directly proportional to the expression or fold change of the gene. 
Color scale bar is represented under each section of the heat map. Control represents SCC25 
cells treated only with the vehicle and treated represents SCC25 cells with 2.0 mM of aspirin 
treatment.  A) Represents genes belonging to cell cycle process especially G2/M transition. 
Aspirin treatment inhibits the promotion cell cycle regulating genes. B) Shows significant 
apoptotic promoting genes PPARG, CASP9, PRKCZ, MOAP1, and IRS2; under expression 
of miR1228 and MCL1 induces apoptosis in treated cells. C) Indicates the expression of 
inflammatory markers and pro-inflammatory cytokines reduction with the aspirin treatment. 
D) Includes the markers for malignancy promoting genes getting down regulated with the 
aspirin treatment. 
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3.4.6 Aspirin inhibits expression of genes that play an important 
role in tumor progression 
Matrix metallo proteinase (MMP) family members (3, 7 and 13), involved in the invasion and 
metastasis of OSCC (Johansson N et al. 1999; Li & Cui 2013; Stokes et al. 2010), were down 
regulated after aspirin treatment (Figure 3.4D). KRT14, one of the intermediate filaments 
reported to be expressed in myoepithelial cells (Prasad et al. 1999) were elevated in OSCC 
samples(Ohkura et al. 2005). Aspirin-treated cells showed a reduction in KRT14 gene 
expression (Figure 3.4D). Aspirin treatment of SCC25 cells reduced the gene expression 
levels of CD151, LAMC2 (gamma2 component of laminin-5) and ITGA6 (Figure 3.4D), 
genes known to be involved in tumour progression (Sadej et al. 2014; Yang et al. 2010). 
SMAD5, which is one of the members of the transforming growth factor family of proteins, 
also associates with cell cycle regulator AURKA to promote tumorigenicity(D'Assoro et al. 
2014) and showed reduced mRNA levels in aspirin treated cells. STMN1, FOS and LOX, 
which are involved in the process of EMT, oral cancer development and progression 
(Albinger-Hegyi et al. 2010; Kouzu et al. 2006; Turatti et al. 2005) were all down-regulated 
in aspirin treated cells (Figure 3.4D). 
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3.4.7 Aspirin treatment leads to down regulation of genes 
associated with OSCC progression 
Differentially expressed genes in the pathways were significantly up regulated in late stage 
OSCC samples (from Chapter 2) were shown in the Table 3.3. Cell cycle progression 
regulators that play an important role in G2/M transition include KIF20A, PLK1, FOXM1, 
cyclin family members (CCNA2, CCNB1 and CCNB2), CEP55, TPX2, HMMR also known 
as RHAMM, aurora kinases (AURKA and AURKB),  survivin (BIRC5), DLGAP5, ECT2 
and PTTG1 were significantly over expressed in OSCC samples in our previous microarray 
data (Table 3.3). Tumor progression markers, LAMC2, ITGA6, MMP13, MMP3, MMP7, 
KRT14, were up regulated in oral cancer samples (Table 3.3). Other pro-inflammatory 
cytokines such as IL1RAP, CXCL1, CXCL10, CXCL11, CXCL13, CXCL14 and OAS3 
were up regulated in OSCC samples and PPARG down regulation was observed in OSCC 
tumour samples (Table 3.3). Aspirin treatment showed down regulation of the above 
mentioned genes in pathways G2/M transition, interferon signaling, mitotic role of polo like 
many genes involved in tumour progression, ECM remodeling and apoptosis (Figure 3.4). It 
can be inferred that the genes that are over expressed in OSCC samples can be suppressed by 
aspirin treatment. Genes involved in the segregation of chromosomes were also suppressed 
by aspirin treatment as shown in Table 3.2 but the oral cancer samples showed up regulation 
of the  same genes involved in the process of segregation of chromosomes (Table 3.4). 
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Table 3.3 Significant genes in OSCC samples (GSE56532) that were differentially 
expressed in aspirin treated cells. 
Pathway/Process Genes Regulation 
G2/M transition CDK1, CKS2, TOP2A, PLK1, CCNB1, CCNB2, CDC25B, BRCA1, PKMYT1 UP 
Mitotic role of polo 
like kinases 
CDC20, CDK1, PLK1, CCNB1, KIF23, CCNB2, PLK4, 
KIF11, CDC25B, PRC1, PTTG1, TGFB1, PKMYT1 UP 
Interferon signaling IFIT1, IFIT3, STAT1, TAP1, BAK1, IFI35, IRF1, MX1, STAT2, OAS1 UP 
Tumor progression 
markers MMP3, MMP7, MMP13, KRT14, LAMC2, ITGA6 UP 
Other cell cycle 
progression genes 
KIF20A, DLGAP5, CDKN3, FBXO5, UBE2C, AURKA, 
BIRC5, CCNA2, CENPA, HMMR, CEP55, AURKB, 
TPX2, CENPE, BUB1, BUB1B, CENPN, FOXM1, 
ECT2, CENPI, CENPK 
UP 
Other Inflammatory 
markers 
IL1RAP, CXCL1, CXCL10, CXCL11, CXCL13, 
CXCL14, OAS3 UP 
Apoptosis PPARG DOWN 
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Table 3.4 List of genes that regulate segregation of chromosomes process in oral 
squamous cell carcinoma tissues (GSE56532). 
Symbol: Name 
Fold 
Change 
TOP2A: topoisomerase (DNA) II alpha 170kDa 3.913 
PLK1: polo-like kinase 1 3.756 
CCNB1: cyclin B1 3.715 
BUB1 (includes EG:100307076): budding uninhibited by benzimidazoles 1 
homolog (yeast) 3.712 
NCAPG: non-SMC condensin I complex, subunit G 3.702 
CCNB2: cyclin B2 3.478 
CCNA2: cyclin A2 3.431 
CENPF: centromere protein F, 350/400kDa (mitosin) 3.258 
NDC80: NDC80 homolog, kinetochore complex component (S. cerevisiae) 3.193 
ECT2: epithelial cell transforming sequence 2 oncogene 3.098 
CENPE: centromere protein E, 312kDa 3.078 
SKA3: spindle and kinetochore associated complex subunit 3 3.047 
KIF2C: kinesin family member 2C 2.904 
PTTG1: pituitary tumor-transforming 1 2.744 
EXO1 (includes EG:26909): exonuclease 1 2.732 
NUF2: NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae) 2.691 
TAP2: transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 2.609 
SGOL1: shugoshin-like 1 (S. pombe) 2.608 
NCAPH: non-SMC condensin I complex, subunit H 2.581 
NUSAP1: nucleolar and spindle associated protein 1 2.45 
SPC25 (includes EG:100144563): SPC25, NDC80 kinetochore complex 
component, homolog (S. cerevisiae) 2.393 
BRCA1: breast cancer 1, early onset 2.375 
BRCA2: breast cancer 2, early onset 2.367 
AURKB: aurora kinase B 2.353 
NCAPG2: non-SMC condensin II complex, subunit G2 2.252 
SMC4: structural maintenance of chromosomes 4 2.172 
DSN1 (includes EG:100002916): DSN1, MIND kinetochore complex component, 
homolog (S. cerevisiae) 2.139 
ZWINT: ZW10 interactor 2.043 
NEK2: NIMA (never in mitosis gene a)-related kinase 2 2.018 
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3.4.8 PPARG mRNA and protein expression in oral cancer and 
their adjacent normal tissue samples 
It is evident from our previous oral cancer microarray data and the present microarray study 
(Table 3.3& Figure 3.4B) that peroxisome proliferator activator receptor-gamma (PPARG) 
was down regulated in oral cancer tissues and oral cancer cells and the aspirin treatment 
induced an increase in PPARG gene expression in SCC25 cells. Quantitative analysis of 
PPARG mRNA levels in normal, early and late stage OSCC samples (n=10 for each group) 
indicated significantly higher levels of mRNA in normal samples in comparison with OSCC 
samples (Figure 3.5A). There was no significant difference between early and late stage 
OSCC samples. In addition, immunohistochemistry analysis of the same tissues was 
consistent with the gene expression profiles showing that PPARG protein is present in 
normal, early and late stage OSCC samples. Normal cells showed PPARG staining from 
moderate to strong in the basal part of the epithelial region (N1 of Figure 3.5B) and some 
tissues showed weak to moderate staining in the N2 (Figure 3.5B). Most of the early and late 
stage OSCC tissues showed weak to moderate staining (E1 and L1 of Figure 3.5B) and very 
few showed moderate to strong (E2 and L2 of Figure 3.5B). E2 and L2 in the Figure were 
well differentiated tumours where the staining is restricted to the epithelial island. E1 and L1 
were poorly and moderately differentiated tumours with weak staining. No significant 
difference in PPARG staining was observed in samples from OSCC patients with different 
levels of differentiated tumours, which is consistent with the intensity scores for this gene 
produced from the microarray data and QPCR results. Normal samples showed statistically 
significant expression of PPARG protein expression when compared to OSCC tissues (Figure 
3.5C). In addition, SCC25 cells showed relatively lower expression of PPARG compared to 
DOK cells (Figure 3.5D). 
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Figure 3.5mRNA and protein level expression of PPARG expression in normal, early 
(stage I and II) and late (stage III and IV) oral cancer tissues. 
A) Total RNA isolated from oral cancer tissue samples was analyzed for mRNA expression 
by Q-PCR with specific primers for PPARG and GAPDH was used as a housekeeping gene. 
The data was compared to the expression values of normal tissues. The data was analyzed 
using one way analysis of variance and the data represented here is having *P value < 0.05. 
NS indicates data non-significant. Number of samples in each group is equal to 10. B) 
Immunohistochemical staining of PPARG in normal oral (n=9), early tumor (n=14) and late 
stage tumor oral cancer samples (n=15) was performed. Although strong staining was 
observed in most of the normal samples (N1), few showed moderate staining (N2). Early 
stage OSCC samples showed weak staining (E1) and also moderate staining (E2). In late 
stage OSCC samples the staining of PPARG is very weak (L1) and some showed moderate to 
strong staining (L2). PPARG staining was observed in the normal samples in the epithelial 
region matching our previous microarray data and the staining intensity score was 
significantly reduced in the early and late stage oral cancer tissues. C) Represents the graph 
for the PPARG staining in normal oral tissue, early and late stage OSCC tissue samples. 
PPARG IHC staining scores were calculated as: staining intensity multiplied with percentage 
of positive cells.  The results represent the mean values and the statistical significance was 
calculated using Mann-Whitney U-test. A *P-Value less than 0.05 was obtained for the 
comparison between normal vs early and normal vs late stage OSCC tumors. A P-Value 
obtained was 0.8786 for the comparison between early and late stage OSCC tumor samples 
which is non-significant (ns). D) Relative PPARG mRNA expression in SCC25 and DOK 
cell lines by QPCR analysis. Total RNA was isolated from SCC25 and DOK cell lines and 
analyzed for mRNA expression using PPARG primers and GAPDH was used as a control. 
The data was analyzed using one way analysis of variance and the data represented here is 
having *P value < 0.05. 
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3.4.9 Phenotypic effects of aspirin treatment on tumorigenic 
properties of oral cancer cells 
Wound healing assays were performed to measure the migration rate of SCC25 cells with and 
without aspirin treatment (2.0 mM for 72 h). In untreated cells, the wound area was 
completely confluent after 72 h whereas the comparable area was only partially confluent 
with aspirin treated cells. Quantitative analysis of the area of closure of the wound in 
untreated and treated cells, performed using ImageJ software (NIH, MD, USA), revealed that 
there was a significant decrease in the number of cells with aspirin treatment (Figure 3.6A). 
Wound closure is less in the aspirin treatment condition due to the inhibition of cell 
proliferation and hence due to this cell migration was also inhibited. When SCC25 cells were 
plated at low density as described in the methods, individual cells exhibited colony growth 
after 7 days, however cells treated with 2.0mM aspirin failed to form colonies (Figure 3.6B). 
The SCC25 cells plated on agarose had the ability to grow spheres however following aspirin 
treatment (2.0mM) cells failed to form spheres (Figure 3.6C).  
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Figure 3.6 Phenotypic effects of aspirin treatment on SCC25 oral cancer cells on 
tumourigenicity. 
A) Wound healing assay.  SCC25 cells were grown to confluence and a scratch was created 
followed by treatment with (2.0 mM) or without (0 mM) aspirin. Images were obtained to 
observe the difference in the migration/proliferation patterns of aspirin treated and untreated 
cells using phase contrast microscopy. The experiment was performed in triplicate and the 
graph (right) indicates the area of wound closure in percentage obtained from the three 
independent experiments and * indicates significant P-Value <0.05. B) The effect of 
clonogenic potential and growth by aspirin on SCC25 cells. SCC25 cells were cultured in the 
presence and absence of 2.0mM aspirin for 7 days. Colonies were formed in the absence of 
aspirin. In the presence of aspirin no colony formation was observed. Values are means ± SD 
of triplicates of each experiment. * indicates significant P-Value <0.05. C) Sphere formation 
assay. SCC25 cells were grown in complete media on agarose coated 6-well plate with and 
without aspirin treatment (2.0 mM) for 7 days and the formation of spheres was observed. 
Mean number of spheres were calculated from minimum of 6 different areas from each well. 
The experiment was performed in three independent sets and the * indicates significant P-
Value <0.05. 
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3.4.10 Aspirin reduces CEP55 protein 
CEP55, a cytokinesis promoter, is one of the downstream regulators of G2/M transition and it 
is the direct transcriptional target of the FOXM1 transcription factor that plays an important 
role in promoting G2/M transitions (Gemenetzidis et al. 2009). The present microarray study 
showed that aspirin affects the cell cycle and in particular G2/M transition pathway and this 
was consistent with a reduction in the expression of the CEP55 gene in oral cancer cells. 
Immunofluorescence and flow cytometer experiments showed high expression of CEP55 in 
untreated SCC25 cells but in aspirin treated cells the expression and the intensity was low 
(Figure 3.7A to D). CEP55 staining in aspirin treated cells was ~ 60%, whereas in untreated 
cells it was ~ 97%. The flow cytometer result clearly indicated that CEP55 expression was 
significantly reduced in aspirin-treated cells consistent with aspirin blocking cell cycle 
progression (Figure 3.7B to D). 
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Figure 3.7Immunofluorescence staining of CEP55, NF-kBp65, PPARG, Vimentin,E-
Cadherin, KRT14 and MMP13 proteins in aspirin treated (2.0 mM) and untreated 
SCC25 cells. 
Cells were stained with respective antibodies raised in rabbit except for KRT14 and vimentin 
raised in mouse. Secondary antibody used for detection includes anti-rabbit alexafluor 488 
and anti-mouse alexafluor 594. Scale bar is 100μm with original magnification, 100x. B) 
FACS analysis of expression of CEP55 in aspirin treated and untreated SCC25 cells. Cells 
were subjected to FACS analysis using antiCEP55 antibody and further treated with 
alexafluor 488 secondary antibodies. Use of secondary antibody alone was considered as 
control to find the specificity of the CEP55 antibody. C) Percentage of cells exhibiting 
positive staining for CEP55 shows there is a decrease in the percentage of CEP55 stained 
cells following aspirin treatment compared to no treatment. D) Mean fluorescence of treated 
and untreated SCC25 cells showing intensity was reduced in the treated sample. 
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3.4.11 Aspirin increases PPARG protein and decreases 
proteins that play an important role in tumour progression 
PPARG protein expression is known to be elevated by treatment with NSAIDs (Vaish, 
Tanwar & Sanyal 2010). It has been shown that upon induction by NSAIDs, PPARG induces 
cell death in tumour cells (Moon et al. 2014). The current microarray study showed elevated 
gene expression of PPARG in aspirin-treated cells (Figure 3.4B). In addition, 
immunofluorescence was performed and increased staining of PPARG was observed in 
aspirin-treated cells (Figure 3.7A).  The current microarray data also revealed decreased 
expression of MMP13 and KRT14 that play an important role in invasion and tumour 
progression of OSCC (Li & Cui 2013; Ohkura et al. 2005) and the immunofluorescence of 
aspirin-treated cells for MMP13 and KRT14 staining revealed decreased staining intensities 
relative to the control, consistent with microarray data. Staining for EMT markers, vimentin 
and E-cadherin, that play an important role in OSCC progression (Chaw et al. 2012) revealed 
decreased staining intensities of vimentin in aspirin-treated cells and no change in the 
staining pattern of E-cadherin was observed between aspirin-treated and untreated cells 
(Figure 3.7A). 
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3.5 Discussion 
There is little understanding of the responses of tumours to aspirin treatment other than its 
anti-inflammatory effects in oral cancer cells (Rao et al. 2010). An earlier study showed that 
aspirin treatment had no toxicity or inhibitory effect on proliferation of normal oral human 
keratinocytes cultured with 2.0 mM aspirin but there was a slight decrease in cell viability 
when aspirin was present in media at 5, 10 and 20 mM(Rao et al. 2010). In contrast apoptotic 
and anti-proliferative effects of aspirin at 2.0 mM concentration has been observed in the 
current and previous study (Rao et al. 2010). In another study 2.5 mM aspirin treatment 
promoted cell death in colon cancer cells (Goel A et al. 2003). Therefore, to better understand 
the molecular mechanisms for aspirin-mediated death of oral cancer cells, SCC25 cells were 
cultured with 2.0 mM aspirin prior to microarray analysis of the cells.  
3.5.1 Aspirin induced broad spectrum effects on inhibiting several 
genes involved in cell cycle progression 
The current microarray results indicated that cell cycle regulators that promote cell division 
were significantly down regulated in aspirin treated cells. These cell cycle regulators are 
altered in many cancer types (Takai et al. 2005) and our earlier microarray study (GSE56532) 
also observed up regulation of genes involved in cell cycle progression. Complex formation 
of cyclin B1 and CDK1 is considered to be an important step for G2/M progression and its 
inhibition leads to G2/M arrest (Takahashi et al. 2000) which was evident in aspirin-treated 
cells. Pathway analysis using IPA also revealed down regulation of all expressed genes 
involved in the regulation of G2/M transition and the mitotic role of polo like kinases 
strongly supporting the broad spectrum effect of aspirin in targeting several genes related to 
cell division. Aspirin treatment also inhibited other important promoters of G2/M transition; 
AURKA, AURKB, PLK1, BIRC5, CDK2, and MCL1 in SCC25 cells.  These genes are often 
over expressed in OSCC tissues and further using specific inhibitors to block each of these 
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genes in oral cancer cells decreased tumorigenic properties as described in previous studies 
(Anderson et al. 2013; Lee et al. 2012; Mihara et al. 2003; Sadej et al. 2014; Scheper, Sauk & 
Nikitakis 2006; Shin et al. 2013; Tanaka et al. 2013; Yoshida et al. 2003). Furthermore, 
studies on aspirin treatment in the oral cancer cell line YD-8, showed down regulation and 
proteolysis of MCL1 through activation of caspases(Park et al. 2010). In order to block these 
genes further to prevent cells undergoing G2/M transition, low doses of aspirin is potentially 
a more effective approach than using gene-specific inhibitors. The DLGAP5 gene was 
identified in the current study as a novel target of aspirin. Increased expression of DLGAP5 
was observed in hepatocellular carcinoma patients (Liao et al. 2013) and it plays an important 
role as a cell cycle regulator during G2/M transition (Tsou et al. 2003). Our study is the first 
to report the association of DLGAP5 gene up regulation in OSCC tumors which potentially 
can be decreased significantly with aspirin treatment. Aspirin has repressed the expression of 
several cell cycle progression genes. Most of these genes play an important role in promoting 
G2/M transition. This study provided evidence that aspirin can target and repress multiple 
genes in order to block G2/M transition. The downstream effector molecule of the G2/M 
pathway, CEP55, also a direct transcriptional target of FOXM1, is elevated in OSCC samples 
(Janus et al. 2011) and was down regulated in aspirin-treated cells further confirmed by 
immunofluorescence and flow cytometer analysis. These observations clearly indicate the 
broad spectrum effects of aspirin by inhibiting several genes promoting cell cycle progression 
including G2/M transition thus repressing the upstream CDK1-CCNB1 complex formation to 
the downstream CEP55 expression. 
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3.5.2 Aspirin induces apoptosis in a caspase dependent 
mechanism and PPARG induction in oral cancer cells 
Many studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs) induce anti-
neoplastic effects through PPARG expression (Gelman, Fruchart & Auwerx 1999; 
Lemberger, Desvergne & Wahli 1996).  Induction of PPARG mRNA is linked to squamous 
epithelium differentiation (Rivier et al. 1998). In the current study, qPCR and 
immunohistochemistry data indicated that OSCC samples showed relatively low levels of 
PPARG expression in comparison to normal samples. SCC25 cells showed relatively low 
expression of PPARG while aspirin treatment induced PPARG expression. An earlier study 
showed that knockdown of PPARG and further treatment with NSAID repressed cell 
inhibitory effects on SCC25 cells (Nikitakis et al. 2002) indicating PPARG expression 
essential for inducing apoptosis during NSAID treatment. Further qPCR analysis indicated 
that PPARG mRNA levels were relatively low in SCC25 cells compared to dysplastic DOK 
cell line. Taken collectively, these studies show that aspirin exerts anti-cell proliferative 
effects through PPARG overexpression in SCC25 cells further indicates manipulation of 
PPARG expression using NSAIDs like aspirin can be a potential therapeutic strategy in oral 
cancer cells.  
Microarray results from the current study indicated up regulation of caspase9 and PRKCZ 
genes in aspirin-treated cells and previous studies have shown that increased PPARG activity 
leads to activation of caspase 9 and apoptosis of hepatocellular carcinoma cells (Shim et al. 
2010). In HEK293 cells, the protein kinase c family member, PRKCZ, is known to increase 
the activation of caspase9 (Brady, Allan & Clarke 2005) clearly indicating apoptotic 
induction in aspirin-treated SCC25 cells might be a caspase dependent mechanism modulated 
by PPARG expression. These studies are consistent with data showing that aspirin induces 
apoptosis in SCC25 cells through a caspase dependent mechanism related to up regulation of 
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MOAP1 (Huang et al. 2012). An earlier study has indicated that the MOAP1 gene is the 
potential target of miR-1228 (Yan & Zhao 2012) and hence the decrease in miR-1228 
expression observed in aspirin-treated cells in the current study correlates with the increased 
MOAP1 gene expression. Taken together this data suggest that aspirin induces an apoptotic 
effect in aspirin treated cells by activation of PPARG through caspase-dependent 
mechanisms. 
3.5.3 Aspirin treatment represses tumor progression markers in 
SCC25 cells 
Earlier reports indicated a role of FOS and LOX in oral cancer progression (Albinger-Hegyi 
et al. 2010) and the current study, showed aspirin treatment reduced expression of both these 
genes in SCC25 cells. Furthermore, gene profiling of aspirin treated cells revealed novel 
targets (MMP13, SMAD5, KRT14, LAMC2, ADAM9, ITGA6, NRG4 and STMN1), that 
play an important role in the progression of oral cancer (Albinger-Hegyi et al. 2010; 
D'Assoro et al. 2014; Johansson N et al. 1999; Kouzu et al. 2006; Prasad et al. 1999; Sadej et 
al. 2014; Turatti et al. 2005; Yang et al. 2010). Our previous microarray study (GSE56532) 
also revealed an up regulation of these genes in OSCC samples and an examination of 
KRT14 and MMP13 expression using immunofluorescence showed down regulation of these 
proteins in aspirin-treated cells supporting the microarray results. CD151, a member of the 
tetraspanin family of proteins, plays an important role in tumor progression and metastasis. It 
binds to laminin binding integrin subunits, particularly the integrin alpha6 (ITGA6) subunit, 
to promote cell spreading, motility, invasion and metastasis (Sadej et al. 2014). Aspirin 
treatment repressed expression of CD151, ITGA6 and LAMC2. It was also shown that 
CD151 associates with laminin-5 component through α6β4 integrin and breast cancer cells 
depleted of any of these components sensitized cells to anticancer drugs, leading to cell death 
(Yang et al. 2010). A recent study showed that transfection of miR-29 in oral cancer cells 
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reduced ITGA6 and LAMC2 expression and tumorigenic properties (Kinoshita et al. 2013). 
Interestingly, the current study showed that aspirin treatment of oral cancer cells rapidly 
reduced expression levels of LAMC2 and ITGA6 genes and therefore is consistent with the 
therapeutic promise of aspirin, unlike gene therapy techniques, to translate into treatment 
strategies (Zhang et al. 2011). Although there was no change in the expression of E-cadherin 
in aspirin-treated cells, vimentin staining was significantly reduced suggesting aspirin can 
most likely inhibit epithelial mesenchymal transition. 
3.5.4 Aspirin inhibits the interferon pathway and pro-
inflammatory genes 
Elevated expression of STAT1 is associated with oral cancer progression as it plays an 
important role in inducing expression of several pro-inflammatory genes (Laimer et al. 2007). 
Aspirin-treated cells showed significant inhibitory effects on the STAT1 mediated interferon 
pathway and our microarray data also indicated suppression of several other pro-
inflammatory genes. Most of these genes were also shown to be elevated in OSCC samples 
from our previous microarray data. Even though it is well-known that aspirin inhibits NF-kB 
and its effectors in SCC25 cells (Rao et al. 2010), here we show that several other 
inflammatory responsive elements, chemokines and pro-inflammatory cytokines, were also 
affected by aspirin treatment of SCC25 cells. 
3.5.5 Inhibition of in-vitro tumorigenic properties of SCC25 cells 
by aspirin 
In-vitro tumorigenic assays clearly indicated that aspirin treatment reduced the tumorigenic 
potential of SCC25 cells inhibiting motility, reproductive motility and anchorage independent 
growth. All of these assays measure not only motility of cells, ability to form colonies, and 
anchorage independent growth, but also rely on cell proliferation (Munshi, Hobbs & Meyn 
2005). Increased cell motility is one of the characteristic features of tumour cells (Rodriguez, 
  Chapter 3 
150 
 
Wu & Guan 2005). When SCC25 cells were treated with aspirin, cell motility was observed 
to be decreased as measured in wound healing assays. The tumorigenic potential of the 
tumour cells is an important feature of reproductive viability (Franken et al. 2006). When 
SCC25 cells were tested for the ability to grow colonies as a measure of tumourigenic 
potential, aspirin treatment did not allow colony formation compared to untreated cells 
indicating aspirin can act on the reproductive viability of SCC25 cells. Anchorage 
independent growth of cells indicates the metastatic potential of cells (Mori et al. 2009) and 
SCC25 cells did not form spheres when treated with aspirin, indicating a loss of metastatic 
potential. 
3.5.6 Segregation of chromosomes, deregulated process in OSCC, 
can be controlled by aspirin treatment 
Mis-segregation of chromosomes during mitosis at higher rates in solid tumors leads to 
chromosomal instability (CIN; (Lengauer, Kinzler & Vogelstein 1997)).  Cyclin dependent 
kinases (CDKs), aurora kinases (AURKs), polo like kinases (PLKs) and centromere proteins 
(CENPs) allow cells to transition from G2-phase into M-phase leading to segregation of 
chromosomes (Adams, Carmena & Earnshaw 2001; Jackman & Pines 1997). Aspirin treated 
cells showed down-regulation of genes associated with segregation of chromosomes in 
contrast to tumors which over express these genes due to mis-segregation of chromosomes 
leading further to CIN (Adams, Carmena & Earnshaw 2001). Further comparison with our 
previous microarray data (GSE56532) revealed overexpression of genes in OSCC samples 
associated with the chromosome separation and the data is consistent with a role for aspirin to 
control the expression of these genes involved in the mis-segregation of chromosomes. 
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3.6 Conclusion 
There are wide varieties of tumour inhibitors that can target a particular gene or protein 
involved in a process or a pathway, currently in different phases of clinical trials, for oral 
cancer treatment (Anderson et al. 2013; Lee et al. 2012; Mihara et al. 2003; Scheper, Sauk & 
Nikitakis 2006; Shin et al. 2013; Tanaka et al. 2013; Yoshida et al. 2003). Aspirin was 
thought to target inflammatory genes in oral cancer cells (Rao et al. 2010), however the 
current study on the global effects of aspirin on the transcriptome has provided new insights 
into the molecular mechanisms exerted by aspirin in oral cancer cells and identified candidate 
novel targets in OSCC tumours. This study strongly suggests that aspirin is a potential 
therapy for the prevention of oral cancer progression and thus future experiments should 
examine the optimal dose, and duration of therapy for clinical use to improve patient survival 
rate. 
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4 Overexpression of the KRT4 gene in the 
oral squamous cell carcinoma cell line 
increases stemness and leads to a EMT 
phenotype 
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4.1 Summary 
Oral squamous cell carcinoma (OSCC) is a disease with high incidence and mortality rates in 
south Asia. Previous microarray data compared an oral cancer cell line, SCC25, and normal 
human oral keratinocytes (HOK) and indicated significant down regulation of the KRT4 gene 
in SCC25 cells. A bioinformatic study correlated KRT4 down regulation in dysplasia samples 
with progression to cancer and there was no differential expression observed in dysplasia 
samples not converted into cancer. These results are consistent with an earlier microarray 
study in our laboratory (GSE56532; chapter2) indicating that low expression of KRT4 may 
be important for oral cancer progression. In order to elucidate the effect of overexpression of 
KRT4 on proliferation and tumorigenic properties in SCC25 cells, the KRT4 gene was over 
expressed. In stably transfected cells, the KRT4 transfected cells showed increased 
proliferation and a significant increase in the expression of N-cadherin expression and 
epithelial mesenchymal transition (EMT) markers. EpCAM, under expressed in EMT, was 
down regulated in KRT4 transfected cells when compared to the vector control cells as 
determined by QPCR and flow cytometry analysis. CD44, used as a marker for increased 
stemness in oral cancer cells, was also increased in SCC25 cells transfected with KRT4. In 
addition, increased expression of myo-epithelial marker, KRT14, was observed in KRT4 
transfected cells. Tumorigenic assays in KRT4 transfected cells led to increased stemness by 
promoting the EMT phenotype with increased tumorigenic potential. In contrast to previous 
studies showing that KRT4 expression can be increased by retinoic acid treatment of 
epidermal keratinocytes, retinoic acid treatment in SCC25 cells decreased expression of 
KRT4, KRT14 and KRT17 genes, reduced expression of CD44 and retained EpCAM 
expression to avoid EMT. These observations suggest the possible role of down regulation of 
KRT4 gene in OSCC tissues may provide new opportunities as a diagnostic and prognostic 
marker. 
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4.2 Introduction 
Oral squamous cell carcinoma (OSCC) is a commonly occurring malignancy of the head and 
neck region (Kademani 2007; Petersen 2003). The 5-year survival rate for OSCC patients has 
not improved for many years, with treatment options generally limited to surgery, followed 
by either radio or chemotherapy. This poor prognosis is also likely due to a lack of clinical 
markers for early detection (Jemal 2012; Jemal et al. 2008). In our previous microarray study 
(GSE56532; chapter2), comparison of normal to late stage OSCC samples revealed a down 
regulation of the KRT4 gene in late stage OSCC. This is in agreement with previous 
microarray studies using the OSCC cell line, SCC25 in comparison to normal human oral 
keratinocytes (HOK), which revealed down regulation of KRT4 gene in SCC25 cells (Rao et 
al. 2010). Other microarray studies have also reported down regulation of the KRT4 gene in 
OSCC tissues (Sakamoto et al. 2011; Toruner et al. 2004; Ye et al. 2008). KRT4 expression 
has been observed in differentiated keratinocytes (Vaidya & Kanojia 2007). Additionally, 
expression of KRT4 is essential for maintaining epithelial integrity (Ness et al. 1998). To 
date, however, no study has reported the effect of KRT4 over expression on the tumorigenic 
potential of SCC25 cells. Among other keratins, KRT17 can be used as a diagnostic marker 
as it showed expression only in OSCC samples compared to normal tissues (Kitamura et al. 
2012). KRT13 is expressed in differentiated stratified non-cornified  squamous cells 
(Bragulla & Homberger 2009) and loss of KRT13 expression is observed in OSCC samples 
(Kitamura et al. 2012). Increased expression of KRT8 and KRT18 was observed in oral 
submucosal fibrosis, leukoplakia and OSCC (Nanda et al. 2012).  
All-trans retinoic acid (ATRA) plays an important role in inducing cellular differentiation in 
cancer cells (Feng et al. 2012; Mirza et al. 2006; Virtanen et al. 2010; Zhang et al. 2013b). 
ATRA receptors also play an important role in the regulation of various molecular 
mechanisms that inhibit cancer cell growth (Dragnev, Petty & Dmitrovsky 2003). Earlier 
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studies have demonstrated an up-regulation of KRT4 gene expression in epidermal 
keratinocytes following treatment with ATRA at low concentrations (Gericke et al. 2013; 
Pavez Lorie et al. 2009; Virtanen et al. 2010). Multilayered human foreskin keratinocytes 
also showed increased KRT4 expression following 1 μM retinoic acid treatment, 
demonstrating characteristics of differentiated cells (Pavez Lorie et al. 2009). In contrast, 
retinoic acid treatment of the multilayered structure of gingival epithelial cells showed 
depletion of KRT4 and KRT14 (Hatakeyama et al. 2004). There have been several studies 
using the SCC25 cell line, a tongue oral squamous keratinocyte cell line that show ATRA 
treatment reduced cell growth (Acquafreda et al. 2010; Le et al. 2000; Le, Soprano & 
Soprano 2002) without any effect on the differentiation status of the cells (Le et al. 2000). 
Further, this study clearly indicated that there was no effect on the differentiation status of the 
cells following ATRA treatment. However, there have been no studies to date to examine the 
effect of ATRA treatment on the expression of KRT4 in SCC25 cells. Therefore, the major 
aim of this study was to investigate the effect of KRT4 overexpression in SCC25 cells on cell 
proliferation and tumorigenic potential, as well as determining the effect of ATRA on KRT4 
expression levels in SCC25 cells. 
4.3 Materials and methods 
4.3.1 Clinical samples 
The present study was conducted with ethical approval from Samkeshama Independent 
Ethics Committee, Hyderabad. The clinical samples from 49 patients with oral squamous cell 
carcinoma (OSCC) were collected from SGCC&RI, Hyderabad. The primary tumour sites of 
OSCC were the floor of the mouth (n=15), buccal mucosa (n=14), tongue (11) and gingiva 
(9). Among the 49 OSCC samples, 24 samples were from the early stage (I & II) and 25 
samples from the late stage (III &IV). Adjacent normal margins from the OSCC patients 
were considered as normal control tissue (n=19). The Union for International Cancer Control 
  Chapter 4 
156 
 
(UICC) designated classification was followed to determine the tumour stage 
classification(Webber et al. 2014). 
4.3.2 Cell line and Culture conditions 
SCC25 oral squamous cell carcinoma (OSCC) cells, obtained from American Type Culture 
Collection (USA), were maintained in a 1:1 mixture of Ham’s F12 and Dulbecco’s modified 
Eagle’s medium containing 10% fetal bovine serum, 0.5 mM sodium pyruvate, 2.5mM L-
glutamine, 1.2g/L sodium bicarbonate, 15 mM HEPES, pencillin/streptomycin and 400ng/mL 
hydrocortisone. SCC25 cells were stably transfected with KRT4-pTARGET using Fugene 
HD transfection reagent (Promega) according to the manufacturer’s protocol. Cells were 
maintained in geniticin (400 μg/mL) for stable selection of cloned cells. Cells were 
maintained at 37°C with 5% CO2. SCC25 cells stably transfected with the KRT4 gene were 
designated as SCC25+KRT4. Clones that were resistant for G418 were pooled and picked for 
further expansion and characterization. 
4.3.3 RNA isolation, RT-PCR and quantitative real time 
polymerase chain reaction (Q-PCR) 
RNA isolation was performed using the RNeasy mini kit (Qiagen) according to the 
manufacturer’s instructions. Q-PCR analysis was performed to find differential expression of 
genes using eva green (Biorad) and analysis of melting point dissociation curve analysis 
according to the manufacturer’s protocol (Biorad CFX system). Total RNA isolated from the 
tissue specimens and cell lines, described previously, were reverse transcribed to generate 
complimentary DNA using Superscript VILO and Superscript-III (Invitrogen) following the 
manufacturer’s protocol. The cDNA (25 ng) was used to perform quantitative real time PCR 
in a 20 μL reaction using the Biorad CFX detector system. Primer sequences (Macrogen) 
were designed using the PCR primer design tool Primer3 (Rozen & Skaletsky 2000) and gene 
specificity was confirmed using the National Center for Biotechnology Information 
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Nucleotide Database. The QPCR included an initial denaturing step for 5 minutes at 95ͼC, 
followed by 40 cycles of 95ͼC for 30 seconds, 60ͼC for 30 seconds and 72ͼC for 30 seconds. 
The expression of each gene was normalized to housekeeping gene GAPDH.  The primers 
used in this study are listed in Table 4.1. 
Table 4.1List of primers used in QPCR analysis and cloning. 
Genes Study Forward Primer (5' to 3') Reverse Primer (5' to 3') 
EpCAM QPCR GCGAGTGAGAACCTACTGGATCAT CGCGTTGTGATCTCCTTCTGAAGT 
CD44 QPCR GCCCAATGCCTTTGATGGACCAAT TTGCTGGGGTAGATGTCTTCAGGA 
CDH2 QPCR CCTGGAGACATTGGGGACTTCATT GGAGCCACTGCCTTCATAGTCAAA 
KRT4 QPCR TGTGAAGCTGGCCTTGGACAT TGCTACCGCTGACCACAGAGAT 
KRT14 QPCR AGAGCTGACCTGGAGATGCAGATT ACATTGACATCTCCACCCACCT 
KRT17 QPCR GTGCAGAGTGGCAAGAGTGAGAT CCTCCAGGGATGCTTTCATGCT 
SP1 QPCR GGTCATACTGTGGGAAACGCTTCA GACACTCAGGGCAGGCAAATTTCT 
c-JUN QPCR GACCTTCTATGACGATGCCCTCAA CAGGTTCAGGGTCATGCTCTGTTT 
GAPDH QPCR TCACCAGGGCTGCTTTTAACTC TGCCATGGGTGGAATCATATTGGA 
KRT4-1 CLONING TGTGATGGGATCCAGTAACC CCTCGTCTCCTCTATCGTCTCTTG 
KRT4 Flag  CLONING CTACTTGTCATCGTCGTCCTTGTAATCTCGTCTCTTGTTCAG 
KRT4-2 
Rev 
CLONING 
CTACTTGTCATCGTCGTCCTT  
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4.3.4 Microarray statistical analysis 
Microarray data analysis was performed for our previous data series (GSE56532; chapter 2) 
using normal samples as a baseline control compared to the dysplasia data series 
(GSE26549).  Normal samples were compared to the dysplasia samples transformed into 
cancer and untransformed dysplasia samples. For analysis of data and determining 
differential gene expression, xRAY Excel® Array analysis software (Biotique Systems, 
www.biotiquesystems.com/Products-Solutions/XRAY) was used. Since the platform used by 
both the data series were the same, background correction for each probe score was done by 
subtracting the median expression score of background probes with similar GC content. The 
samples were normalized using full quantile normalization (Irizarry et al. 2003). Nested 
analysis of variance and mixed model were used to identify significant gene expression 
changes (Montgomery 2000) and the Benjamini and Hochberg method was used to perform 
multiple tests correction to find significant P-Value and fold change(Hochberg & Benjamini 
1990). 
4.3.5 Cell proliferation assay 
SCC25 and SCC25+KRT4 cells were seeded at a density of 3000 cells per well in 100 μL 
media. The cells were grown for 5 consecutive days with and without 1 μM retinoic acid 
treatment and at the end of each day, 20 μL of MTS reagent (Promega) was added and 
incubated at 37qC for 4 hours to observe the rate of proliferation in SCC25 and 
SCC25+KRT4 cells. Absorbance readings were obtained at 490 nm wavelength using a 
spectrophotometer (Biorad). All-trans retinoic acid (ATRA, Sigma) was dissolved in 
dimethyl sulfoxide (DMSO, Sigma) and the final concentration of DMSO was less than 0.1 
%. Cells treated with DMSO without ATRA were considered as a control. 
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4.3.6 Immunofluorescence 
To examine the expression of KRT14 the transfected KRT4 SCC25 cells were seeded in 8-
well chamber slides (Thermo Fisher Scientific Inc.) and incubated for 1-2 days until they 
reached 80% confluence. The growth media was aspirated and the cell monolayers were 
washed thrice with PBS. Cells were fixed with paraformaldehyde (3.5 %) at room 
temperature for 10 minutes. Cells were washed three times with ice-cold PBS and further 
permeabilized using 0.1 % Triton X-100 for 10 minutes at room temperature, and 
subsequently washed twice with PBS. Blocking was performed by treating with 1% BSA in 
PBS for 30 minutes at room temperature to avoid non-specific binding. The cells were 
washed three times with PBS before adding the primary antibodies (mouse monoclonal anti-
KRT14 antibody (Abcam) and mouse anti-flag antibody (Sigma)) and incubated overnight at 
4ͼC. The primary antibody was removed and the cells were washed three times with PBS 
prior to the secondary antibody being added (anti-mouse alexa fluor-594 (Life 
Technologies)). The cells were then incubated for one hour at room temperature before being 
washed three times with PBS and counterstained with Hoechst dye (Sigma, 0.1 μg/mL) to 
stain the nucleus. A PBS wash was repeated twice and the intensity of the fluorescence was 
observed using a fluorescent microscope (Nikon, Melville, USA). Images were captured 
using software NIS elements F 3.0 (Nikon, Melville, USA). Secondary conjugated antibody 
only was used as a negative control. 
4.3.7 Immunohistochemistry 
To examine the expression of KRT4 protein in clinical samples of normal, early and late 
stage OSCC, immunohistochemistry was performed on formalin fixed paraffin embedded 
tissue.  Tumour tissue and adjacent normal sections stored at - 80ͼC were fixed in 10% 
formalin, dehydrated and embedded in paraffin immediately. Thin sections (4 μm) were 
deparaffinised using xylene, and further hydrated in a series of ethanol dilutions (100%, 90% 
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and 70% (v/v)). The sections were treated with hydrogen peroxide (3% in methanol) to block 
the endogenous peroxidase activity. Antigen retrieval was performed using 10mM citrate 
buffer by boiling the sections at 95ͼC for 25 minutes. Sections were treated for 30 minutes 
with 5% of goat serum (Invitrogen) as a blocking solution and then incubated with primary 
antibody (rabbit polyclonal KRT4 antibody (Abcam)) overnight at 4ͼC before being treated 
with HRP- conjugated goat anti-rabbit HRP (1:100 (Abcam)) as a secondary antibody for 60 
minutes at room temperature. The 3, 3- Diaminobenzidine (DAB, Cell Signaling 
Technologies) was used for chromogenic detection. Sections were counter stained using 
haematoxylin (Poly Sciences) and the sections were mounted with DPX histamount (Sigma). 
Images were captured and analysed using a Nikon Eclipse Ti-S microscope and NIS-
Elements F 3.0 (Melville, USA). ImageJ software was used to analyse stained and unstained 
sections following the software instructions(Abramoff MD, Magalhaes PJ & S. 2004). 
Staining was scored based on the intensity and area of staining. A minimum of 5 fields for 
each section was analysed in a ‘blind’ assessment and the staining percentage score was 
determined. The intensity of staining was scored as follows; +1, weak; +2, moderate; +3, 
strong. Primary antibody was replaced by serum in negative controls to assess the staining 
specificity. The staining intensity obtained was multiplied with the percentage of positive 
stained cells to produce a staining score for KRT4 (Shimada et al. 2005; Tanaka et al. 2003). 
Statistical significance was assessed by using the Mann-Whitney U-test and the P-Value 
<0.05 was considered as significant. 
4.3.8 Flow cytometry analysis 
SCC25 and SCC25+KRT4 cells grown to confluence were washed twice with PBS and 
detached using 0.25% trypsin-EDTA solution. Cells were collected by centrifugation and 
further washed twice with PBS. Approximately 1x106 cells were incubated with CD44 (V450 
Mouse Anti-Human CD44 (BD Biosciences)), CD133 (Mouse anti-human CD133 
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(MiltenyiBiotec)) and EpCAM (Mouse Anti-Human EpCAM (BD Biosciences)) antibodies 
according to the manufacturer’s instructions. The cells were incubated for 30 min at room 
temperature followed by two washes in PBS. Since the primary antibodies were already 
tagged with fluorescence, cells were resuspended in PBS and were analyzed on the FACS 
Canto II (Becton Dickinson) using FACS DIVA software comparing with appropriate 
controls. 
4.3.9 Wound healing assay 
SCC25 and SCC25+KRT4 cells were grown to confluence in a 6-well plate. Cells were 
scraped in a straight line with a sterile 200PL pipette tip and then washed with PBS. Cells 
were then incubated with serum free media for 48 h. The wound healing process was 
observed under the microscope and images were obtained from different fields of the same 
scratch. Cell migration was analysed using ImageJ software(Abramoff MD, Magalhaes PJ & 
S. 2004). The experiment was repeated in triplicate and a P-Value of < 0.05 was considered 
significant. 
4.3.10 Sphere formation assay 
The sphere formation was performed as previously described (Chen et al. 2012). Briefly, 
SCC25 and SCC25+KRT4 cells were harvested using 0.25% (w/v) trypsin-EDTA solution 
and cells were plated at a density of 3x104 cells on agarose coated wells in culture media. 
Media was changed every 2 days and the cells were cultured for 7-8 days. Spheres formed 
were imaged using light microscope (Nikon, Melville, USA). 
4.3.11 Statistical analysis 
The Student’s t-test was used for analysis of significance for the cell proliferation assay, cell 
migration, clonogenic assay, sphere formation and Q-PCR analysis. A P-Value of <0.05 was 
considered significant. 
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4.4 Results 
4.4.1 KRT4 expression in early and late stage oral squamous cell 
carcinoma (OSCC) samples 
Our previous microarray study (GSE56532; chapter2) indicated down regulation of KRT4 
gene in late OSCC samples. Further validation by Quantitative PCR (QPCR) analysis of early 
(stage I & II, n=10) and late stage (stage III & IV, n=10) samples showed a marked decrease 
in the expression of the KRT4 gene (Figure 4.1A) in comparison to normal samples (n=10). 
Immunohistochemical (IHC) analysis of KRT4 showed either an absence or weak staining in 
early and late stage OSCC samples while strong staining was observed in the supra basal 
epithelial region of normal samples (Figure 4.1B). The IHC score further indicated significant 
low or no staining of KRT4 in early and late stage OSCC samples (Figure 4.1C). 
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Figure  4.1 KRT4 expression in normal, early (stage I and II) and late (stage III and IV) 
oral cancer samples. 
A) Q-PCR analysis was performed to analyze the mRNA expression with specific primers for 
KRT4 and GAPDH was used as a control. The data was compared to the expression values of 
normal tissues. The data was analyzed using one way analysis of variance and the data 
represented here is having ***P value < 0.0001. NS indicates data non-significant. Number 
of samples in each group is equal to 10. B) Immunohistochemical (IHC) staining of KRT4 in 
normal oral (n=9), early tumor (n=14) and late stage tumor oral cancer samples (n=15) was 
performed. Strong staining was observed in the supra basal region of the epithelial cells in 
normal samples and no or very weak staining was observed in OSCC samples. C) Graphical 
representation of KRT4 staining in normal oral tissue, early and late stage OSCC tissue 
samples. KRT4 IHC staining scores were calculated as: staining intensity multiplied with 
percentage of positive cells.  The results represented the mean values and the statistical 
significance was calculated using Mann-Whitney U-test ***P-Value less than 0.0001 was 
obtained for the comparison between normal vs early and normal vs late stage OSCC tumors. 
Comparison between early and late stage OSCC samples is non-significant (ns). 
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4.4.2 Bio-informatic analysis of GSE56532 and GSE26549 data 
series revealed KRT4 down regulation and KRT17 up 
regulation in dysplasia with cancer 
Further microarray data analysis was performed for normal and late stage OSCC samples 
from our previous microarray data series (GSE56532; chapter 2) and dysplasia data from 
GSE26549. Normal sample data from GSE56532 was used as control for comparison. The 
GSE26549 database from the gene expression omnibus (GEO) has dysplasia data with 
approximately 6-years follow up study of patients with dysplasia progressing to oral 
squamous cell carcinoma. Out of 86 patients, 35 dysplastic patients progressed to OSCC. 
This database was divided into two groups: dysplasia with cancer (DWC) and dysplasia 
without cancer (DWOC). Analysis of these groups compared to normal samples revealed a 
down regulation of KRT4 in late stage OSCC (FC = -59.71) and DWC (FC = -20.61) (Table 
4.2) with the probe set ID 7963534. There was no differential regulation of KRT4 observed 
following comparison between normal and DWOC. In comparison to normal samples KRT14 
was significantly up regulated in DWC, DWOC and OSCC samples (Table 4.2). Further 
KRT17 expression was up regulated in DWC (FC = 2.31) and OSCC samples (FC = 8.01), 
though there was no significant change in the expression of KRT17 in DWOC was observed. 
 
Table 4.2Analysis of KRT4, KRT14 and KRT17 genes in DWOC, DWC and OSCC 
samples compared to the normal samples. P value < 0.01 and FC>2 were considered as 
significant in the analysis. 
Gene ProbesetID 
Dysplasia without cancer 
(DWOC) 
Dysplasia with Cancer 
(DWC) OSCC 
KRT4 7963534 No significant change -20.61 -59.71 
KRT17 8005449 No significant change 2.31 8.01 
KRT14 8015366 2.61 3.41 3.91 
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4.4.3 Stable transfection of KRT4 in SCC25 cells 
KRT4 cDNA was synthesized from the SCC25 cDNA using primer set KRT4-1 (Table 4.1) 
by reverse transcription PCR. Total size of the cDNA synthesized was 1828 bp (Figure 
4.2A). Flag tag was inserted just before stop codon TAG. Forward primer from KRT4-1 set 
and the KRT4 Flag reverse primer (Table 4.1) were used for cloning KRT4 insert with flag 
tag before stop codon TAG into pTARGET plasmid (Promega). Transformation was 
performed using JM109 competent cells (Promega).  Further colony PCR (Figure 4.2B) was 
performed to confirm the KRT4 insert with flag tag (1841 bp) followed by DNA sequencing 
(Macrogen). The generated construct along with the plasmid was utilized to transfect oral 
squamous cell carcinoma cell line, SCC25. Plasmid without the KRT4 insert was considered 
as a negative control. Further, stable transfection of KRT4 cDNA in SCC25 cells (5 x103 per 
each well of 96-well-plate) was performed using Fugene (Promega). After 48 h of 
transfection, positive clones were selected using geniticin (400 μg/ml) and the resistant 
clones were allowed to grow for 2 to 3 weeks. Media was changed as required. Around 20 to 
30 visible colonies were transferred to 6-well plate for further growth and the cells (SCC25 
and SCC25+KRT4) were maintained in selective media containing geniticin (400 μg/ml). 
Positive RNA was isolated from SCC25 and SCC25+KRT4 cells and quantitative PCR 
(QPCR) analysis revealed a 50-fold greater expression of KRT4 in SCC25+KRT4 compared 
to control cells (Figure 4.3A). As the KRT4 construct was tagged with a Flag-tag insert, an 
antibody against the Flag tag was used to image the cells using fluorescent staining. Cells 
were confirmed to be stably transfected with KRT4 and the cells showed abundant KRT4 
expression specific following transfection (Figure 4.3B). 
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Figure 4.2KRT4 cDNA synthesis and colony PCR analysis. 
A) KRT4 specific primers were used to synthesize cDNA (1828 bp) by RT-PCR. The 
synthesized cDNA was visualized on 1% agarose gel electrophoresis. Left lane shows PCR 
product of KRT4 construct and right lane shows 1 kb ladder (Invitrogen). B) Colony PCR of 
KRT4 from the bacterial colonies grown on selection media containing ampicillin. Lane 1, 4 
and 5 represents pTRAGET plasmids containing KRT4 insert. Lane 2 and 3 represents 
negative control with pTARGET and without KRT4 insert (1841 bp). 
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Figure 4.3KRT4 expression in vector control (SCC25) and KRT4 transfected 
(SCC25+KRT4) cells. 
A) QPCR analysis was performed to analyse mRNA levels of KRT4 in SCC25 and 
SCC25+KRT4 cells. Expression values of KRT4 were normalized to GAPDH, housekeeping 
gene, used as a control and *** indicates significant P-Value < 0.0001. B) 
Immunofluorescence analysis of KRT4 expression. KRT4 constructed was inserted with flag-
tag at 3’end. After stable expression of KRT4 in SCC25 cells, mouse anti-flag antibody was 
used for detection of KRT4 expression followed by detection with anti-mouse alexafluor 594 
(red) secondary antibody. Nucleus was stained by Hoechst dye (Blue). Original magnification 
is 100x, Scale bar is 100 μm. 
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4.4.4 Phenotypic effects of KRT4 transfection in SCC25 cells 
Morphological examination of SCC25+KRT4 cells revealed compact growth with the 
majority forming round colony-like structures, as compared to SCC25 cells (Figure 4.4A). 
Moreover, the sphere formation assay revealed no significant difference in the number of 
spheres formed between the two cell types although the SCC25+KRT4 cells showed 
irregularly shaped large spheres, as compared to SCC25 cells which formed round shaped 
spheres (Figure 4.4B). Additionally, the wound healing assay demonstrated a faster wound 
closing with SCC25+KRT4 cells, with the closure of the wound observed at 48 h, whereas 
the SCC25 cells did not show complete wound closure at this time (Figure 4.4C). The 
experiment was performed in triplicate and the results were considered significant (p<0.05). 
4.4.5 Effect of retinoic acid on cell proliferation and KRT4 mRNA 
expression 
SCC25 and SCC25+KRT4 cells were cultured with and without 1 μM of retinoic acid in 
media for 5 days. The retinoic acid had a limited effect in inducing cell death in SCC25 cells 
although there was a significant decrease in viable cells from day two (Figure 4.5A). As a 
significant decrease in viable cells was observed on day two, the effect of retinoic acid on 
KRT4 expression was analysed by QPCR in treated and untreated SCC25 and SCC25+KRT4 
cells. However, there was no significant change in the expression of KRT4 in SCC25+KRT4 
cells with or without retinoic acid (Figure 4.5B). There was however, significant decrease in 
KRT4 expression observed in SCC25 cells treated with retinoic acid (Figure 4.5B).  
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Figure 4.4Phenotypic effects of KRT4 transfection in SCC25 cells. 
A) Morphological examination of SCC25 and SCC25+KRT4 cells. Cells grown were 
observed under microscope for morphological examination. SCC25+KRT4 cells show more 
compact growth compared to SCC25 cells. B) Sphere formation assay. Spheres formed by 
SCC25+KRT4 are large and irregular in shape and SCC25 cells formed round shaped 
spheres. The number of spheres formed did not show any significant difference. C) Wound 
healing assay. Cells were grown till confluence and the well was scratched using a sterile tip 
and further washed with PBS to remove dead cells. Cells were observed every day for the 
closure of the wound area. At 48 h, SCC25+KRT4 showed complete closure of the wound 
area and the asterisk (*) indicates significant P-Value <0.05. 
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Figure 4.5Effect of retinoic acid treatment on cell proliferation and KRT4 expression 
levels in SCC25 and SCC25+KRT4 cells. 
A) SCC25 and SCC25+KRT4 cells were treated with and without 1μM of retinoic acid for 5 
consecutive days. MTS assay was performed to measure the cell growth and the absorbance 
values obtained at 490 nm after adding MTS reagent to the cells after each day of treatment. 
Untreated cells were considered as control. Student t-test was performed to obtain the 
significant *P-Value < 0.05. B) QPCR analysis was performed to analyse mRNA levels of 
KRT4 in SCC25 and SCC25+KRT4 cells treated with and without retinoic acid (RA, 1 μM) 
for 48 h. Expression values of KRT4 were normalized to GAPDH, housekeeping gene, used 
as a control and * indicates significant P-Value < 0.05. Untreated cells were considered as 
control. There was significant reduction in the expression of KRT4 in SCC25 cells treated 
with retinoic acid and there was no significant decrease observed in SCC25+KRT4+RA cells 
compared to their controls. 
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4.4.6 KRT14 and Epithelial mesenchymal transition (EMT) 
marker expression in SCC25 and SCC25+KRT4 cells 
Following stable transfection of KRT4 into SCC25 cells, to observe the changes in the 
tumorigenic properties of SCC25 cells, quantitative PCR analysis was performed for EMT 
markers, E-cadherin, vimentin, N-Cadherin, snail, twist and slug. A significant increase in the 
expression of N-cadherin was observed in the SCC25+KRT4 cells (Figure 4.6A). Earlier 
studies indicated that EpCAM expression decreased due to the EMT process (Frederick et al. 
2007) and CD44 expression in oral cancer cells was directly related to the increased stemness 
of the cancer cells (Sun et al. 2012).  These studies were in agreement, with QPCR analysis 
showing a significant decrease in the expression of EpCAM and a significant increase in the 
expression of CD44 in SCC25+KRT4 cells as compared to vector control SCC25 cells 
(Figure 4.6A) consistent with proliferating epithelial cells expressing KRT14 (Fuchs & Green 
1980). The QPCR and immunofluorescence analysis revealed a significant increase in the 
expression of KRT14 in SCC25+KRT4 cells (Figure 4.6A and B). 
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Figure 4.6Expression of CDH2, CD44, EpCAM and KRT14 expression in vector control 
(SCC25) and KRT4 transfected (SCC25+KRT4) cells. 
A) QPCR analysis was performed to analyse mRNA levels of CDH2, CD44, EpCAM and 
KRT14 in SCC25 and SCC25+KRT4 cells. Expression values of these genes were 
normalized to GAPDH and * indicates significant P-Value < 0.05. B) Immunofluorescence 
analysis of KRT14 expression. Immunofluorescence analysis was performed to identify 
KRT14 expression in SCC25 and SCC25+KRT4 cells using mouse anti-kertain 14 antibody 
followed by detection with anti-mouse alexafluor 594 (red) secondary antibody. Nucleus was 
stained by Hoechst dye (Blue). Original magnification is 100x, Scale bar is 100 μm.  
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4.4.7 Flowcytometric analysis of cancer stem cell markers in 
SCC25 and SCC25+KRT4 cells with and without retinoic 
acid treatment 
To further validate the expression of CD44 and EpCAM, KRT4 in transfected 
(SCC25+KRT4) and vector control cells (SCC25) with and without retinoic acid treatment (1 
PM) were subjected to flow cytometry analysis. Further, CD133 was also included due to its 
role in EMT and purported role in cancer stem cells (Sun et al. 2012). However, results 
indicated CD133 staining was not present in any of the cells (Figure 4.7B). The 
EpCAM+/CD44+ stained cells were increased in SCC25+RA and reduced in SCC25+KRT4 
cells (Figure 4.7A) in comparison to SCC25 cells. CD44+/EpCAM- stained cells were 
increased in SCC25+KRT4. CD44-/EpCAM+ stained cells were reduced in SCC25+KRT4 
and retinoic acid treated cells (Figure 4.7A). 
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Figure 4.7The FACS profile of cancer stem cell markers - CD44, EpCAM and CD133 in 
SCC25 and SCC25+KRT4 with and without retinoic acid treatment. 
A) Flow cytometric analysis showed CD44 (labelled with PerCP cy5.5) and EpCAM 
(labelled with FITC) expression in SCC25 and SCC25+KRT4 cells treated with and without 
1 μM retinoic acid. SCC25+RA and SCC25+KRT4+RA cells represents with 1PM retinoic 
acid treatment for 48 h. B) Flow cytometric analysis of SCC25 cells with CD133 staining 
(labelled with APC). SCC25 unstained represents isotype control without CD133 labelling. 
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4.4.8 Retnoic acid treatment leads to a decrease in the expression 
of KRT14, KRT17, c-JUN and SP1 genes 
Since retinoic acid treatment reduced mRNA levels of KRT4 in SCC25 cells, it was 
considered that it may also play an important role in the regulation of KRT14 and KRT17 
genes that were up regulated in OSCC samples as shown in our previous microarray data 
(GSE56532). Further, the expression of transcription factors that possibly induce the 
expression of KRT14 and KRT17 genes, c-JUN and FOS were also analysed. In comparison 
with SCC25, KRT14 expression was significantly increased in SCC25+KRT4 and there was 
no significant increase in the expression of other genes in SCC25+KRT4 (Figure 4.8). 
However, after retinoic acid treatment, the genes for KRT14, KRT17 and their regulators, c-
JUN and SP1 were significantly down regulated both in SCC25 and SCC25+KRT4 cells 
(Figure 4.8). 
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Figure 4.8Expression of KRT14, KRT17, SP1 and c-JUN in vector control (SCC25) and 
KRT4 transfected (SCC25+KRT4) cells with and without retinoic acid treatment. 
A) QPCR analysis was performed to analyse mRNA levels of KRT14, KRT17, SP1 and c-
JUN in SCC25 and SCC25+KRT4 cells with and without retinoic acid treatment. SCC25+RA 
and SCC25+KRT4+RA cells represents with 1PM retinoic acid treatment for 48 h. 
Expression values of these genes were normalized to GAPDH and * indicates significant P-
Value < 0.05. 
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4.5 Discussion 
Oral squamous cell carcinoma (OSCC), a relatively common cancer worldwide, has a poor 
prognosis and a low 5-year survival rate due to secondary tumours, local recurrence and 
distant metastasis (Sano & Myers 2007; Vered, Yarom & Dayan 2005). The lack of clinical 
markers for early detection has contributed to the poor prognosis in oral cancer patients, and 
thus a detailed understanding of genes and their role in tumour progression and metastasis 
may assist with advancement in diagnosis and therapeutics of this disease. Many gene profile 
studies have been conducted on oral tumours relative to normal surrounding margins. Most of 
these studies revealed down regulation of the KRT4 gene in their gene profile studies 
(Ohkura et al. 2005; Sakamoto et al. 2011; Toruner et al. 2004; Ye et al. 2008), which is 
consistent with our previous microarray analysis of advanced (stage III and IV) OSCC in 
comparison with the normal surrounding margins (GSE56532). The OSCC cell line, SCC25, 
derived from human tongue, is a well characterized cell line, with data from microarray 
analysis showing down regulation of KRT4 in SCC25 in comparison to normal human oral 
keratinocytes (Rao et al. 2010). These studies suggest that there might be a significant role 
for the down regulation of KRT4 gene in oral cancer progression. Therefore, to validate this 
as a possible therapeutic target, we studied whether the over expression of the KRT4 gene in 
SCC25 cell lines affected their tumorigenic properties.  
4.5.1 SCC25 cells transfected with KRT4 gene revealed EMT 
phenotype 
KRT4 mRNA and protein expression was examined in early (stage I and II) and late stage 
(stage III and IV) OSCC samples, which confirmed the down regulation of KRT4 compared 
to normal counterparts, consistent with our previous microarray data (GSE56532). Stable 
transfection of KRT4 was achieved with selection against geniticin and the morphological 
observation of the cells revealed compact growth of KRT4 transfected cells, possibly due to a 
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gain in cellular structural supporting intermediate filaments with more adhesion and 
migratory/ proliferative ability (Chu et al. 1993). The sphere formation and wound healing 
assay showed formation of irregular shaped large tumour spheres and a rapid complete 
closure of the wound in KRT4 transfected cells. These results indicated an increase in 
reproductive and migratory ability of the cells, consistent with earlier studies which indicated 
keratin over expression led to an increase in the migratory and invasive ability of cells (Chu 
et al. 1993). SCC25 cells transfected with KRT4 also gained phenotypic changes, showing 
compact growth with tightly packed cells closely related to holoclone like structures. Earlier 
studies indicated OSCC cells that form holoclone like colonies have more cancer stem cell 
like properties with epithelial mesenchymal transition (EMT) properties (Harper et al. 2007), 
indeed KRT4 transfected SCC25 cells showed significant up regulation of the EMT marker, 
N-cadherin (CDH2). In addition, CD44 expression, both mRNA and protein, was increased in 
KRT4 transfected cells, revealing increased stemness. The higher level of CD44 expression 
in agreement with Shigeishi and colleagues, who reported that cells capable of forming 
holoclone like structures exhibited an increased CD44 expression, compared to other tumour 
cells (Shigeishi et al. 2013). Further, to confirm the EMT phenotype of SCC25 cells, 
epithelial cell adhesion molecule (EpCAM), a protein known to be down regulated in cells 
undergoing EMT process (Frederick et al. 2007), was analysed for mRNA and protein 
expression. We found that KRT4 transfected cells revealed a much lower level of EpCAM 
expression compared to vector control cells, confirming the EMT phenotype. An earlier study 
also revealed low EpCAM expression was associated with increased tumour size (Hwang et 
al. 2009) and the decreased CD44+/EpCAM+ and increased CD44+/EpCAM- cells may led to 
the increased tumorigenic properties of SCC25+KRT4 cells. CD133 protein levels were also 
assessed as previous studies have shown CD133 expression in cells with cancer stem cell like 
properties (Sun et al. 2012). To the contrary, SCC25 cells did not show any positive staining 
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for CD133, which correlates with a previous study showing that CD133 identified cancer 
stem cell like cells of mesenchymal origin but not of epithelial origin (Margaritescu et al. 
2011). Therefore, as SCC25 cells are of epithelial origin (Rheinwald & Beckett 1981), 
CD133 expression would not be expected, although this is contrary to a previous report that 
demonstrated moderate CD133 staining in SCC25 cells (Spiegelberg et al. 2014). KRT14 is a 
marker highly expressed in proliferating epithelial cells (Fuchs & Green 1980). Increased 
KRT14 mRNA and protein levels in KRT4 transfected cells were observed which suggest an 
increased tumourigenicity with EMT phenotype (Kato et al. 2007). KRT4 is a terminal 
epithelial differentiation marker (Vaidya & Kanojia 2007) and its loss was observed in OSCC 
samples (Lallemant et al. 2009) and epithelial dysplasia samples (Sakamoto et al. 2011). 
KRT4 overexpression led to EMT phenotype further leading to increased tumorigenic 
properties of SCC25 cells. Over expression of KRT4 may not have therapeutic importance 
and impact on the differentiation of SCC25 cells but due to overexpression of KRT4, 
increased cell structural fragment, may led to increased cell spreading and migration leading 
to increased tumorigenic properties (Chu et al. 1993). 
4.5.2 Comparison of GSE56532 and GSE26549 data series 
revealed a reciprocal pattern of KRT4 and KRT17 
expression in dysplasia samples that progressed cancer 
Differential regulation of 3 keratin genes (KRT14, KRT17 and KRT4) was observed in late 
OSCC samples when compared to normal samples (GSE56532). KRT4 was down regulated; 
and KRT14 and KRT17 were up regulated in late OSCC samples. Further comparison of 
normal data from GSE56532 with dysplasia samples from GSE26549 revealed a significant 
down regulation of KRT4 and up regulation of KRT17 in dysplasia samples (progressed to 
cancer) and the same pattern of expression was also observed even in late stage OSCC 
samples indicating down regulation of KRT4 and up regulation of KRT17 in dysplasia may 
be prognostic markers for oral cancer. This reciprocal pattern of KRT4 and KRT17 
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expression was also recently observed in cervical squamous cell carcinoma (Escobar-Hoyos 
et al. 2014). However, additional studies assessing the expression of KRT4 and KRT17 in 
dysplasia samples are required to confirm this hypothesis which is based on microarray 
database analysis.  
4.5.3 Retinoic acid decreased cell growth and stemness of SCC25 
and SCC25+KRT4 cells 
Earlier studies indicated that retinoic acid treatment increased the expression of KRT4 genes 
in epidermal keratinocytes (Virtanen et al. 2010) and decreased KRT4 mRNA in gingival 
keratinocytes (Hatakeyama et al. 2004), although the effects of retinoic acid on the 
expression of differentially regulated keratins (KRT4, KRT14 and KRT17 from GSE56532 
data) in SCC25 cells have not been determined. Previous studies have indicated retinoic acid 
(all-trans retinoic acid, ATRA) at low concentrations (1 μM) does not allow SCC25 cells to 
enter into the mitotic phase (Le, Soprano & Soprano 2002). In addition, ATRA at low 
concentrations (1 μM) has been used to induce cell growth inhibition and induction of KRT4 
expression in epidermal keratinocytes (Gericke et al. 2013; Virtanen et al. 2010).  In this 
study, ATRA treatment (1 μM) led to a decrease in the cell growth and reproductive ability of 
the SCC25 cells. Further, it reduced KRT4 mRNA expression in SCC25 cells but not in 
KRT4 transfected cells indicating ATRA may act on the promoter binding site and thus 
regulates KRT4 expression. Flow cytometry analysis indicated a decreased expression of 
CD44, involved in the increased stemness of SCC25 cells (Shigeishi et al. 2013), in KRT4 
transfected cells treated with ATRA. The other cytokeratins, KRT14 and KRT17, which were 
shown to be significantly differentially up regulated in our previous microarray study 
(GSE56532) were repressed after ATRA treatment. The KRT14 and KRT17 genes are known 
to be involved in the progression of carcinoma (Miettinen, Kovatich & Karkkainen 1997; 
Reis-Filho et al. 2003). The present study also showed that ATRA treatment down regulated 
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the expression of transcription factors, SP1 and c-JUN, that are involved in the activation the 
supra basal (KRT4) and basal keratin genes (KRT14 and KRT17) (Rossi et al. 1998). It is 
clear from the present study that ATRA treatment represses the expression of KRT4, KRT14 
and KRT17 genes including their transcription factors, C-JUN and SP-1. It also reduces the 
tumorigenic properties in SCC25 and SCC25+KRT4 cells by decreasing the expression of 
CD44 expression. 
Previous studies indicated that KRT4 gene expression depends on the status of growth and 
differentiation of keratinocytes (Fuchs & Green 1980). A possible explanation for down 
regulation of KRT4 in OSCC samples is over expression of cyclin-D1 protein in oral cancer 
cells which allows cells to proliferate profusely leading to reduction in the KRT4 promoter 
activation by SP1 (Opitz, Jenkins & Rustgi 1998; Wanner et al. 1997). Overexpression of 
cyclinD1 is also associated with poor differentiation in OSCC samples (Angadi & 
Krishnapillai 2007). Further studies would be interesting to examine if KRT4 promoter 
activation by SP1 occurs due to silencing of cyclinD1 expression. 
4.6 Conclusion 
Collectively, the present study suggests KRT4 down regulation does not have therapeutic 
significance as it’s over expression has promoted further stemness in SCC25 cells but it may 
have prognostic and diagnostic importance. Further studies have to be carried out to find the 
expression of KRT4 in dysplasia samples with a follow up study to further use it as a 
prognostic marker. 
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5.1 Summary 
Extracellular matrix plays an important role in the normal physiology of tissues and 
progression to disease. It forms an important communicating link between the epithelial cells 
and the non-cellular factors in the microenvironment. Earlier studies indicated that only 0.3% 
of mammary cells undergo cell proliferation in a 24 h time period. Recent studies have 
indicated that mammary ECM plays an important role in regulating the signals at different 
phases of lactation. The present study examines the fate of mammary and oral cancer cells 
grown in the ECM from lactating mammary gland. Our findings show that non-tumorigenic 
cells, MCF10A and DOK cells did not proliferate but the tumorigenic and metastatic cells, 
SCC25 and MDA-MB-231 underwent apoptosis when grown on mammary ECM isolated 
from lactating mice. In addition, the cytokinesis marker, CEP55, was repressed in the oral 
and breast cancer cells. In contrast, these cells proliferated normally on mammary ECM 
isolated from mice undergoing involution. External microarray data analysis of mammary 
tissue further revealed over expression (~16 fold) of QSOX1 gene, which promotes cellular 
quiescence, in lactating mammary gland. A recent study has indicated that QSOX1 
overexpression in breast cancer cells led to reduced proliferation and tumorigenic properties. 
This extracellular protein in mammary ECM may be responsible for signaling reduced 
cellular proliferation. The present study has shown that ECM from lactating mammary gland 
can regulate signals to oral and breast cancer cells to halt cell division. This preliminary 
observation provided insights into the potential role of ECM factors present in lactating 
mammary gland as therapeutic targets to control cancer cell division. 
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5.2 Introduction 
The tumour microenvironment plays an important role in the regulation of cancer cell 
behaviour (Bhowmick, Neilson & Moses 2004; Bissell & Labarge 2005). Recent research has 
also revealed that non-cellular components of the microenvironment, the extracellular matrix 
(ECM), also play an important role in tumour progression (Erler et al. 2009; Erler et al. 2006; 
Levental et al. 2009; Paszek et al. 2005; Sternlicht et al. 1999). ECM promotes integrity, 
proliferation and maintenance of tissue morphology and also influences the fundamental 
characteristics of the cell (Hynes 2009; Lu et al. 2011; Stickens et al. 2004; Wiseman & Werb 
2002). Several mechanisms regulate the dynamics of ECM including synthesis, degradation 
and remodelling required during developmental processes (Page-McCaw, Ewald & Werb 
2007) and deregulation of these mechanisms can lead to disorganized ECM with cellular 
abnormalities resulting in fibrotic and cancer conditions (Cox & Erler 2011). ECM is also 
responsible for maintaining the polarity and architecture of epithelial tissues including 
mammary gland and the loss of polarity due to aberrant ECM dynamics is often associated 
with the cancer progression (Akhtar et al. 2009; Ghajar & Bissell 2008).  
ECM not only provides strong support to the mammary gland architecture but also acts as a 
communicating link between the extracellular environment and the epithelial cells (Akhtar et 
al. 2009). The ECM protein profile is different in various stages of mammary gland 
development including pregnancy, lactation and involution (Schedin et al. 2004; Warburton 
et al. 1982). During involution, the majority of the epithelial cells undergo apoptosis followed 
by ECM remodelling and an irreversible change in the mammary gland to a pre-pregnant 
stage (Watson 2006). This ECM remodelling process is due to significant expression of 
matrix metalloproteinases (MMPs) (Green & Lund 2005) and the expression profile of 
MMPs during involution was found to be similar to that of developing mammary gland 
tumours (Almholt et al. 2007). The activation of inflammatory responsive elements during 
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involution is highly similar to that of the tumour microenvironment and in the wound healing 
process (Schedin et al. 2007; van Kempen et al. 2003). 
Previous studies have indicated that mammary gland proliferation is low during lactation and 
mammary epithelial cells undergo a quiescence stage (Capuco et al. 2003; Knight & Peaker 
1982). A recent study from our lab has indicated that ECM isolated from different phases of 
lactation provides regulatory signals in-vitro to mammary epithelial cells (MECs) so they 
behave in a similar way to that observed at the phase of lactation from which the ECM was 
isolated (Wanyonyi et al. 2013). From the studies stated above, there is clear evidence that 
lactating glands show less proliferation and as the ECM can govern tumour progression, it 
would be interesting to observe if factors in lactating ECM inhibits metastatic and 
tumourigenic potential on breast and oral cancer cells, irrespective of their tumourigenic 
potential. Hence, the present preliminary study addressed whether extracellular matrix 
isolated from mammary gland during lactation included factors for inhibiting cell division of 
breast and oral cancer cells. 
5.3 Materials and methods 
5.3.1 Animals 
BALB/c mice were used and were obtained from Monash Animal Services, Melbourne, 
Australia. The experiments were approved by Deakin University Animal Ethics Committee. 
Mammary glands were dissected from the lactating mice (day 15). In addition, lactating mice 
(day 15) were separated from pups and mammary glands were dissected from mice at day 4 
of involution. All tissues were immediately frozen and stored at -80qC till further use. 
5.3.2 Cell lines 
MCF10A was a generous gift from Dr. Patrick Humbert, PeterMac Cancer Research Institute, 
Melbourne. Cells were grown as previously described (Bruzzone et al. 2014). Briefly cells 
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were maintained in Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F12 medium 
containing 10% fetal bovine serum (Life Technologies), 20 ng/ml epidermal growth factor, 2 
Pg/ml insulin, 0.1 PM hydrocortisone, 100 IU/ml pencillin and 100 Pg/ml streptomycin. 
MDA-MB-231 and SCC25 were obtained from American Type Culture Collection (ATCC). 
MDA-MB-231 cells were cultured in DMEM media supplemented with 10% fetal bovine 
serum, 100 IU/ml pencillin and 100 Pg/ml streptomycin. SCC25 cells were grown in 1:1 
mixture of DMEM and Ham’s F12 media supplemented with 10% fetal bovine serum, 100 
Pg/ml streptomycin, 100 IU/ml pencillin and 400 ng/ml hydrocortisone. DOK cells were 
purchased from the European Culture of Cell Cultures (ECACC) and the cells were grown in 
DMEM media supplemented with 2 mM glutamine, 5 Pg/ml hydrocortisone, 10 % fetal 
bovine serum, 100 IU/pencillin and 100 Pg/ml streptomycin. All cells were cultured at 37qC 
with 5% CO2 conditions. 
5.3.3 External microarray dataset and data analysis 
Data analysis was performed using publicly available microarray data as represented in the 
table 1. Lactating mammary gland (day 9 and day 15) and involuting mammary gland (day 4) 
data files were obtained from three individual studies as represented in the Table 5.1. The 
data considered for the comparative analysis from three individual studies used the same 
array platform (Affymetrix MG U74 Aver 2).  The CEL files (n=11) were normalized using 
gene spring software (Agilent) by robust multi-array average method (RMA). Normalized 
intensity values of late lactation data (day 9 and day 10; n=6) was compared to the late 
involution (day 4; n=5) and the fold change values were obtained after employing Benjamin-
Hochberg multiple testing correction. Genes that were differentially regulated were 
considered with significant P-Value <0.01 and with fold change value > 2. A heat map was 
generated using hierarchical clustering explorer software (version 3.5). 
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Table 5.1 Data considered for the external microarray study analysis. 
Data considered for microarray analysis Reference 
Day 4 Involution (n=2), Day 10 Lactation (n=2) (Clarkson et al. 2004) 
Day 4 Involution (n=3) (Stein et al. 2004) 
Day 9 Lactation (n=4) (Rudolph et al. 2003) 
 
5.3.4 Extracellular matrix preparation from mammary gland 
tissue 
Extracellular matrix (ECM) was isolated from mammary gland tissue during lactation (day 
15) and involution (day 4) using a homogenization method with successive steps of several 
high salt washes followed by urea extraction (O'Brien, Fornetti & Schedin 2010). Briefly, 
frozen mammary gland tissue was pulverized into fine powder using a mortar and pestle 
containing liquid nitrogen. Homogenization of powdered tissue (1 g) was performed in high 
salt buffer (2 ml) composed of 200 Pg/ml phenyl methyl sulfonyl fluoride (PMSF), 2 mM n-
ethylmaleimide (NEM) and protease inhibitory cocktail (Sigma). Insoluble ECM proteins 
were further enriched from the homogenate by a second high salt wash and urea extraction 
followed by ultra-speed centrifugation for 1h at 100,000 x g between the washes. ECM was 
dialysed sequentially to eliminate urea and protease inhibitors. Ham’s F12 and M199 (1:1 
ratio) media without serum was used for the final dialysis of ECM and ECM was removed 
from the dialysis membrane, aliquoted and stored at -20qC until use.  
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5.3.5 Cell culture on ECM 
ECM (40 μL) from lactating and involuting mammary gland were coated on to each well of a 
96- well plate which was incubated at 37qC for 1h. Cells (4 x 103) were seeded onto the 
extracellular matrix for further experimental analysis (Figure 5.1). 
5.3.6 Live/dead cell staining 
Cells (4 x 103) were seeded onto the lactation and involution matrix and incubated for 3 
consecutive days. Live/dead cell staining was performed every 24 h using calcein AM and 
propidium iodide according to the manufacturer’s instructions (Cayman Chemical) with 
minor modification. The PBS wash was not performed and after adding reagents, the cells 
were incubated for 40 min at 37qC in the dark. The stain was removed and replaced by 
media. The images were assessed using fluorescent microscope (Nikon) within 1h. 
5.3.7 Cell proliferation assay 
MTS (Promega) reagent was used to measure the cell viability. MTS was added (20 Pl) to 
each well containing cells on ECM and incubated for 4 h at 37qC in dark. The absorbance 
value was measured at 490 nm using a spectrophotometer (Bio-Rad). 
5.3.8 Annexin V staining 
To assess apoptosis, annexin V staining was performed according to the manufacturer’s 
instructions. Briefly, media was carefully removed and cells washed with cold PBS. Annexin 
V buffer containing Hoechst dye (Sigma), propidium iodide and annexin V FITC (Life 
Technologies). Annexin V buffer was added to the cells and incubated for 30 min at 37qC in 
the dark. The reagent was removed carefully and replaced by annexin V buffer without dyes. 
Further the images were assessed using a fluorescent microscope (Nikon). 
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Figure 5.1 Schematic representation of culture of cells on ECM extracted from lactating 
and involuting mammary gland. 
Each well of a 96 well plate was coated with 40 Pl of ECM and incubated for 1h at 37qC. 
Cells were seeded on the ECM. 
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5.3.9 Actin staining 
Media was removed carefully and the cells were washed twice with PBS. Further cells were 
treated with 4% paraformaldehyde for fixation and 0.1% triton-x-100 for permeabilization. 
Cells were stained overnight at 4⁰C with rhodaminephalloidin (Life Technologies) according 
to the manufacturer’s instructions. Cells were washed with PBS twice and the images were 
obtained using fluorescent microscope (Nikon, USA). 
5.3.10 CEP55 staining 
Cells were fixed with 4% paraformaldehyde for 10 min at room temperature (RT) and were 
washed with PBS twice. Cells were then permeabilized using 0.1% triton-x-100 in PBS for 
15 min at RT. Cells were washed with PBS twice and were blocked with 1% bovine serum 
albumin (BSA) in PBS for 30 min at RT. The cells were incubated with primary antibody, 
rabbit monoclonal anti-CEP55 antibody (Abcam) at 4qC overnight, washed three times with 
PBS and incubated with secondary antibody, rabbit alexa flour 488 (Life Technologies), for 
1h at RT. Cells were washed three times with PBS, counterstained with nuclear stain, 
Hoechst dye (Sigma) and the images were obtained using fluorescent microscope (Nikon). 
5.3.11 Tumour sphere growth 
SCC25 cells (3 x 104) were cultured in agarose coated 6-well plates to examine sphere 
formation as described previously (Chen et al. 2012). Cells were seeded in 2 ml of complete 
media and allowed to grow spheres for 7 to 8 days. Spheres were then collected by 
centrifugation at 800 x g for 5 min. The pellet containing spheres was carefully disturbed by 
tapping the tube and spheres grown on the plastic surface as monolayers. Once the 
monolayers reached confluence, the procedure of sphere growth was repeated twice. Finally, 
spheres were collected and placed on to wells coated with mammary ECM from lactating and 
involuting mice. The spheres were cultured for 72 h at 37ͼC and stained with Hoechst dye 
(Sigma). 
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5.4 Results 
5.4.1 Mammary ECM during lactation inhibits cell proliferation 
Cells (MCF10A, DOK, SCC25 and MDA-MB-231) grown on the ECM isolated from 
lactation mammary gland (lactation matrix) and involution mammary gland (involution 
matrix) were further analysed for a proliferation effect on these two matrices. Cells cultured 
on plastic for each cell line were also considered as a reference. Analysis of cell proliferation 
and viability revealed a significant reduction in cell viability at day 1 and 2 of culture in both 
the cancer cell lines, MDA-MB-231 and SCC25, when grown on lactation matrix (Figure 
5.2). MDA-MB-231 did not show a significant reduction in viable cells on day3 on lactation 
matrix in comparison to day2 but SCC25 cells showed significant reduction in viable cells at 
both time points (Figure 5.2). Cells grown on involution matrix showed no growth inhibition 
and the growth pattern of the cells was almost equivalent to that of cells grown on plastic 
(Figure 5.2). The non-tumorigenic cells, DOK and MCF10A, showed no growth in the 
lactation matrix and there was no significant cell death observed (Figure 5.2). Although DOK 
cells showed no change in the cell growth on lactation matrix during the first 2 days of 
culture, there was a significant increase in growth on day 3. The cells grown on lactation 
matrix, involution matrix and plastic for 48 h were subjected to live/dead cell staining using 
calcein AM and propidium iodide. Live cells were stained with calcein AM (green) and dead 
cells were stained with propidium iodide (red). No effective cell death was found in the cells 
grown on involution matrix and plastic (Figure 5.3A to D). Non-tumorigenic cells, DOK and 
MCF10A, did not show significant cell death when grown on lactation matrix (Figure 5.3A 
and C). In contrast, there was a considerable effect on the cell viability of tumorigenic MDA-
MB-231 and SCC25 cells, grown on lactation matrix (Figure 5.3B and D).  
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Figure 5.2Effect on proliferation of cells grown on lactation matrix, involution matrix 
and plastic. 
MCF10A, MDA-MB-231, DOK, SCC25 cells grown on lactation matrix, involution matrix 
and plastic were measured for cell viability using MTS reagent on day0, day1, day2 and day3 
at 490 nm wavelength. The asterisk (*) indicates significant P-Value < 0.05 reduction in the 
cell viability of tumorigenic cells, MDA-MB-231 and SCC25 cells (Students-t-test). In this 
experiment, biological and technical triplicates were considered for the statistical analysis.  
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Figure 5.3Live/dead cell staining of cells grown on lactation matrix, involution matrix 
and plastic surface for 48h. 
MCF10A (A), MDA-MB-231 (B), DOK (C) and SCC25 (D) cells were grown for 48 h on 
lactation matrix, involution matrix and plastic surface. Further cells were stained with calcein 
AM and propidium iodide stains. Calcein AM stains live cells (green) and propidium iodide 
stains dead cells (red). 
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5.4.2 Morphology of the cells cultured on mammary ECM 
The morphology of cells, SCC25 and MDA-MB-231 cells grown on the lactation matrix were 
round and the cells grown on the ECM isolated from the involution matrix had a flat 
morphology due to cell attachment to the plastic as revealed by the actin staining (Figure 
5.4). Actin staining also revealed formation of sphere like structures by MDA-MB-231 cells 
whereas SCC25 cells were unable to form any spheres (Figure 5.4) on the lactation matrix. 
5.4.3 Lactation ECM induces apoptosis in cancer cells 
A significant reduction in cell viability was observed in cells grown on lactation matrix from 
day 1 as shown in the Figure 5.2. Therefore the SCC25 and MDA-MB-231 cells grown on 
lactation and involution matrix were subjected to annexin V staining for the detection of 
apoptosis. SCC25 and MDA-MB-231 cells grown on involution matrix were stained only 
with Hoechst dye indicating presence of live cells (Figure 5.5). Both the cancer cell lines 
grown on lactation matrix were apoptotic with the presence of early and late apoptotic cells 
(Figure 5.5). Live and dead cells were also observed in the lactation matrix (Figure 5.5). 
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Figure 5.4Morphology of the MDA-MB-231 and SCC25 cells grown on lactation and 
involution matrix. 
Morphology of the tumorigenic cells, MDA-MB-231 and SCC25 cells, were observed by 
actin staining using rhodamine-phalloidin reagent (Red) after growing cells on lactation and 
involution matrix for 48 h at 37qC. 
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Figure 5.5Annexin V staining of breast and oral cancer cells grown on lactation (LM) 
and involution matrix (IM). 
SCC25 (oral) and MDA-MB-231 (breast) cancer cells were grown on lactation matrix for 24 
h and annexin V staining was performed. Early apoptotic cells were stained with annexin V 
(green) and nuclei with Hoechst dye (blue). Late apoptotic cells were stained with annexin V 
(green) and nuclei with propidium iodide (red). Dead cells show no annexin V staining but 
only nuclei staining with propidium iodide (red). Live cells only show nuclei staining with 
Hoechst dye (blue). 
 
 
Annexin V Hoechst Propidium Iodide Merge
M
DA
M
B2
31
 (I
M
)
M
DA
M
B2
31
 (L
M
)
SC
C2
5 
(IM
)
SC
C2
5 
(L
M
)
EA
EA
LA
LA
DC
DC
LC
LC
LC
LC
  Chapter 5 
204 
 
5.4.4 Repression of CEP55 expression in the cells grown on 
lactation ECM 
Mammary epithelial cells during lactation showed low proliferation and cellular quiescence 
was observed (Capuco et al. 2003) which may result from ECM regulation. CEP55 protein is 
often expressed during cytokinesis (van der Horst, Simmons & Khanna 2009). SCC25 cells 
and MDA-MB-231 cells grown on lactation and involution matrix for 48 h were analysed for 
CEP55 expression using immunofluorescence. Results indicated all cells of both tumorigenic 
cell lines grown on involution matrix expressed CEP55 but only a few cells grown on 
lactation matrix showed CEP55 expression (Figure 5.6A and B). 
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Figure 5.6Immunofluorescence analysis of CEP55 expression in cells grown on lactation 
and involution matrix. 
MDA-MB-231 (A) and SCC25 (B) cells were grown on lactation and involution matrix for 
48 h and the cells were further analysed for CEP55 expression. Cells were treated with rabbit 
anti-CEP55 primary antibody and further anti-rabbit alexafluor 488 seccondary antibody was 
used for detection of CEP55 expression (green). Cells were counterstained with Hoechst dye 
(blue). Arrow marks indicate cells without CEP55 expression. 
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5.4.5 Microarray data analysis 
External datasets were analysed for the comparison of gene expression in late lactation and 
late involution stages of mammary gland in mice. Analysis using Gene Spring software 
revealed significant differentially regulated genes (1000) with significant P-Value less than 
0.01 and fold change greater than 2. Principal component analysis showed a clear distinction 
between the two sample types considered for comparison (lactation and involution) (Figure 
5.7).In addition, the gene profile was analysed for the expression of genes involved in ECM 
remodelling and genes promoting cellular quiescence using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID 6.7) program (Dennis et al. 2003). Most of 
the genes related to ECM remodelling were up regulated in involuting mammary gland 
(Table 5.2). Further analysis of the genes indicated important inflammatory response-
promoting genes that were up regulated in involuting mammary gland compared to the 
lactating mammary gland (Table 5.3). Analysis of the genes among the significant 
differentially regulated genes promoting cellular quiescence revealed over expression of the 
QSOX1 gene. This gene is related to cells undergoing cellular quiescence (Coppock et al. 
2000) and was up regulated in lactating mammary gland (Table 5.4). The gene for beta actin 
(ACTB) expression was found to be down regulated and epidermal growth factor (EGF) was 
up regulated in lactating mammary gland in comparison to the involuting mammary gland 
(Table 5.4). 
5.4.6 Growth of in-vitro tumour spheres on the lactation and 
involution matrices 
Spheres were produced from SCC25 cells as described in the methods. Spheres grown on the 
ECM from lactating mammary gland did not show attachment to the plastic whereas the 
spheres grown on the involution matrix attached to the plastic (Figure 5.8). 
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Figure 5.7Principal component analysis of involution and lactation microarray datasets. 
Principal component analysis (PCA) was performed using Gene Spring software on the 
sample data sets belonging to lactation (blue) and involution data (red) using gene spring 
software. 
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Table 5.2 Candidate genes involved in ECM remodelling expressed in involuting 
mammary gland. 
Probeset ID Gene Symbol Fold change 
92366_at LAMA2 2.140463 
100123_f_at, 100124_r_at ITGB1 2.738437, 2.0766518 
101039_at, 101130_at COL4A2 2.5104058, 3.410371 
101055_at CTSA 2.902003 
101093_at COL4A1 2.460734 
101110_at COL4A3 3.480342 
101963_at CTSL 4.375176 
98543_at CTSS 11.06912 
95338_s_at, 95339_r_at MMP12 6.470666, 6.356155 
98833_at MMP3 15.25365 
160118_at MMP14 2.024899 
97930_f_at CD151 2.348199 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 5 
210 
 
Table 5.3 Candidate genes involved in inflammatory response in involuting mammary 
gland. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.4 Expression of ACTB and QSOX1 genes in lactating mammary gland (in 
comparison to involuting mammary gland). 
 
Probeset ID Gene Symbol Fold change 
101578_f_at ACTB -2.2066 
96602_g_at QSOX1 16.47514 
96603_at QSOX1 6.416567 
102774_at EGF 20.3785 
 
 
 
 
 
 
Probeset ID Gene Symbol Fold change 
101930_at NFIX 4.213352 
102255_at OSMR 10.74777 
98427_s_at NFKB1 3.906747 
100333_at SAA2 5.036271 
102712_at SAA3 4.375075 
160253_at IFIT3 5.753367 
101465_at STAT1 2.135606 
16198_f_at CCR5 4.23181 
92459_at CCL8 6.085688 
93397_at CCR2 3.31197 
94761_at CCL7 2.324498 
96953_at CCL14 2.962281 
98008_at CCL1 2.881356 
102736_at CCL2 3.913044 
104388_at CCL9 5.033845 
160511_at CCL12 3.840237 
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Figure 5.8Growth of SCC25 in-vitro tumour spheres in lactation and involution 
matrices. 
SCC25 cells were enriched for formation of spheres on agarose. Spheres were then placed on 
lactation and involution matrices and were cultured for 72 h. Spheres were stained with 
Hoechst dye (blue). 
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5.5 Discussion 
Extracellular matrix (ECM) is the major part of the epithelial cell microenvironment and 
plays a major role in controlling the cellular behaviour, adhesion, proliferation, 
differentiation, migration and apoptosis (Hynes 2009). Changes in ECM composition lead to 
modification of ECM dynamics thereby resulting in the altered tissue architecture (Engler et 
al. 2009; Lopez, Mouw & Weaver 2008). Mammary gland is emerging as a powerful model 
to investigate the mechanoinduction of the signals induced by ECM that can lead to the 
changes in cellular behaviour further affecting the tissue. Previous studies indicated that cell 
proliferation in the mammary gland is low during lactation and most of the mammary 
epithelial cells are quiescent (Capuco et al. 2003; Knight & Peaker 1982). An earlier study 
indicated that mammary epithelial cells (MECs) grown on the mammary ECM of a specific 
phase of lactation behave and respond like cells belonging to the phase of ECM irrespective 
of the phase of lactation from which the MECs were isolated (Wanyonyi et al. 2013). This is 
consistent with the conclusion that ECM plays a major role in promoting cellular quiescence 
during lactation. This preliminary study has explored the effects of lactation matrix on the 
growth of non-tumorigenic and tumorigenic oral and breast cancer cells. 
5.5.1 Lactation matrix promotes cellular quiescence in all cell 
types and induces apoptosis in tumour cells 
In the current study, tumorigenic cells (SCC25 and MDA-MB-231) and non-tumorigenic 
cells (MCF10A and DOK) demonstrated considerable proliferation when cultured on 
involution matrix, most likely due to the cells being able to penetrate the matrix and reach the 
plastic underneath. In contrast, there was no growth observed when the cells were cultured on 
lactation matrix which did not allow the cells to penetrate, consistent with previous findings 
that  lactation matrix promotes cellular quiescence (Capuco et al. 2003). It was observed that 
some of the tumorigenic cells showed cell death when cultured on lactation matrix. The 
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presence of factors in the mammary ECM during lactation may promote cell death only in 
tumorigenic cells and/or lack of the factors essential for the tumorigenic cell survival may 
induce apoptosis in these cells (Elmore 2007). In the current study, the morphology of the 
tumorigenic cells grown on lactation and involution matrix was studied using actin staining. 
The cells cultured on lactation matrix showed a rounded shape and were unable to penetrate 
the matrix and attach to the plastic surface whereas the cells cultured on the involution matrix 
were able to penetrate and attach to the plastic. In addition, enriched SCC25 tumour spheres 
were did not attach to the plastic when cultured on lactation matrix but did attach to plastic 
following culture on involution matrix. Microarray data analysis in the current study revealed 
over expression of epidermal growth factor (EGF) gene in lactating mammary gland 
compared to involuting mammary gland. An earlier study revealed EGF induced detachment 
of cells from the extracellular matrix (ECM) and induced dephosphorylation of focal 
adhesion kinase (FAK) reducing the cell attachment and motility (Lu et al. 2001). The 
mammary matrix from lactating gland has retained EGF that has been sequestered toECM to 
reduce the cell attachment.Tissue inhibitor of metalloproteinases (TIMPs) inhibit the activity 
of MMPs (Bourboulia & Stetler-Stevenson 2010) and the current microarray analysis didn’t 
show any significant over expression of TIMPs in lactating mammary gland suggesting that 
there might be other factors in the mammary ECM that block the cells to penetrate and attach 
to the plastic surface. 
5.5.2 Reduction of cytokinesis marker expression, CEP55, in 
tumour cells grown on lactation matrix 
Centrosomal protein 55kDa, CEP55, is a cell division marker (van der Horst, Simmons & 
Khanna 2009) and is often overexpressed in several types of cancers including oral and breast 
cancers (Inoda et al. 2009; Waseem et al. 2010). When grown on involution matrix, all the 
SCC25 and MDA-MB-231 cells expressed CEP55 protein whereas on lactation matrix only a 
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few cells expressed CEP55 which is consistent with the fact that cancer cells require survival 
signals for their proliferation (Elmore 2007). 
5.5.3 Genes promoting ECM remodelling and inflammatory genes 
in involution 
In the current microarray data analysis, over expression of genes related to chemokines and 
several inflammatory response mediators (especially STAT1, OSMR, CCR5 and NFKB1) 
and over expression of genes related to ECM remodelling (matrix metalloproteinases 
(MMP12, MMP3, MMP14), cysteine proteinases (CTSA, CTSL, CTSS), ECM components 
(COL4A1, COL4A2, COL4A3 and LAMA2), cell surface receptors (ITGB1 and CD151)) 
genes were observed in involuting mammary gland. The present analysis correlates with 
previous studies indicating involution matrix undergoes ECM remodelling and induces an 
inflammatory response which is similar to the cancer microenvironment (Almholt et al. 2007; 
Green & Lund 2005; Schedin et al. 2007; van Kempen et al. 2003). Lactation matrix did not 
allow the cells to penetrate and it has further promoted cell death in the tumorigenic cells. 
Hoever, an important question remaining to be addressed is what limits the cells from 
penetrating the matrix. In contrast, involution matrix might lack these factors and hence the 
cells can penetrate and attach to the plastic surface. A comparison of these 2 matrices will 
potentially provide this information. 
5.5.4 Cell quiescence promoting gene, QSOX1, may play a 
prominent role in controlling the cell proliferation 
Cellular quiescence is one of the prominent features of the mammary epithelial cells during 
lactation (Capuco et al. 2003). Earlier studies indicated that laminin 1 promoted cellular 
quiescence (Spencer et al. 2011) but it was also observed in other studies that there was no 
change in the expression of the laminin during pregnancy, lactation and involuting stages of 
mammary gland development (Schedin et al. 2004; Woodward et al. 2001). In the present 
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microarray analysis, differential expression of the laminin-1 gene was not observed in 
lactating mammary gland in comparison to the involuting mammary gland which is 
consistent with the earlier studies (Schedin et al. 2004; Woodward et al. 2001). Further the 
current microarray analysis showed beta actin (ACTB) levels in lactation mammary gland 
were reduced in comparison with the involution mammary gland. An earlier study indicated 
that during cellular quiescence, promoted by laminin 1 molecule, depletion of nuclear beta 
actin levels were also observed (Spencer et al. 2011). Studies have shown nuclear actin is 
essential for transcriptional activity and chromatin arrangement during cell division (Chuang 
et al. 2006; Dundr et al. 2007; Lenart et al. 2005). Microarray data analysis also revealed 
significant up regulation of QSOX1 gene in lactation mammary gland (in comparison to 
involution mammary gland) in the present study. QSOX1 is an extracellular protein (Musard 
et al. 2001) and it plays an important role in the promotion of cellular quiescence and was 
inversely correlated with the aggressiveness of the breast tumours (Pernodet et al. 2012). 
Recent studies suggested that QSOX1 is essential for the incorporation of laminin into the 
extracellular matrix and blocking QSOX1 leads to reduced cellular adhesion and migration 
(Ilani et al. 2013). From these observations it is clear that over expression of QSOX1 might 
play a role in recruiting laminin into the ECM of lactating mammary gland for promoting 
cellular quiescence. To our knowledge, the complete profile of ECM composition at different 
stages of mammary gland development (pre-pregnancy, pregnancy, lactation and involution) 
has not been determined. Further studies to identify the ECM proteins might be beneficial to 
better understand the role of these proteins and their function. 
 
 
  Chapter 5 
216 
 
5.6 Conclusion 
Collectively, the current study has provided some basic insights into the importance of 
lactation matrix to reduce proliferation of oral and breast cancer cells. However, a 
comprehensive identification of the ECM components and their potential signalling 
mechanisms may provide strategies for developing novel therapeutic interventions for cancer 
treatment. Unravelling the factors in the lactating mammary matrix that induces cell death 
only in the tumorigenic cells might provide new strategies in tissue engineering for cancer 
patients that have undergone surgical tissue excision. 
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6 General Discussion 
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6.1 Overview 
Oral squamous cell carcinoma (OSCC) has no clinically proven biomarker (Funk et al. 2002) 
and the survival rate of patients has not improved for the past few years despite advances in 
cancer research (Weinberg & Estefan 2002). Most of the gene profile studies on OSCC 
samples revealed genes that were either up or down regulated in OSCC tissues (Suhr et al. 
2007; Toruner et al. 2004; Ziober et al. 2006). However, this has not translated into in depth 
knowledge on the molecular mechanisms employed by the cancer cells and which are 
essential to understand the complexity of the disease, and specifically to provide a better 
understanding of the abnormal processes. Recent studies have proposed several molecular 
markers that have been correlated with the clinical outcome of OSCC leading to 
tumorigenesis and progression (Chen et al. 2013; da Silva et al. 2014; Ren et al. 2014). 
However, due to tumour heterogeneity, finding a single clinically proven marker for OSCC is 
problematic and hence additional gene profiling studies and experimental approaches are 
required. This will allow researchers to study the common defective processes and genes 
differentially regulated so that a combination of genes as diagnostic or therapeutic candidates 
can be identified for further studies. 
6.2 Oral cancer progression requires over expression 
of genes involved in inflammation, G2/M 
transition, fibrosis and extracellular matrix 
remodeling 
 
Earlier studies have revealed the application of gene expression profiles as an important 
clinical test with well-designed, independent and multiple validation studies (Cardoso et al. 
2008). Identifying the changes in gene expression of late stage OSCC leads to understanding 
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the disease occurrence and development process including identification of markers to predict 
oral cancer progression. Microarray analysis of late stage (stage III and IV) OSCC and 
adjacent normal samples was performed in chapter two to detect differentially expressed 
genes in late stage OSCC that may serve as markers for therapeutic or early detection of 
OSCC. Further pathway analysis revealed hepatic stellate cell activation, G2/M transit ion, 
interferon signaling and oncostatin-M signaling as significant pathways expressed in late 
stage OSCC. Along with these pathways, genes involved in extracellular matrix (ECM) 
remodeling were also differentially regulated in late stage OSCC. Most of the genes over 
expressed in these pathways were involved in inducing inflammation, fibrosis, cell cycle 
progression and ECM remodeling processes. This is consistent with other studies showing 
over expression of genes involved in segregation of chromosomes observed in cancers (Sato 
et al. 2001). Genes involved in the cell cycle progression were up regulated and they promote 
G2/M transition and segregation of chromosomes process. There are no reports on the 
association of the hepatic stellate cell activation pathway with the oral cancer gene profile. 
Chapter two studied this association for the first time and it is interesting to note that this 
pathway includes genes that are associated with promoting inflammation, fibrosis and ECM 
remodeling processes. 
Comparison of genes that regulate the significant pathways and processes revealed no 
significant difference in expression within early (stage I and II) and late stage OSCC (Stage 
III and IV) samples except for fibronectin1 (FN1). FN1 is a fibrosis marker in renal and 
hepatocellular cancers (Cui et al. 2014; Steffens et al. 2012), and demonstrated a significant 
difference in expression between early and late stage OSCC samples. Late stage samples 
showed a marked increase in FN1 expression associated with the desmoplastic reaction and 
scarring of the tissue. This result clearly indicated that FN1 might be of diagnostic 
importance to differentiate early and late stage OSCC tumors. The current study had a limited 
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source of samples and hence studies in a large number of samples in the future need to be 
conducted in correlation with clinical characteristics of patients. In hepatic fibrotic 
conditions, FN1 levels were detected at higher levels (Bataller & Brenner 2005). Fibronectin, 
exists in serum and cellular form and includes two isoforms called ED-A and ED-B that are 
expressed in limited amounts in the normal tissue but are pre-dominantly expressed in the 
hepatic fibrosis condition (Ffrench-Constant et al. 1989; Jarnagin et al. 1994). Further 
expression studies on the FN1 isoform in OSCC tissues can provide more specificity. It 
would also be interesting to examine the levels of the serum form of FN1 levels in blood 
samples of OSCC patients which might enable FN1 to be used as a non-invasive diagnostic 
marker for OSCC detection. FOXM1 and CEP55 are important regulators of G2/M transition 
(Gemenetzidis et al. 2009; Waseem et al. 2010) and were significantly up regulated in OSCC 
samples. Further comparison of expression of these molecules in the dysplastic cell line, 
DOK and OSCC cell line, SCC25, revealed no significant difference in their expression 
between these cells. FOXM1 over expression is an early event in oral cancer progression 
(Gemenetzidis et al. 2009) and no significant difference in expression of FOXM1 and CEP55 
clearly indicates that G2/M transition was an early event of oral cancer progression. No 
significant difference in STAT1, interferon signaling regulator, and OAS1, downstream 
effector molecule of interferon signaling was observed in the current study. Inflammation 
mediators other than STAT1 and OAS1 include cytokines IL1A and IL1B also did not show 
any differential expression between SCC25 and DOK cells indicating inflammation might 
also be an early event in OSCC and additional studies need to be conducted in clinical 
samples for further support.  
Marked over expression of MMP13, that promotes ECM remodeling (Borzi et al. 2010), 
tumour angiogenesis (Kudo et al. 2012b) and cell proliferation (Meierjohann et al. 2010), was 
observed in SCC25 cells compared to DOK cells. Further, IHC analysis revealed a significant 
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increase in MMP13 expression in early and late stage OSCC samples indicating that MMP13 
expression might be induced during the onset of malignancy.  MMP13 knock down in SCC25 
cells resulted in reduced cell proliferation and tumorigenic properties indicating MMP13 
targeting might be of therapeutic importance in OSCC malignancy.  
OSCC lacks clinical markers and the present study has provided detailed information on 
molecular mechanisms essential for oral cancer progression. Existence of tumor 
heterogeneity in oral cancer clearly indicates that a single gene cannot become responsible 
for the cause and progression of oral cancer (Severino et al. 2008; Zhang et al. 2013a). 
Hence, a combination of genes from the pathways and processes deregulated may give an 
opportunity for utilizing these genes as diagnostic or therapeutic targets. Hepatic stellate cell 
activation pathway was the top most significant pathway differentially expressed in the 
OSCC profile. This pathway is promoted by factors that can induce inflammation, fibrosis 
and ECM remodeling processes further promoting abnormal cell proliferation (Chapter 2). 
Non-invasive methods for detection of cancer are superior to invasive methods as they cause 
no discomfort to the patients, and interestingly CCL5, IL8, MMP13 are secretory proteins 
that are part of the hepatic stellate cell activation pathway. Earlier study has shown IL8 is 
found in elevated levels in OSCC compared to healthy saliva samples (Punyani & Sathawane 
2013). An elevated level of CCL5, which is also known as RANTES helps in increasing the 
motility of oral cancer cells (Chuang et al. 2009). No studies have so far tested CCL5 levels 
in patient salivary samples. In the present study the secretory protein, MMP13 was elevated 
in OSCC patients and a combination of IL8, CCL5 and MMP13 proteins may potentially be 
performed as a protein marker panel which would be requiring validation in large number of 
salivary samples for the early detection of OSCC. Sensitivity and specificity of these markers 
play an important role in declaring these markers as diagnostic markers for oral cancer. This 
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might provide an opportunity to create a noninvasive early detection method for oral cancer 
for improving the survival outcome of these cancer patients. 
Significant over expression of MMP13 in oral cancer cells compared to dysplastic cells and 
gene knockdown studies clearly suggest that MMP13 can be potential target for oral cancer 
prevention (Chapter 2). In a complex multicellular organization, gene therapies might not 
play a significant role in oral cancer therapeutics and further using specific inhibitors of 
MMP13 might allow cancer cells to evade and find alternate pathway to endure tumour 
growth and progression. Hence, there is a need for broad spectrum therapeutic drugs that can 
target multiple pathways and/or genes that contribute towards the oral cancer progression. 
6.3 Aspirin is a potential therapy in the prevention of 
oral cancer progression 
Earlier studies have indicated that oral cancer progression is due to continuous over 
expression of genes related to inflammation further leading to chronic inflammation in the 
patients with OSCC (Carlos & Contreras 2004; Liu et al. 2010; Tezal et al. 2009). Chapter 
two also revealed expression of genes related to inflammation is an early and on-going 
process during oral cancer progression. Recently, several non-steroidal anti-inflammatory 
drugs (NSAIDs) have gained popularity due to their anti-tumorigenic effects through anti-
inflammatory properties (Goodman & Grossman 2014; Macfarlane, Lefevre & Watson 
2014). Aspirin, acetyl salicylic acid, is one of the widely used NSAIDs and is often termed as 
a “wonder drug” (Razzak 2012). Previous studies have shown that aspirin had anti-
inflammatory effects through NF-kB suppression which is highly expressed in oral cancer 
SCC25 cells compared to normal human oral keratinocytes (HOK) (Rao et al. 2010). The 
molecular mechanisms exerted by aspirin have not been studied. Hence, the current study 
examined the molecular mechanisms by which aspirin evoked anti-tumorigenic properties. It 
is also essential to optimize the concentration of the drug so that it does not affect the normal 
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cells. An earlier study indicated that aspirin (2.0 mM) showed anti-proliferative effects in 
SCC25 cells but there was no effect on cell viability in HOK cells when aspirin was added to 
cell culture media at 2.0 mM concentration (Rao et al. 2010).  
Microarray analysis was performed on SCC25 cells treated with and without 2.0 mM aspirin 
as described in chapter three and results revealed that G2/M transition and interferon 
signaling were the most affected pathways in SCC25 cells following aspirin treatment. This 
clearly indicatedthat aspirin can target a basic stimulator of oral cancer, as G2/M transition 
and interferon signaling were early events in oral cancer progression (chapter two). Further, it 
was observed that approximately more than 50 genes that play an important role in G2/M 
transition and cell cycle progression were significantly down regulated. To support the anti-
proliferative property of aspirin, all the genes expressed and involved in the segregation of 
chromosomes were significantly down regulated in contrast to the up regulation of these 
genes in OSCC tissues as described in the chapter two results. Furthermore it was also 
observed that apoptosis inducers PPARG and CASP9 were over expressed in aspirin treated 
SCC25 cells. Earlier studies indicated that NSAIDs show anti-neoplastic effects leading to 
cell death in oral cancer cells through over-expression of PPARG (Lehmann et al. 1997; 
Nikitakis et al. 2002). The current study indicated down regulation of PPARG gene in late 
stage OSCC samples compared to the normal samples. Further IHC analysis also indicated 
PPARG expression levels were significantly lower in OSCC samples (early and late stage) 
than their normal counterparts. PPARG expression was also significantly down regulated in 
SCC25 cells compared to the DOK cells. It was also known that PPARG expression was 
essential for squamous epithelial differentiation (Rivier et al. 1998). Aspirin treatment 
showed an increase in the expression of PPARG compared to untreated SCC25 cells and this 
increase might be essential to induce differentiation and anti-tumorigenic properties in 
SCC25 cells.  
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Chapter two results indicated overexpression of genes promoting fibrosis through hepatic 
stellate cell activation pathway. Earlier studies indicated that PPARG can inhibit the fibrotic 
phenotype further repressing the hepatic stellate cell activation (Qian et al. 2012). Since 
OSCC progression involved activation of markers for fibrosis, aspirin treatment would be 
beneficial to control fibrosis in oral cancer. Chapter two also indicated over expression of 
genes related to ECM remodeling in OSCC samples. ECM remodeling is one of the essential 
processes for cancer invasion and metastasis (Catalano et al. 2013). Unlike inflammation, 
targeting genes for therapeutic purpose involved in ECM remodeling is highly critical as 
MMP inhibitors were clinically unsuccessful towards prevention of tumor progression (Ulisse 
et al. 2009). Aspirin treatment reduced most of the genes involved in ECM remodeling 
andanalysis described in Chapter two revealed significant over expression of MMP13 in 
SCC25 cells compared to DOK cells. Aspirin treatment reduced the expression of MMP13 in 
SCC25 cells. It also reduced the expression of other matrix proteinases MMP3, MMP7 and 
ADAM9 that are involved in ECM remodeling(Stott-Miller et al. 2011; Vincent-Chong et al. 
2013). Further tumour progression markers, STMN1, SMAD5, CD151, FOS, NRG4 and 
LOX were significantly down regulated in aspirin treated cells. ECM protein, laminin5, 
consists of 3 subunits (D, E andJ) synthesized by the genes LAMA3, LAMB2 and LAMC2. 
LAMA3, LAMB2 and LAMC2 were over expressed in OSCC samples (from chapter two 
results) and earlier studies have reported laminin-5 expression is high during ECM 
remodeling(Yurchenco & Cheng 1993) and aspirin treatment significantly reduced 
expression of the LAMC2 gene. The corresponding integrin sub unit for laminin-5 binding is 
D6E4(Kinumatsu et al. 2009). Both the integrin subunits, D6E4 synthesized by genes ITGA6 
and ITGB4, were up regulated in OSCC samples (Chapter 2) and these play significant role 
in ECM remodeling and cancer progression(Marinkovich 2007). Aspirin treatment reduced 
ITGA6 expression in SCC25 cells indicating aspirin is efficient in reducing expression of 
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both the ligand and its receptor to avoid further signaling. Other studies have shown up 
regulation of KRT14, myoepithelial marker, as one of the essential factors for oral cancer 
progression(Ohkura et al. 2005). Chapter 2revealedover expression of KRT14 gene in OSCC 
samples and aspirin treatment down regulated the expression of KRT14 gene (Chapter 3). It 
is clearly evident that aspirin is targeting the genes responsible for promoting the hallmarks 
of cancer, cell cycle progression, inflammation and ECM remodelling (Hanahan & Weinberg 
2011) and in addition, in-vitro tumorigenic assays performed on aspirin treated cells showed 
anti-tumorigenic properties of aspirin in SCC25 cells.  
In current research most of the drugs examined for cancer treatment target a specific gene 
and/or protein (Olasz et al. 2010; Ortiz-Ruiz et al. 2014). However, patient relapse and 
tumour recurrence are the main disadvantages of these drugs (Sinha et al. 2013; Wang et al. 
2013). Chapter three described sequential targeting strategies of aspirin by repressing the 
expression of genes involved in inflammation, G2/M transition, fibrosis and also ECM 
remodelling. This is a significant result indicating aspirin can act on several genes that are 
targets for oral cancer prevention. Further research needs to be performed by clinicians on 
dosage and duration of treatment based on the tumour grade. Combination of aspirin with low 
doses of chemotherapeutic agents for oral cancer like 5-fluorouracil and cisplatin (Syed et al. 
2015) can be employed to enhance the efficacy of therapy with low toxic effects but several 
research studies need to be performed before progressing to the human studies. 
6.4 Down regulation of KRT4 is an indicator for 
malignant transformation in OSCC but not a 
therapeutic target 
KRT4, a differentiation factor in epithelial cells, was down regulated in late stage OSCC 
samples as revealed in chapter two. Many gene profile studies also indicated down regulation 
of KRT4 gene in OSCC samples (Sakamoto et al. 2011; Toruner et al. 2004; Ye et al. 
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2008).Further, KRT4 gene was found to be down regulated in SCC25 cells when compared 
with normal human oral keratinocytes (Rao et al. 2010). In the current study changes in 
KRT4 gene expression was confirmed by quantitative PCR (QPCR) and changes in protein 
by immunohistochemistry analysis (chapter four). Meta-profiling of microarray data 
(GSE56532) with external data set (GSE26549) indicated that KRT4 loss was seen in 
dysplasia samples that progressed cancer and there was no differential regulation of KRT4 
observed in the dysplasia samples that had not progressed to cancer. This indicated that 
KRT4 loss may be important for oral cancer progression and it’s over expression could affect 
the tumorigenicity of oral cancer cells as the KRT4 gene was expressed in terminal 
differentiated epithelial cells (Vaidya & Kanojia 2007). Stable transfection and expression of 
the KRT4 gene in SCC25 cells increased tumorigenic properties of the cells leading to over 
expression of epithelial mesenchymal transition markers. Cells showing overexpression of 
KRT4showed increased positive staining for KRT14, myoepithelial marker, which plays an 
important role in tumour progression and is consistent with elevated KRT14 expression in 
OSCC samples (chapter two). The morphology of KRT4 stably transfected cells resembled 
that of a holoclone like structure with compact growth of cells having cancer stem cell like 
properties (Barrandon & Green 1987). CD44 expression was higher in oral cancer cells with 
more tumorigenic potential (Yen et al. 2013) and additional studies revealed that increased 
stemness of cancer cells was correlated with the increased expression of CD44 (Locke et al. 
2005). Flowcytometry analysis of CD44 in KRT4 transfected cells indicated increased 
expression compared to KRT4 untransfected cells. Further studies should be performed 
todetermine if the holoclone structure was due to CD44+ and KRT14+ cells.  EpCAM is 
known to be down regulated in EMT cells (Frederick et al. 2007). KRT4 transfected SCC25 
cells showed an increase in expression of EMT marker (N-cadherin) andEpCAM expression 
was found to be low in these cells compared to SCC25 cells suggesting EMT progression was 
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due to increased KRT4 expression. Further,in-vitro tumorigenic assays revealed KRT4 cells 
showed more cell motility and aggressive tumour sphere formation than non-transfected cells. 
Epidermal keratinocytes when treated with retinoic acid showed KRT4 expression (Virtanen 
et al. 2010) and in contrast the gingival epithelial cells showed down regulation of the KRT4 
gene (Hatakeyama et al. 2004). To date the effect of retinoic acid on SCC25 cells had not 
been examined and the current study showed SCC25 cells treated with lower concentrations 
of retinoic acid (1 μM) demonstrated down regulation of KRT4 and CD44 gene expression. 
Microarray results (chapter 2) indicated differential expression of 3 keratin genes (KRT4 
down regulated; KRT14 and KRT17 up regulated) in OSCC samples. Retinoic acid also 
reduced the levels of KRT14 and KRT17 genes that play an important role in tumour 
progression (Miettinen, Kovatich & Karkkainen 1997; Reis-Filho et al. 2003). Elevated levels 
of KRT17 expression were found in cervical (Escobar-Hoyos et al. 2014) and oral cancer 
samples (Kolokythas et al. 2011). Transcription factors, c-JUN and SP1, that induce the 
expression of basal and supra basal keratins (Rossi et al. 1998) were repressed by retinoic 
acid treatment and in addition, the treatment led to repressed expression of KRT4, KRT14 
and KRT17 genes. In contrast, it is interesting that aspirin did not show any effect on the 
KRT17 expression (Chapter 3) but retinoic acid treatment resulted in down regulation of 
KRT17 (chapter 4). Further research has to be conducted on the combination of drugs such as 
aspirin and retinoic acid that may effectively target the genes that promote oral cancer 
progression. It is clearly understood from these findings that KRT4 does not have therapeutic 
importance in oral cancer cells. Down regulation of KRT4 in dysplasia samples which 
progressed into cancer clearly suggests KRT4 gene might act as a prognostic marker for oral 
cancer occurrence and progression. Further analysis of KRT4 and KRT17 expression in large 
number of dysplasia clinical samples and follow up studies for cancer development might 
reveal KRT4 and KRT17 as markers for prognosis.  
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6.5 Sequential signaling events during oral cancer 
progression 
The major challenge in the prevention of oral cancer progression is tumour 
heterogeneity(Severino et al. 2008). It is known from several studies that this disease is not 
due to abnormality of single gene but due to sequential switch –on-off of several genetic 
events(Mao 2012). Hence, there is a requirement for the development and discovery of drugs 
that can target these sequential genetic events more broadly. Based on the results from the 
chapters 2, 3 and 4, the sequential steps of oral carcinogenesis events were summarised in 
Figure 6.1.  Significant differential regulation of genes that promote interferon signaling and 
G2/M transition were not found between tumourigenic SCC25 cells and dysplastic DOK cells 
indicating that these two pathways might be early events before progressing to malignancy. 
Previous studies clearly stated FOXM1, which plays an important role in the G2/M transition 
is early event in the oral cancer progression(Gemenetzidis et al. 2009). Elevated MMP13 
expression was found in malignant oral cancer samples and SCC25 cells showed over 
expression (~150 fold) of this gene in comparison to DOK cells indicating MMP13 
expression may only be correlated with malignancy. FN1 over expression during fibrosis of 
the tumour tissue resulting in scarring and desmoplastic reaction may occur in the late stage 
malignancy. External data analysis of dysplastic samples with normal and oral cancer 
samples indicated that KRT4 down regulation and KRT17 up regulation is an indication for 
samples that can progress into cancer. These sequential steps of molecular events have to be 
further confirmed in large number of samples for their clinical use as diagnostic, prognostic 
and therapeutic markers.   
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Figure 6.1 Schematic representation of signaling events during oral cancer progression. 
Normal mucosa changes to dysplastic cells due to abnormal expression of genes involved in 
G2/M transition and interferon signaling pathways. Further KRT4 down regulation and 
KRT17 over expression may be an indicator for the dysplastic lesions progressing towards 
malignancy. FN1 overexpression in late stage malignant oral samples induces the 
desmoplastic reaction leading to the scarring of the tissue. 
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6.6 Mammary ECM from lactating mice can halt 
cancer cell division 
ECM remodelling is one of the hallmarks of cancer development (Catalano et al. 2013). 
OSCC profiling in chapter two revealed up regulation of several genes involved in ECM 
remodelling. In chapter five, preliminary studies revealed the importance of ECM 
composition in modulating the behaviour and growth of oral, SCC25 and breast, MDA-MB-
231 cancer cells cultured on mammary ECM isolated from lactating mice. ECM remodelling 
is an important feature of mammary gland involution (Radisky & Hartmann 2009) and 
mechanisms that play a major role in promoting tumour growth and progression also play an 
important role in ECM remodelling during mammary gland involution (McDaniel et al. 2006; 
O'Brien et al. 2010). Mammary gland cells during lactation showed low rates of cellular 
proliferation (Capuco et al. 2003; Knight & Peaker 1982). A previous study from our lab 
indicated extracellular matrix also regulates signals to mammary epithelial cells to impact on 
epithelial phenotype(Wanyonyi et al. 2013). Microarray analysis was performed for finding 
the comparison between lactating mammary gland (day 9 and day 10) and involuting 
mammary gland (day 4) using the data obtained from the previous studies (Clarkson et al. 
2004; Rudolph et al. 2003; Stein et al. 2004). This comparison study revealed upregulation of 
matricellular proteins, matrix metalloproteinases, ECM proteins, and inflammatory cytokines 
in involuting mammary gland compared to lactating mammary gland data which correlates 
with the earlier studies indicating that the involuting gland facilitates inflammation and ECM 
remodelling processes (Jindal et al. 2014; Martinson et al. 2014). Since earlier studies showed 
lactating mammary gland had very few epithelial cells showing proliferation (Capuco et al. 
2003; Knight & Peaker 1982),current experiments targeted culture of the oral and breast 
cancer cells, SCC25 and MDAMB231, on mammary matrix from lactating gland to reveal 
significant reduction in the cell viability. The cells were unable to penetrate the matrix and 
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attach to the surface. There is no reduction in the cell viability for the cell types grown on the 
involuting matrix and the cells were able to penetrate and attach the surface. Further, the 
marker for cytokinesis, CEP55 (Mondal et al. 2012), was reduced in expression in breast and 
oral cancer cells cultured on lactation matrix. 
ECM has the capacity to regulate tumour growth, development and spreading of cancer cells 
(Hanahan & Weinberg 2011; Pickup, Mouw & Weaver 2014). Recent studies showed 
attempts to modulate the tumour microenvironment, includingin-vitro siRNA therapies, 
hydrogel based nanoparticle cancer therapeutics and controlling the tumour micro 
environment by targeting the secretory inflammatory mediators or carcinoma associated 
fibroblasts may not be effective as targeted approach due to tumour heterogeneity(Kostourou 
& Papalazarou 2014; Salo et al. 2014; Xu et al. 2014) and the current study showed halt in 
the cell proliferation of two different cancer cell lines. After decades of research in breast 
cancer, matrix from involuting mammary gland was examined for bioactivity given the over 
expression of genes related to inflammation, matrix metalloproteinases and matricellular 
proteins related to cancer (Avivar-Valderas, Wen & Aguirre-Ghiso 2014b, 2014a; O'Brien et 
al. 2011; O'Brien et al. 2012; Oskarsson 2013). However, in the current study the question 
remains as to why the cells were unable to divide on matrix from lactating mammary gland. It 
may might be due to local factors in the mammary gland (Sinowatz et al. 2000). Further 
studies are required to find the mechanisms underlying the effect of cell death of cancer cells 
grown on lactation matrix. These studies may reveal new mechanisms for inhibiting tumour 
growth. A comparative study of the proteins and bioactive compounds need to be performed 
for mammary ECM from lactation and involuting gland to find the differential factors that 
influence the growth of the cancer cells. Since the data is preliminary, it further requires 
evidence to support the concept that differential local factors in the lactating ECM can 
promote cell death in cancer cells. Earlier study showed that breast cancer cells mixed with 
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mammary involuting ECM further increases tumorigenicity (McDaniel et al. 2006) and it 
would also be interesting to perform these tumorigenic experiments by mixing the tumour 
cells with mammary ECM from lactating tissue. This will clearly suggest whether the 
mammary ECM during lactation has any capacity to inhibit the growth of the cancer cells in-
vivo. Further, knowing the factors in mammary ECM of lactating gland, that promote the halt 
in cell division, might be of therapeutic importance in controlling cancer development and 
progression. 
Summary 
1. Microarray analysis revealed overexpression of genes related to interferon signaling 
and G2/M transition pathway is an early and progressing event during oral cancer 
development. FN1 may act as a diagnostic marker for differentiating early and late 
stage OSCC samples. MMP13 is a potential therapeutic target for oral cancer 
treatment. This study clearly suggested a requirement for broad spectrum drugs that 
can target several abnormally expressed genes without affecting the surrounding 
normal tissue. 
2. Aspirin at low concentrations emerged as an effective potential therapeutic drug in 
targeting oral cancer by targeting genes that promote cell cycle progression, 
inflammation and ECM remodelling processes. 
3. KRT4 and KRT17 may become prognostic indicators for identification of oral cancer 
progression of dysplastic lesion. Retinoic acid is effective in down regulating the 
KRT14 and KRT17 genes implicated as over expressing genes in oral cancer.  
4. Mammary ECM during lactation has factors that can halt the cell proliferation of oral 
and breast cancer cells and there is need for further research on decoding these factors 
to improve the therapeutic strategies in treating the cancer. 
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Future Directions 
It is evident that oral cancer is due to deregulation of several genes in specific pathways and 
processes. Combination of IL8, CCL5 and MMP13 proteins may potentially be performed as 
a protein marker panel that requires validation in large number of salivary samples for the 
early detection of OSCC through non-invasive methods causing no discomfort to the patients. 
Further sensitivity and specificity of these markers followed by study in large number of 
samples will declare them as diagnostic markers for oral cancer thus improving the survival 
outcome of oral cancer patients. Aspirin can repress expression of several genes that are 
targets for oral cancer prevention. Due to its broad spectrum effect that can target multiple 
pathways and/or genes that contribute towards the oral cancer progression, further research is 
required on dosage and duration of treatment based on the tumour grade. To enhance the 
efficacy of therapy with low toxic effects, combination of aspirin with low doses of 
chemotherapeutic agents for oral cancer such as 5-fluorouracil and cisplatin can be employed, 
though several research studies are required prior to human trials. Down regulation of KRT4 
and up regulation of KRT17 in dysplasia samples which progressed into cancer from the bio-
informatic analysis clearly suggests that KRT4 and KRT17 genes might act as prognostic 
marker for early detection of OSCC. Further gene expression studies of KRT4 and KRT17 
expression in large number of dysplasia clinical samples including follow-up studies for 
cancer development might reveal KRT4 and KRT17 as markers for prognosis. Since the data 
clearly shows that ECM can control the proliferation of tumour cells in-vitro, further 
tumorigenic experiments will provide evidence in-vivo by mixing the breast cancer cells with 
mammary ECM from lactating and involuting tissue. Further, knowing the factors and signal 
events involved in mammary ECM of lactating gland, that promotes the halt in cell division, 
might be of therapeutic importance in controlling cancer development and progression. 
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